



The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection

A Technology Assessment

Final Report

April 15, 2014

Completed by:

Institute for Clinical and Economic Review



AUTHORS:

Jeffrey A. Tice, MD
Associate Professor of Medicine
Division of General Internal Medicine
Department of Medicine
University of California San Francisco

Daniel A. Ollendorf, MPH, ARM
Chief Review Officer, Institute for Clinical and Economic Review

Steven D. Pearson, MD, MSc, FRCP
President, Institute for Clinical and Economic Review

**DATE OF
PUBLICATION:**

April 15, 2014

About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. ICER receives funding from government grants, non-profit foundations, health plans, provider groups, and health industry manufacturers. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide the foundation for a more effective, efficient, and just health care system. More information about ICER is available at www.icer-review.org

About CTAF

The California Technology Assessment Forum (CTAF) – a core program of ICER – develops rigorous evidence reports and provides a public venue in which the evidence on the effectiveness and value of health care services can be discussed with the input of all stakeholders. CTAF seeks to help patients, clinicians, insurers, and policymakers interpret and use evidence to improve the quality and value of health care.

The CTAF Panel is an independent committee of medical evidence experts from across California, with a mix of practicing clinicians, methodologists, and leaders in patient engagement and advocacy, all of whom meet strict conflict of interest guidelines, who are convened to evaluate evidence and vote on the comparative clinical effectiveness and value of medical interventions. More information about CTAF is available at www.ctaf.org

Table of Contents

Abbreviations.....	v
Executive Summary.....	ES1
Introduction	1
1. Background	3
2. Clinical Guidelines	12
3. Coverage Policies	14
4. Previous Systematic Reviews and Technology Assessments.....	18
5. Ongoing Studies	20
6. Evidence Review (Methods & Results)	26
7. Model of Clinical and Economic Outcomes of Treatment Strategies for Hepatitis C.....	54
8. Questions and Discussion	87
References	98
APPENDIX	110

Abbreviations used in this report

AEs:	Adverse events
AST/ALT:	aspartate aminotransferase/alanine aminotransferase
BOC:	Boceprevir
CDC:	Centers for Disease Control and Prevention
CI:	Confidence interval
CMS:	Centers for Medicare & Medicaid Services
CTAF:	California Technology Assessment Forum
DARE:	Database of Abstracts of Reviews of Effects
DAA:	Direct-acting antiviral agent
FDA:	US Food and Drug Administration
HCC:	Hepatocellular carcinoma
HCV:	Hepatitis C virus
HR:	Hazard ratio
IFN	Interferon
NR:	Not reported
NS:	Not significant
OR:	Odds ratio
P:	Pegylated interferon
PBO:	Placebo
PR:	Pegylated interferon plus ribavirin
Q8:	Taken every 8 hours
QALY:	Quality-adjusted life year
R:	Ribavirin
RCT:	Randomized Controlled Trial
SMV:	Simeprevir
SOF:	Sofosbuvir
SVR:	Sustained virologic response
SVR12:	SVR at 12 weeks
TVR:	Telaprevir
US:	United States

Executive Summary

This assessment for the California Technology Assessment Forum (CTAF) evaluates the evidence on the comparative clinical effectiveness and value of two drugs recently approved by the FDA for the treatment of chronic hepatitis C: simeprevir and sofosbuvir. Chronic hepatitis C is a common infection that is a major cause of chronic liver disease, liver failure, and hepatocellular carcinoma, and it is the leading indication for liver transplantation in the Western world.¹ Prior to 2011, the combination of pegylated interferon and ribavirin (PR) was the gold standard of therapy for the treatment of chronic hepatitis C. Approximately half of patients with genotype 1, the most prevalent type of hepatitis C in the US, could expect with PR therapy to clear the virus from their bloodstream entirely and maintain a sustained virologic response (SVR) 24 weeks after the end of treatment. PR therapy can be difficult, however, as both interferon and ribavirin can produce bothersome side effects, and in some cases, dangerous levels of anemia, neutropenia, and/or thrombocytopenia.² The 2011 introduction of first generation direct-acting antiviral (DAA) protease inhibitors boceprevir (Victrelis®, Merck & Co.) and telaprevir (Incivek®, Vertex Pharmaceuticals, Inc.) resulted in substantially improved SVR rates in many patients when used with PR regimens. This improvement has come with new challenges, however, including significant additional side effects and drug-drug interactions as well as stringent dosing requirements and high pill burdens for patients.³

Novel DAA agents have been developed with the potential for simplified dosing, fewer side effects and drug-drug interactions, and in some patients, the promise of interferon- and/or ribavirin-free treatment, particularly for genotypes 2 and 3 (the other common genotypes in the US). These new agents include the recently-approved second generation protease inhibitor simeprevir (Olysio®, Janssen Products, LP) and polymerase inhibitor sofosbuvir (Sovaldi™, Gilead Sciences, Inc.), as well as several other agents that are currently in late-stage clinical trials. Uncertainties remain with these new agents, however, as data on treatment-related side effects and their performance in particular patient populations are still emerging in the published literature. In addition, the costs of treatment are likely to increase substantially, with the two new agents expected to cost approximately \$70,000 and \$170,000 per course of therapy, depending on the duration of therapy.^{4,5} Accordingly, the California Technology Assessment Forum has chosen to review the evidence on the comparative clinical effectiveness and comparative value of new DAA agents for chronic hepatitis C in relation to the existing standard of care in multiple patient populations.

This assessment will address the following questions: 1) among patients with genotype 1, are treatment regimens incorporating simeprevir and sofosbuvir equivalent or superior to the previous standard of care: pegylated interferon plus ribavirin and one of the first generation protease inhibitors telaprevir or boceprevir; 2) among patients with genotypes 2 and 3, is the combination of sofosbuvir and ribavirin equivalent or superior to the previous standard of care, pegylated

interferon plus ribavirin; and 3) among interferon-ineligible or intolerant patients, is the combination of sofosbuvir plus ribavirin or sofosbuvir plus simeprevir equivalent or superior to no treatment. The purpose of this assessment is to help patients, providers, and payers address these important questions and to support dialogue needed for successful action to improve the quality and value of health care for patients with hepatitis C.

Methods

The lack of head-to-head trials makes it difficult to assess the relative efficacy of the different drug regimens. In order to assess the relative efficacy of various treatment options, we performed a network meta-analysis, a form of indirect comparison that synthesizes direct and indirect evidence in a network of clinical trials to compare multiple interventions for the same indication. Network meta-analysis allows for indirect comparisons between therapies as long as they have the same type of control group (often placebo) in randomized trials.

To examine the potential clinical and economic impact of the introduction of sofosbuvir and simeprevir in California, we also developed a cohort model that assessed these effects over time horizons of one year, five years, and 20 years. Our model examined outcomes in different hypothetical cohorts of chronic hepatitis C patients organized by genotype, prior treatment status (i.e., treatment-naïve versus treatment-experienced), and eligibility for interferon therapy. Within each of these strata, outcomes and costs were assessed for a cohort of 1,000 hypothetical patients, age 60 years. We focused on genotypes 1, 2, and 3, as these represent over 97% of the hepatitis C population in the US.

Results

Genotype 1

Table ES1 on the next page summarizes the key benefits and harms for the treatment options for genotype 1. Among treatment-naïve patients, the first generation protease inhibitors increase the SVR at 12 weeks (SVR12) from the 40% range with PR to the 70% range. However, a large number of pills have to be taken about every 8 hours, and there are burdensome new side effects. These include a marked increase in anemia, with nearly 50% of patients taking telaprevir requiring erythropoietin stimulating agents for a median of 15 weeks during the course of treatment. Also common were nausea for both boceprevir and telaprevir, 20% more patients experiencing taste disturbance for boceprevir, and 20% more patients experiencing generalized pruritus with telaprevir. The drugs also have a large number of important drug interactions. Despite these problems, triple therapy with one of the two first generation protease inhibitors and PR was considered the standard of care for treatment of genotype 1 until the approval of simeprevir and sofosbuvir.

Table ES1. Summary of Benefits and Harms for Genotype 1 by Prior Treatment Status and Interferon Eligibility.

Treatment Approach (weeks)	SVR12 (Percent)	Treatment Burden	Adverse effects	Interferon -ineligible
Genotype 1				
<i>Treatment-naïve</i>				
PR (48)	47	48 weeks with weekly injections	Fatigue (50-60%), fever (40-45%), anemia (\leq 30%)	No
BOC(24) + PR(48)	73	Add Q8 pills	Anemia (\leq 50%), more nausea and dysgeusia, drug interactions	No
TVR(12) + PR(48)	74	Add Q8 pills	Anemia (\leq 50%), more nausea and pruritus, drug interactions	No
SMV(12) + PR(24-48)*	84	Add 1 pill to PR	No increase in anemia	No
SOF(12) + PR(12)	83	Add 1 pill to PR Fewer weeks	No increase in anemia	No
SMV(12) + SOF(12)	No data (Likely >90)	No P, maybe no R	Not reported yet	Maybe
<i>Treatment-experienced</i>				
PR (48)	22	48 weeks with weekly injections	Fatigue (50-60%), fever (40-45%), anemia (up to 30%)	No
BOC(24) + PR(48)	64	Add Q8 pills	Anemia (\leq 50%), more nausea and dysgeusia, drug interactions	No
TVR(12) + PR(48)	70	Add Q8 pills	Anemia (\leq 50%), more nausea and pruritus, drug interactions	No
SMV(12) + PR(24-48)*	70	Add 1 pill to PR	No increase in anemia	No
SOF(12) + PR(12)	No data (FDA estimate 71)	Add 1 pill to PR Fewer weeks	No increase in anemia	Maybe
SMV(12) + SOF(12)	90	No P, maybe no R	Not reported yet	Yes

Abbreviations: Q8 = taken every 8 hours; P = pegylated interferon; R = ribavirin

* Excluding patients with the Q80K mutation (approximately 10-15% of genotype 1 patients)

Among patients without the Q80k polymorphism, simeprevir appears to significantly improve the SVR12 compared with triple therapy. Additional benefits of simeprevir are reductions in the incidence of anemia and the pill burden for patients: simeprevir requires only one pill per day. It should be noted, however, that there are no published data from head-to-head trials of simeprevir and either of the first generation protease inhibitors, nor are there data on the impact of treatment on important long term patient outcomes such as the incidence of cirrhosis, liver decompensation, hepatocellular carcinoma, transplant, or death. Adverse events (AEs) specifically associated with simeprevir include pruritus, photosensitivity-induced rashes, and hyperbilirubinemia, but these are generally not severe and are easily managed.

Sofosbuvir plus PR also appears to cause less anemia and certainly represents a lower pill burden than standard triple therapy. It also requires only 12 weeks of PR rather than the 24 to 48 weeks

with the first generation protease inhibitors. Simeprevir plus PR in patients without the Q80K polymorphism and sofosbuvir plus PR appear to have very similar SVR12 rates for genotype 1 patients who are treatment-naïve or treatment-experienced. Most of the data for sofosbuvir, however, come from uncontrolled studies. Because of the shorter course of PR, sofosbuvir + PR has fewer severe/life-threatening (grade 3 and 4) AEs and fewer patients discontinuing treatment due to AEs, with no consistent pattern of an increase in AEs other than anemia (23% versus 14% for PR). As with simeprevir, this combination cannot be used in patients who are interferon-ineligible, and there are no long-term outcome data.

The preliminary data on simeprevir plus sofosbuvir (an off-label use not indicated by the FDA) with or without ribavirin come from uncontrolled trials and should be considered preliminary at this point but are nonetheless encouraging. The available data for treatment-experienced patients shows SVR12 rates averaging 90%; the SVR12 of treatment-naïve patients should be even better. This regimen is interferon-free, so can be used in interferon-ineligible patients. Since it is interferon-free (and perhaps ribavirin-free), simeprevir plus sofosbuvir should have markedly lower adverse event rates than regimens including PR.

Genotype 2

The story is more straightforward for genotype 2 (see Table ES2 on the next page). The combination of sofosbuvir plus ribavirin is superior in clinical effectiveness to prior standard treatment options. Among treatment-naïve patients, there was a large increase in SVR12 seen in the randomized FISSION trial and supported by the non-randomized VALENCE trial. The SVR12 for treatment-experienced patients was 86% and 90% in the two uncontrolled studies, but it was high enough to assume at least non-inferiority to PR therapy. The sofosbuvir-based regimen is interferon-free, which decreases grade 3 and 4 AEs, markedly decreases patients discontinuing therapy because of AEs, and reduces interferon-associated AEs such as fatigue, fever, myalgias, and headaches. Sofosbuvir therapy does not come with an increase in the anemia seen with the first generation protease inhibitors – in fact the incidence of anemia was lower in the sofosbuvir arms of the trials. The treatment course is also half as long (12 versus 24 weeks). Since the sofosbuvir-based regimen is interferon-free, the benefits should be even greater in those genotype 2 patients who are treatment-naïve but ineligible for interferon because of psychiatric or other co-morbidities. In the POSITRON trial, the SVR12 was 93% compared to 0% for treatment-naïve patients and 76% versus 0% for treatment-experienced patients.

Table ES2. Summary of Benefits and Harms for Genotype 2 by Prior Treatment Status and Interferon Eligibility.

Treatment Approach (weeks)	SVR12 (Percent)	Treatment Burden	Adverse effects	Interferon-ineligible
Genotype 2				
<i>Treatment-naïve</i>				
PR (24)	78	24 weeks with weekly injections	Fatigue (50-60%), fever (40-45%), anemia (up to 30%)	No
SOF(12) + R(12)	97	Shorter, no P	Less fatigue, less anemia	Yes
<i>Treatment-experienced</i>				
PR (24)	No data	24 weeks with weekly injections	Fatigue (50-60%), fever (40-45%), anemia (up to 30%)	No
SOF(12) + R(12)	88	Shorter, no P	Less fatigue, less anemia	Yes

Abbreviations: P = pegylated interferon; R = ribavirin

Genotype 3

The story is more complex for genotype 3 (see Table ES3 on the next page). For interferon-eligible patients, the existing randomized trial data do not demonstrate the superiority of sofosbuvir + PR to PR alone. Among treatment-naïve patients in the genotype 3 subgroup of the randomized phase 3 FISSION trial, 12 weeks of sofosbuvir plus ribavirin had a lower SVR12 than 24 weeks of PR (56% versus 62%). The SVR12 of the same regimen in the genotype 3 subgroup of the POSITRON study was similarly low at 61%. Given the poor outcomes at 12 weeks, the uncontrolled VALENCE study examined longer treatment courses, and the SVR consistently increased with increasing lengths of therapy to 16 and 24 weeks (56% to 93%). Similarly, the VALENCE study also showed that the SVR for treatment-experienced patients increased from 12 weeks (30%) to 16 weeks (62%) to 24 weeks (77%). These results should be confirmed in a second trial, but they formed the basis for the FDA approved regimen of 24 weeks of sofosbuvir for patients with genotype 3. The FDA approval also took into account that the sofosbuvir-based regimen is interferon-free, which decreases grade 3 and 4 AEs, markedly decreases patients discontinuing therapy because of AEs, and reduces interferon-associated AEs such as fatigue, fever, myalgias, and headaches. The treatment course is the same length as PR but without the injections and side effects of interferon. Since the sofosbuvir-based regimen is interferon-free, the benefits should be even greater in those genotype 3 patients who are treatment-naïve but ineligible for interferon because of psychiatric or other co-morbidities. In the POSITRON trial, the SVR12 was 61% compared to 0% for treatment-naïve patients and 76% versus 0% for treatment-experienced patients.

Table ES3. Summary of Benefits and Harms for Genotype 3 by Prior Treatment Status and Interferon Eligibility.

Treatment Approach (weeks)	SVR12 (Percent)	Treatment Burden	Adverse effects	Interferon-ineligible
Genotype 3				
<i>Treatment-naïve</i>				
PR (24)	62	24 weeks with weekly injections	Fatigue (50-60%), fever (40-45%), anemia (up to 30%)	No
SOF(24) + R(24)	93	Shorter, no P	Less fatigue, less anemia	Yes
<i>Treatment-experienced</i>				
PR (24)	No data	24 weeks with weekly injections	Fatigue (50-60%), fever (40-45%), anemia (up to 30%)	No
SOF(24) + R(24)	77	Shorter, no P	Less fatigue, less anemia	Yes

Abbreviations: P = pegylated interferon; R = ribavirin

Model Results Evaluating Clinical and Economic Outcomes of Hepatitis C Treatment Scenarios

Consistent with the findings of our systematic review and network meta-analysis, our model demonstrates that therapeutic regimens containing simeprevir or sofosbuvir have the potential to substantially increase the number of patients achieving SVR relative to previous therapeutic options, and sofosbuvir also provides the first effective interferon-free option for patients ineligible or intolerant to interferon.

For many patient subpopulations, however, the benefits of sofosbuvir and simeprevir come at a substantially increased cost. The costs for initial treatment regimens including sofosbuvir or simeprevir are expected to range from a low of approximately \$88,000 to a high exceeding \$175,000 per patient, depending on the drugs selected and the duration of initial treatment. Many patients who are treated with an initial course and who fail to achieve a prolonged SVR would likely be retreated, adding further to the estimated treatment costs over a one-year time frame.

For many comparisons with the previous standard of care, we estimate that the incremental cost required to achieve one additional SVR with newer treatment regimens is greater than \$300,000. While the “cost per additional SVR” is not a common measure of cost-effectiveness in the literature, the costs per SVR generated in this analysis are generally higher than those previously published for telaprevir versus PR (\$189,000),¹¹⁸ alternative regimens of PR versus standard PR therapy (\$17,000-\$24,000),¹¹⁹ and even highly active antiretroviral therapy in HIV patients (\$1,000-\$79,000).¹²⁰

The clinical advantages of newer treatment regimens would therefore come with a substantial potential impact on health care budgets should a large number of patients be treated. As estimated by our model, we anticipate the average increase in treatment costs to be approximately \$70,000 per patient for the newer agents. For example, in an employer-sponsored group health plan with 1 million enrollees, with an assumed underlying infection rate of 1.7%, there would be approximately 17,000 patients in this population infected with hepatitis C. If even 50% of this population comes forward for treatment, the immediate one-year budget impact for the plan would be estimated to be nearly \$600 million, or approximately \$50 on a per member, per month basis. It would be impossible for this magnitude of immediate increased spending to be accommodated within the budgets established by current health care premium structures, provider risk-sharing contracts, and patient co-payments.

Using an estimate that 50% of infected individuals in California would know of their infection and would be considered for treatment, we estimate that replacing current care with simeprevir and sofosbuvir-based regimens would raise drug expenditures by \$22 billion in a single year. We looked for potential cost offsets to drug treatment resulting from downstream reductions in liver-related complications that would be expected with successful treatment of hepatitis C infection. For every 1,000 patients treated, our model estimated that switching from previous standard treatments to the most effective new regimens in all patients would prevent 18 liver-related events over five years and 70 events over 20 years. At a 5-year time horizon, however, cost offsets would still be estimated to represent less than 10-20% of upfront treatment costs. Even at a 20-year horizon, if all patients infected with hepatitis C are treated with the new regimens, the cost offset will only cover approximately three-quarters of initial drug costs.

The budget impact and cost offset figures change substantially under our second treatment scenario in which only patients with advanced liver fibrosis are started on the new treatment regimens, with other patients treated with existing pre-DAA regimens. Treating this smaller group of patients is estimated to result in an increase in initial drug expenditures of \$7 billion in the first year for the population of California, one-third of the extra amount needed to treat all infected patients. Costs saved by reducing liver-related complications in this subgroup would total only 17% of added drug costs at five years, but at 20 years, estimated cost offsets would produce a net savings to the statewide health care system of approximately \$1 billion.

We must emphasize several important limitations of our budget impact analyses. First, while there were sufficient data to perform a network meta-analysis for patients with genotype 1 infection, estimates could not be generated for all stratifications of interest for the model, and we could not even attempt quantitative synthesis for patients with genotypes 2 or 3. We therefore often had to resort to basing the input to the model on point estimates from individual studies, which in some cases involved small numbers of patients. Our results are therefore quite sensitive to the estimates of drug effectiveness and should be viewed with caution.

In addition, as described previously, we modeled only the immediate clinical effects of treatment as well as the potential downstream benefits of preventing liver-related complications. While we presented pooled rates of discontinuation due to adverse events from available clinical trial data, we assumed equally across all drug regimens that all patients completed their course of therapy and were fully compliant while doing so. This assumption likely does not adequately reflect the benefits of better adherence to newer regimens with shortened courses of interferon or no interferon at all.

For the 20-year time horizon analyses of clinical and economic outcomes, we did not try to include estimates of the impact of competing risks of morbidity and mortality for patients as they neared 80 years of age. If we had attempted to model these competing risks, the estimates of liver-related complications and resulting potential cost offsets would have been lower, serving to make the budget impact of newer regimens even more unfavorable.

We estimated the costs of medication using published wholesale acquisition costs or average wholesale prices.¹¹² Of note, however, telaprevir costs have increased substantially over the past 1.5 years, even as its use has declined to near zero.⁹⁷ We chose to model telaprevir costs using estimates from the time period in which it was considered the previous standard of care for triple therapy (\$4,920 per week) rather than using a more current, and what we believe to be artificially-inflated, price.

Finally, our analyses did not consider other possible benefits to patients from greater treatment success, such as improved quality of life and reduced absenteeism from work or school. Full analysis of all potential outcomes and costs of these new treatment options will only be possible through additional data collection and/or the development of complex simulation models that approximate the natural history of hepatitis C and its treatment.

CTAF Public Meeting – Voting Results and Policy Issues

During a March 10, 2014 public meeting, the CTAF Panel deliberated and voted on key questions related to the comparative clinical effectiveness and comparative value of new treatments for hepatitis C. The key questions addressed the most important issues in applying the evidence to support clinical practice and medical policy decisions. Following its deliberation on the evidence and subsequent voting, the CTAF Panel engaged in a moderated discussion with a Policy Roundtable composed of clinical experts, a patient advocate, payer representatives, and a representative from a manufacturer of one of the new agents. This discussion was distilled into nine specific recommendations that are described on pages 92-97 of this report. Among the key themes are:

- 1) Even though the CTAF panel voted that the new drugs are likely superior in terms of clinical effectiveness for most patients and offer clinical benefits beyond current treatments, serious limitations in the evidence base remain. Further evidence is needed to more fully evaluate the comparative clinical effectiveness and value of these new treatments.
- 2) A majority of the CTAF Panel rated the new treatments as “low value” compared with older drugs due to the magnitude of the potential impact on health care budgets of treating large numbers of patients with these high-priced drug regimens. Because the financial impact of using these new drugs to treat all eligible patients with hepatitis C is untenable, policy makers should seek avenues to achieve reductions in the effective price of these medications.
- 3) Panel members and outside experts nearly all agreed that for both clinical and cost reasons, not every patient with hepatitis C needs to be immediately treated with the new drugs. Informed, shared decision-making about the timing of treatment should be encouraged. Given the circumstances, it is reasonable to consider prioritizing treatment with the new drugs for patients who need urgent treatment and have some evidence of liver fibrosis but do not have advanced liver disease.
- 4) Additional policy measures to increase the likelihood of clinical benefit from treatment while reducing the financial impact should be considered. Payers seeking to achieve these goals should consider use of prior authorization criteria that a) require patient commitment, b) utilize “futility rules” that define when a lack of early response should lead to discontinuation of treatment, and c) require that the new drugs be prescribed by specialists with experience treating patients with hepatitis C.

Introduction

This assessment for the California Technology Assessment Forum (CTAF) evaluates the evidence on the comparative clinical effectiveness and value of two drugs recently approved by the FDA for the treatment of chronic hepatitis C: simeprevir and sofosbuvir.

Chronic hepatitis C is a common infection that is a major cause of chronic liver disease, liver failure, and hepatocellular carcinoma (HCC), and it is the leading indication for liver transplantation in the Western world.¹ Prior to 2011, the combination of pegylated interferon and ribavirin (PR) was the gold standard of therapy for the treatment of chronic hepatitis C. Approximately half of patients with genotype 1, the most prevalent type of hepatitis C in the US, could expect with PR therapy to clear the virus from their bloodstream entirely and maintain a sustained virologic response (SVR) 24 weeks after the end of treatment. PR therapy can be difficult, however, as both interferon and ribavirin can produce bothersome side effects, and in some cases, dangerous levels of anemia, neutropenia, and/or thrombocytopenia.² The 2011 introduction of first generation direct-acting antiviral (DAA) protease inhibitors boceprevir (Victrelis®, Merck & Co.) and telaprevir (Incivek®, Vertex Pharmaceuticals, Inc.) resulted in substantially improved SVR rates in many patients when used with PR regimens. This improvement has come with new challenges, however, including significant additional side effects and drug-drug interactions as well as stringent dosing requirements and high pill burdens for patients.³

Novel DAA agents have been developed with the potential for simplified dosing, fewer side effects and drug-drug interactions, and in some patients, the promise of interferon- and/or ribavirin-free treatment, particularly for genotypes 2 and 3 (the other common genotypes in the US). These new agents include the recently-approved second generation protease inhibitor simeprevir (Olysio®, Janssen Products, LP) and polymerase inhibitor sofosbuvir (Sovaldi™, Gilead Sciences, Inc.), as well as several other agents that are currently in late-stage clinical trials. Uncertainties remain with these new agents, however, as data on treatment-related side effects and their performance in particular patient populations are still emerging in the published literature. In addition, the costs of treatment are likely to increase substantially, with the two new agents expected to cost approximately \$70,000 and \$170,000 per course of therapy, depending on the duration of therapy.^{4,5} Accordingly, the California Technology Assessment Forum has chosen to review the evidence on the comparative clinical effectiveness and comparative value of new DAA agents for chronic hepatitis C in relation to the existing standard of care in multiple patient populations.

This assessment will address the following questions: 1) among patients with genotype 1, are treatment regimens incorporating simeprevir and sofosbuvir equivalent or superior to the previous standard of care, pegylated interferon plus ribavirin and one of the first generation protease inhibitors telaprevir or boceprevir; 2) among patients with genotypes 2 and 3, is the combination of

sofosbuvir and ribavirin equivalent or superior to the previous standard of care, pegylated interferon plus ribavirin; and 3) among interferon-ineligible or intolerant patients, is the combination of sofosbuvir plus ribavirin or sofosbuvir plus simeprevir equivalent or superior to no treatment. The purpose of this assessment is to help patients, providers, and payers address these important questions and to support dialogue needed for successful action to improve the quality and value of health care for patients with hepatitis C.

1. Background

1.1 Hepatitis C

The worldwide prevalence of hepatitis C infection is estimated to be between 120 and 170 million.⁶ Estimates for the prevalence of hepatitis C in the United States range from 3.0 to 5.2 million people.⁷⁻¹⁰ It is the leading cause of liver failure requiring liver transplant.¹¹

There are six major genotypes of hepatitis C.¹² The most common genotype in the United States is genotype 1 (70-75%), followed by genotype 2 (13-17%) and genotype 3 (8-12%).¹³⁻¹⁸ Genotypes 4 to 6 are uncommon in the United States (1% or less) and will not be considered further in this review. Knowledge of the viral genotype is important because response to therapy varies by genotype.

The acute phase of hepatitis C infection is asymptomatic for most patients. The Centers for Disease Control and Prevention (CDC) estimates that among 100 people infected with hepatitis C, only 20 to 30 will develop symptoms (see Table 1 below).¹²¹ The symptoms are primarily fatigue, decreased appetite, nausea, and jaundice. Of 100 people infected with hepatitis C, 70 to 80 will not have any symptoms, and 75 to 85 will remain chronically infected with hepatitis C.¹⁹⁻²¹ Between 60 and 70 of these individuals will develop chronic liver disease, and 5 to 20 will develop cirrhosis over 20 years.^{22,23} Evaluation of death certificates and modeling studies suggest that these statistics may underestimate the morbidity and mortality from HCV infection.¹²²⁻¹²⁴

Table 1. Natural History of Hepatitis C Infection.

Condition	Number of individuals
Infection with hepatitis C	100
Develop symptoms	20-30
Remain asymptomatic	70-80
Develop chronic infection	75-85
Develop chronic liver disease	60-70
Develop cirrhosis over 20-30 years	5-20
Die from cirrhosis or liver cancer	1-5

The development of chronic hepatitis is partly dependent on an individual's genetics. Variants in interleukin 28 (IL28) predict clearance of the virus. Approximately half of patients with the IL28 CC variant spontaneously clear the virus while only 16 to 20% of those with the IL28 TT variant clear the virus.²⁴⁻²⁶ This will be important to consider in treatment trials as patients carrying the IL28B CC virus are more likely to respond to treatment with interferon.^{27,28}

The majority of patients with chronic hepatitis C infections are asymptomatic and unaware of their infections unless they have been screened. It is estimated that approximately half of patients infected with hepatitis C in the United States are unaware of their infection and that less than 15% have received treatment.^{9,29,30} The majority of Americans infected with the hepatitis C virus or HCV (~76%) were born between the years of 1945 and 1965.³⁰ Both the CDC and the US Preventive Services Task Force (USPSTF) now recommend hepatitis C screening for all Americans born during that time frame.^{31,32}

Chronic hepatitis C is a slowly progressive disease. Between 20 and 30% of patients develop cirrhosis over 20 to 30 years of infection.^{22,23} The median time from infection to cirrhosis is estimated to be about 40 years, which means that approximately half of patients infected 40 years ago will have developed cirrhosis. Once bridging fibrosis or cirrhosis develops, patients with chronic HCV infection are at risk for the development of hepatocellular carcinoma. Factors associated with progression to cirrhosis include male sex, alcohol intake, elevated aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, elevated total bilirubin, low albumin, low platelets, and higher fibrosis scores.^{22,23,33-36}

1.2 Definitions

- *Cirrhosis*: progressive scarring of liver tissue that may affect performance of chronic hepatitis C treatment. Cirrhosis is typically biopsy-proven in clinical trials of chronic hepatitis C therapies.
- *Decompensated cirrhosis*: the presence of cirrhosis plus one or more complications including esophageal varices, ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome, or hepatocellular carcinoma.
- *Genotype*: a classification of hepatitis C based on genetic material in the RNA strands of the virus. There are 6 main genotypes, which are further divided into subtypes in some cases.
- *Interferon-ineligible*: patients in whom interferon therapy is contraindicated due to such conditions as anemia, alcohol abuse, advanced or decompensated cirrhosis, or severe psychiatric disorder.
- *Interferon-intolerant*: patients who discontinue interferon therapy prematurely due to side effects.
- *Sustained virologic response (SVR)*: absence of detectable HCV RNA, measured 12-24 weeks following the completion of treatment.
- *Relapse*: recurrence of detectable viral RNA at some point after achieving an undetectable HCV viral load during treatment.

- *Null response*: no reduction of at least 1 log₁₀ in HCV RNA during prior treatment.
- *Partial response*: greater than a 1 log₁₀ reduction in HCV RNA during prior treatment, but never achieving undetectable viral RNA.
- *Treatment-naïve*: not previously treated for chronic hepatitis C infection.
- *Treatment-experienced*: one or more previous attempts at treatment of chronic hepatitis C infection. This group may contain a mix of patients who relapsed, those with a partial response, and those with a null response to prior treatment.

The **METAVIR score** is a standardized measure of fibrosis and inflammation seen on a liver biopsy. The fibrosis score ranges from 0 to 4, and the inflammation activity score is measured from 0 to 3.

Fibrosis score:

F0 = no fibrosis

F1 = portal fibrosis without septa

F2 = portal fibrosis with few septa

F3 = numerous septa without cirrhosis

F4 = cirrhosis

Activity score:

A0 = no activity

A1 = mild activity

A2 = moderate activity

A3 = severe activity

The fibrosis score is particularly useful because patients with higher fibrosis scores are more likely to progress to cirrhosis and HCC and may warrant earlier treatment.

The **Ishak scale** is a second commonly reported histologic grading system for liver fibrosis that ranges from 0 to 6.

Ishak Scale

1 = no fibrosis (normal)

2 = fibrous expansion of some portal areas ± short fibrous septa

3 = fibrous expansion of most portal areas ± short fibrous septa

4 = fibrous expansion of portal areas with marked bridging (portal to portal, portal to central)

5 = marked bridging with occasional nodules (incomplete cirrhosis)

6 = cirrhosis

A rough approximation of how the two scoring systems compare is as follows:

<u>Ishak</u>	<u>METAVIR</u>
0	0
1,2	1
3	2
4,5	3
6	4

1.3 Treatment of Chronic Hepatitis C Infection

The primary goal of HCV treatment is the prevention of cirrhosis and hepatocellular carcinoma. The combination of pegylated interferon plus ribavirin (commonly referred to as “PR”) has been the backbone of treatment for patients infected with HCV. Treatment is guided by genotype. Patients infected with genotype 1 tend to have a poor response to PR. As noted earlier, the first generation direct-acting antiviral agents (DAAs) – the protease inhibitors boceprevir and telaprevir – were approved for treatment of genotype 1 in 2011. The cure rate with triple therapy (a DAA plus PR) is approximately double the cure rate of the combination of interferon and ribavirin alone. New DAAs have been developed that are effective for multiple genotypes and offer the promise of interferon-free therapy. Because the natural history for the development of cirrhosis and HCC is long, treatment success is usually measured by the maintenance of a sustained virologic response (SVR), defined as undetectable serum HCV RNA for at least 24 weeks (SVR24) after the completion of treatment. In recent trials, the FDA has allowed the SVR 12 weeks after the completion of treatment (SVR12) to be the primary outcome.

SVR is a reasonable, but imperfect measure of cure, and it varies somewhat based on when it is measured. For example, the recent PILLAR trial,³⁷ a phase 2B trial of simeprevir, reported the number of participants who had undetectable RNA at the end of treatment and at 12, 24, and 72 weeks after treatment. The number of patients with undetectable HCV RNA declined from 336 at the end of treatment to 303 (12 weeks), 300 (24 weeks) and 293 (72 weeks), respectively. Thus SVR12 was a reasonably stable representation of SVR24 (only 3/303 or about 1% relapsed between those two time points). However, relapses did continue over time, with an additional 7/300 (2.3%) relapsing between 24 and 72 weeks of follow-up. In a meta-analysis of long-term outcomes, the percent of patients with long-term cure following SVR24 ranged from 98% to 100%.³⁸

A number of factors have been identified that predict a poor response to treatment. Patients with genotype 1 have a lower SVR24 than patients with the other genotypes. Among patients infected with genotype 1, the subtype 1a has a lower response rate than subtype 1b. Patients with the IL28B CC genotype respond better than patients with the CT or TT genotype. Other poor prognostic factors include a higher HCV RNA viral load, higher levels of fibrosis of the liver, older age, black race, obesity, and metabolic syndrome. Among patients who have been treated in the past, those who had a relapse after SVR respond better to new treatment than those with only a partial response to initial therapy, and patients with an initial null response to therapy are the least likely to respond to new treatment.

Treatment of Genotype 1

Pegylated interferon plus ribavirin

Pegylated interferon plus ribavirin (PR) was the primary treatment of HCV for more than 10 years. In clinical trials, the SVR24 for patients with genotype 1 treated with PR ranged from 40% to 50%, but it was about 20% lower in real-world studies in part because of the poor tolerability of PR therapy and because of the special nature of patients willing to participate in clinical trials.³⁹⁻⁴¹ Interferon requires a weekly injection and commonly causes fatigue (50% to 60%), headache (50% to 60%), myalgias (40% to 55%), and fever (40% to 45%).⁴² Other common side effects of PR include anemia (hemoglobin < 10 g/dL) in up to 30% of patients, generalized pruritis (25% to 30%), and psychiatric symptoms such as depression (up to 25%), insomnia, and anxiety (15% to 25%).⁴² Ribavirin may cause birth defects, so women of child-bearing age must be on birth control during treatment.

For genotype 1, patients are treated for 48 weeks with once weekly subcutaneous injections of pegylated interferon and twice daily oral ribavirin taken with food. Routine monitoring is performed with dose reductions recommended for neutropenia, thrombocytopenia, anemia, depression, and worsening renal function.

Boceprevir and Telaprevir

The first generation protease inhibitors boceprevir and telaprevir were the first two DAAs approved by the FDA. Since their approval in 2011, the standard of care for the treatment of genotype 1 has been PR in combination with either boceprevir or telaprevir.⁴³⁻⁴⁵ Among treatment-naïve patients, PR plus boceprevir or telaprevir has a SVR24 between 70% and 75%. Patients with the IL28B CC genotype respond well to interferon. In this group, the response to PR plus either boceprevir or telaprevir is between 80% and 90%.

The length of treatment is guided by the patient's liver histology, response to prior treatment, and the change in viral load during the first weeks of treatment. The treatment algorithm for boceprevir starts with four weeks of PR. Among treatment-naïve patients, this is followed by 24 weeks of PR plus boceprevir with no additional treatment if the patient has an undetectable HCV RNA during weeks 8 to 24 (so-called response guided therapy). Those with detectable RNA at week 8 receive an additional 8 weeks of PR + boceprevir (32 weeks total) followed by an additional 12 weeks of PR alone. Among treatment-experienced patients, the four weeks of PR is followed by 32 weeks of PR plus boceprevir with no additional treatment if the patient has an undetectable HCV RNA during weeks 8 to 24. Treatment-experienced patients with detectable RNA at week 8 receive 32 weeks of PR plus boceprevir and then an additional 12 weeks of PR alone. For both treatment-naïve and experienced patients, if the HCV RNA level is ≥ 100 IU per ml at week 12 or detectable at week 24,

treatment is stopped. Patients with cirrhosis, a prior null response, or less than a one log decrease in HCV RNA during the 4 week PR run in (i.e., a period of therapy with PR before initiating boceprevir) should also be considered for 48 weeks of treatment.

The treatment algorithm for telaprevir is somewhat simpler. Everyone starts with 12 weeks of PR plus telaprevir. Patients who are treatment-naïve or relapsed following prior SVR receive an additional 12 weeks of PR. Those who have HCV RNA > 1000 IU per ml at week 4 or 12 should stop therapy at that time. Prior partial responders and null responders and those who are treatment-naïve but who have detectable HCV RNA at weeks 4 and / or 12 receive an additional 36 weeks of PR. All patients with cirrhosis should be considered for an additional 36 weeks of PR therapy rather than 12 weeks, even if their HCV RNA level is less than 25 IU per ml.

Challenges with boceprevir and telaprevir therapy

The marked improvement in SVR24 with the addition of boceprevir or telaprevir to PR comes with significant practical and clinical trade-offs. Patients must take either 6 or 12 pills per day spaced every 7 to 9 hours, and the pills must be taken with at least 20 grams of fat. Both medications increase the risk for severe anemia that is already common with PR treatment (increased from 30% with PR to 50% with either boceprevir or telaprevir).⁴² Boceprevir causes a bitter or metallic taste (40% versus 20% with PR), and telaprevir causes rashes and pruritus (20% more than PR alone).⁴² The combination of PR plus boceprevir or telaprevir is associated with serious adverse event rates between approximately 40% and 50%.^{42,46,47} Neither can be used as monotherapy because resistance develops quickly.^{48,49} Finally, boceprevir and telaprevir are strong inhibitors of the cytochrome P450 (CYP) 3A4 enzyme, leading to many potential drug interactions with statins, benzodiazepines, colchicine, St. John's wort, anticonvulsants, sulfonylureas, and some reverse transcriptase inhibitors.

Treatment of Genotypes 2 and 3

Pegylated interferon plus ribavirin

Neither boceprevir nor telaprevir is approved for treatment of genotypes 2 and 3 and therefore the standard of care for these patients has been 24 weeks of PR. The duration of treatment is half that for genotype 1, but the response rate is significantly higher. The SVR24 of patients with genotypes 2 or 3 in clinical trials ranged from 75% to 85%, although the real world experience is again somewhat lower.

Newly-Approved Treatment Regimens

Boceprevir and telaprevir were the first two DAAs approved by the FDA. Since then, more than 30 additional DAAs have entered clinical trials. The new drugs attack different targets in the HCV life cycle and include NS3/4A protease inhibitors, nucleoside and nucleotide polymerase inhibitors, non-nucleoside polymerase inhibitors, NS5A inhibitors, and cyclophilin inhibitors.

The goals of the new therapies include simpler dosing regimens (fewer pills, shorter duration), fewer side effects, fewer drug interactions, and higher cure rates. Two new DAAs were approved in late 2013: simeprevir and sofosbuvir. At least two additional DAAs, faldaprevir and daclatasvir, are likely to be approved in 2014.⁵⁰ Many physicians are monitoring patients with chronic HCV infections but not treating them while waiting for new medical therapies (sometimes referred to as warehousing). Physicians expect that these new therapies will provide high cure rates without the severe side effects of current therapies, which require the use of interferon.

Simeprevir is a NS3/4A protease inhibitor that was approved by the FDA for the treatment of HCV genotype 1 in November 2013. It is considered a second-generation protease inhibitor (boceprevir and telaprevir were first generation protease inhibitors). A major improvement of simeprevir compared with earlier protease inhibitors is the dosing schedule. It may be taken once a day rather than six to twelve pills divided into doses taken every eight hours. A second major improvement is that it does not appear to increase the risk for anemia, which has been a major problem with the first generation protease inhibitors. Simeprevir must be used in combination with PR because viral resistance develops rapidly with monotherapy. Significant new adverse reactions associated with simeprevir include photosensitivity reactions, some of which have required hospitalization, and pruritus. The FDA indication for simeprevir is for genotype 1 only: simeprevir 150 mg once daily with PR for 12 weeks followed by an additional 12 weeks of PR for treatment-naïve patients and patients who relapsed or by an additional 36 weeks of PR for prior partial and null responders (see Table 2 below).

Table 2. FDA Indications for Simeprevir and Sofosbuvir.

Drug	Genotype	Treatment
Simeprevir	1	<ul style="list-style-type: none">• 150 mg daily with PR x 12 weeks plus PR for an additional 12 to 36 weeks
Sofosbuvir	1, 4	<ul style="list-style-type: none">• 400 mg daily with PR x 12 weeks• Alternate if interferon (IFN)-ineligible: 400 mg daily with R x 24 weeks
Sofosbuvir	2	<ul style="list-style-type: none">• 400 mg daily with R x 12 weeks
Sofosbuvir	3	<ul style="list-style-type: none">• 400 mg daily with R x 24 weeks
Sofosbuvir	HIV co-infected	<ul style="list-style-type: none">• Same as above based on genotype

Sofosbuvir is the first drug in the class of HCV NS5B nucleotide analog polymerase inhibitors to be approved. Sofosbuvir is the third approved drug given breakthrough designation by the FDA. The goal of the breakthrough therapy program is to speed up the development and review of drugs that have substantial benefits over available therapy for serious or life-threatening conditions. The FDA requires substantially less evidence to support the approval of drugs with breakthrough designation. Like the other DAAs, sofosbuvir should not be prescribed as monotherapy. It has been studied in combination with PR, with ribavirin alone, with simeprevir, and in combination with other DAAs that have not yet received FDA approval. Like simeprevir, sofosbuvir only needs to be taken once daily. Unlike simeprevir, sofosbuvir is also approved to treat genotypes 2, 3, and 4 in addition to genotype 1 (see Table 2 on previous page). The details of therapy are guided by genotype, prior treatment status, interferon eligibility, and liver histology. The FDA indication for patients with genotype 1 is sofosbuvir 400 mg daily with PR for 12 weeks; patients who are interferon-ineligible may consider sofosbuvir 400 mg plus R alone for 24 weeks. The FDA indication for patients with genotype 2 is sofosbuvir 400 mg daily with R for 12 weeks. The FDA indication for patients with genotype 3 is sofosbuvir 400 mg daily with R for 24 weeks. For patients who are HIV co-infected, the treatment varies by genotype but is the same as for patients who are not HIV co-infected.

2. Clinical Guidelines

The American Association for the Study of Liver Diseases (AASLD) / Infectious Diseases Society of America (IDSA) / International Antiviral Society – USA (IAS USA)

<http://www.hcvguidelines.org>

On January 29, 2014, the AASLD, IDSA, and IAS-USA took the unusual step of jointly creating and updating an online guideline for the treatment of chronic hepatitis C because of the rapidly evolving treatment environment: the FDA is expected to approve an array of new drugs over the next few years. For genotype 1, they recommend sofosbuvir plus PR or sofosbuvir plus simeprevir (in interferon-intolerant patients). They recommend simeprevir + PR as an alternative therapy for patients with genotype 1 without the Q80K polymorphism. For genotypes 2 and 3, they recommend sofosbuvir plus ribavirin.

The Department of Veterans Affairs (VA)

<http://www.hepatitis.va.gov/provider/guidelines/2012HCV>

The 2012 VA guidelines recommend PR plus either boceprevir or telaprevir for treating genotype 1 infections and PR alone for treating genotype 2 and 3 infections. An updated version of these guidelines following FDA approval of simeprevir and sofosbuvir is expected in Spring 2014.

National Institute for Health and Care Excellence (NICE)

<http://cks.nice.org.uk/hepatitis-c>

Current treatment guidelines at NICE recommend treatment with PR as the initial therapy for all genotypes but were last revised in March 2010. NICE is currently reviewing the new DAA drugs.

European Association for the Study of the Liver (EASL)

<http://www.easl.eu/2013HCVguideline>

In December 2013, EASL updated its HCV treatment guidelines. They recommend that treatment should not be deferred for patients with significant fibrosis (METAVIR F3 or F4). They recommend PR plus either boceprevir or telaprevir for treating genotype 1 infections and PR alone for treating genotype 2 and 3 infections.

The Canadian Association for the Study of the Liver (CASL)

<http://www.hepatology.ca>

Current CASL recommendations (from June 2012) are to use PR plus either boceprevir or telaprevir for treating genotype 1 infections and PR alone for treating genotype 2 and 3 infections. No recommendations including the new DAA therapies have been made to date.

The Japan Society of Hepatology (JSH)

<http://JSH2014HCVguidelines>

In January 2014, the JSH updated their guidelines for the management of genotype 1. They recommend simeprevir plus PR as the primary therapy for most patients with telaprevir plus PR as an alternative. They do not comment on sofosbuvir as it is not approved for use in Japan.

3. Coverage Policies

Coverage policies of a variety of public and private payers for simeprevir and sofosbuvir were reviewed in February 2014 and are described below.

3.1 Simeprevir

Medicare & Medicaid

No publicly-available coverage policies, prior authorization protocols, or formulary designations for simeprevir were available from the Centers for Medicare & Medicaid Services (CMS) or Medi-Cal, California's Medicaid agency.

Regional Private Payers

HealthNet

https://www.healthnet.com/static/general/unprotected/html/national/pa_guidelines/olysio_natl.html

HealthNet has published an interim prior authorization protocol that provides coverage for simeprevir + PR for chronic hepatitis C patients with genotype 1 but without the Q80K polymorphism. Coverage is not authorized for monotherapy with simeprevir, in patients who have failed prior treatment with any protease inhibitor (including simeprevir), or in patients with any known contraindication to interferon (e.g., decompensated liver disease, uncontrolled autoimmune hepatitis).

National Private Payers/Pharmacy Benefit Managers

Aetna

http://www.aetna.com/products/rxnonmedicare/data/2014/GI/hepatitis_c.html

Coverage is limited to patients with chronic hepatitis C virus genotype 1 with compensated liver disease who receive concurrent therapy with PR. Use of simeprevir is not covered in combination with any other protease inhibitor therapy (including sofosbuvir), in genotype 1 patients with the Q80K polymorphism, or in those who have failed previous therapy with protease inhibitors.

Anthem/Express Scripts

http://www.anthem.com/provider/noapplication/f0/s0/t0/pw_e210962.pdf?na=pharminfo

Simeprevir + PR is covered in adult genotype 1 patients with chronic hepatitis C and compensated liver disease who are negative for the Q80K polymorphism.

CVS-Caremark

http://www.caremark.com/portal/asset/FEP_Criteria_Olysio.pdf

CVS-Caremark has published prior authorization criteria stating that simeprevir + PR is approved for use in patients with genotype 1 chronic hepatitis C who have compensated liver disease, have not been previously treated with any protease inhibitor, have not had a liver transplant, and do not expect to reduce or interrupt simeprevir dosing. Monotherapy with simeprevir is not approved.

Humana

http://apps.humana.com/tad/tad_new/Search.aspx?criteria=simeprevir&searchtype=freetext&policyType=both

Humana limits coverage to adult patients who have a diagnosis of genotype 1 hepatitis C with evidence of compensated liver disease and concurrent therapy with PR. Simeprevir is not covered in combination with other protease inhibitors or sofosbuvir, in combination with medications that are either potent CYP3A4/5 inducers or CYP3A4/5 inhibitors, in patients with the Q80K polymorphism, or in those who have previously received a treatment with a protease inhibitor.

3.2 Sofosbuvir

Medicare & Medicaid

No publicly-available coverage policies, prior authorization protocols, or formulary designations for sofosbuvir were available from CMS or Medi-Cal, California's Medicaid agency.

Regional Private Payers

HealthNet

https://www.healthnet.com/static/general/unprotected/html/national/pa_guidelines/sovaldi_natl.html

HealthNet has published an interim prior authorization protocol that ties coverage for sofosbuvir to the FDA-approved indications and therapy durations. Monotherapy with sofosbuvir (i.e., without ribavirin) is not covered.

National Private Payers/Pharmacy Benefit Managers

Aetna:

http://www.aetna.com/products/rxnonmedicare/data/2014/GI/hepatitis_c.html

Aetna provides coverage for sofosbuvir + PR in patients with genotypes 1 or 4, and coverage for sofosbuvir + R in genotypes 2 and 3. Additionally, sofosbuvir + R may be used in genotype 1 patients who are ineligible for interferon, defined by Aetna as including: recent suicide attempt, severe depression, or previous interferon-related adverse events. Combination therapy with simeprevir is not covered.

Anthem/Express Scripts

http://www.anthem.com/provider/noapplication/f0/s0/t0/pw_e210963.pdf?na=pharminfo

Sofosbuvir is generally covered in adult patients with chronic hepatitis C who have evidence of compensated liver disease (including cirrhosis). Coverage is tied to FDA-approved indications and therapy durations. Sofosbuvir + R may be used in genotype 1 patients who are ineligible for interferon, defined by Anthem as including: autoimmune hepatitis, Child-Pugh liver function score >6, or known hypersensitivity to interferon.

CVS-Caremark

http://www.caremark.com/portal/asset/FEP_Criteria_Sovaldi.pdf

CVS-Caremark has published prior authorization criteria stating that sofosbuvir + PR (genotypes 1 and 4) or sofosbuvir + R (genotypes 2 and 3 as well as genotype 1 patients ineligible for interferon) must be used only in adults with chronic hepatitis C who do not have renal impairment, decompensated cirrhosis, liver cancer awaiting transplant, or significant or unstable cardiac disease. Sofosbuvir monotherapy is not allowed in any situation. The occurrence of liver transplant is a trigger for discontinuation of sofosbuvir.

Humana:

http://apps.humana.com/tad/tad_new/Search.aspx?criteria=sofosbuvir&searchtype=freetext&policyType=both

Humana limits coverage of sofosbuvir to adult patients who have a diagnosis of chronic hepatitis C *with* evidence of compensated liver disease. Additionally, coverage for genotype 1 patients is limited to those who have failed to achieve SVR with a prior regimen containing a protease inhibitor or who have documented contraindications to interferon therapy (e.g., hypersensitivity to interferon, hepatic decompensation, hemoglobinopathies). Coverage for genotypes 2, 3, and 4 is not restricted other than based on the general criteria above and FDA-approved treatment regimens. Use of sofosbuvir as monotherapy or in combination with any other protease inhibitor (including simeprevir) is not considered medically necessary and is not covered.

4. Previous Systematic Reviews and Technology Assessments

We were unable to identify any technology assessments of the new DAAs. Four systematic reviews used network meta-analysis to evaluate the efficacy of boceprevir and telaprevir because there are no head-to-head comparisons of treatment regimens including the two drugs. There were no systematic reviews evaluating simeprevir or sofosbuvir.

4.1 Formal Health Technology Assessments

No formal health technology assessments were identified. However, the Canadian Agency for Drugs and Technologies in Health (CADTH) is currently undertaking a review of new DAA agents (among patients with genotype 1 chronic hepatitis C only), and NICE is undertaking individual technology assessments of sofosbuvir and simeprevir according to their labeled indications in Europe (i.e., all genotypes for sofosbuvir, genotypes 1 and 4 for simeprevir).

4.2 Systematic Reviews

Cure 2012

Cure S, Diels J, Gavart S, Bianic F, Jones E. Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. *Current medical research and opinion*. Nov 2012;28(11):1841-1856.

This systematic review and Bayesian network meta-analysis of 11 studies found that both boceprevir and telaprevir combined with PR were better than PR alone in treatment-naïve and treatment-experienced patients. The authors highlighted a trend towards better outcomes with telaprevir.

Cooper 2013

Cooper C, Lester R, Thorlund K, et al. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. *QJM : monthly journal of the Association of Physicians*. Feb 2013;106(2):153-163.

This systematic review and Bayesian network meta-analysis of 11 studies found that both boceprevir and telaprevir combined with PR were better than PR alone. In the treatment-naïve,

telaprevir had lower rates of anemia and neutropenia but higher rates of rash and pruritus. In the treatment-naïve, telaprevir had higher rates of all adverse events compared with boceprevir.

Kieran 2013

Kieran J, Schmitz S, O'Leary A, et al. The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. Jan 2013;56(2):228-235.

This systematic review and Bayesian network meta-analysis of 10 studies found that both boceprevir and telaprevir combined with PR were better than PR alone. In the subgroup of patients who had relapsed following SVR, telaprevir-based treatments were more effective than boceprevir-based treatments.

Sitole 2013

Sitole M, Silva M, Spooner L, Comee MK, Malloy M. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. *Clinical therapeutics*. Feb 2013;35(2):190-197.

This systematic review and Bayesian network meta-analysis of eight studies found that both boceprevir and telaprevir combined with PR had higher SVR than PR alone, but with an increase in drug-related adverse events. They highlighted the lack of data on long-term outcomes such as hospitalization for liver disease, HCC, and mortality.

5. Ongoing Studies

We did not include studies focusing exclusively on the treatment of HCV genotypes 4, 5, or 6 nor did we include combinations with drugs that are not yet FDA approved.

Two of the ongoing studies of simeprevir stand out as likely to answer key open questions. The first (NCT01485991) is a randomized trial comparing simeprevir to telaprevir in treatment-experienced patients. This will be the first study to compare the new DAAs to the previous standard of care for treating HCV genotype 1. The second (NCT01349465) is the three-year follow-up of patients in the phase 2 and 3 trials: this should give at least preliminary information on the impact of treatment on disease progression. The list of studies below does not include several ongoing studies of interferon-free combinations of simeprevir with DAAs that do not have FDA approval including daclatasvir, IDX-719, TMC-647055, and GSK-23336805.

None of the studies of sofosbuvir listed on clinicaltrials.gov have a PR or PR plus boceprevir or telaprevir control group. There are no trials with primary outcomes beyond SVR12. The list of studies below does not include several ongoing studies of interferon-free combinations of sofosbuvir with DAAs in development that do not yet have FDA approval including daclatasvir, ledipasvir, GS-5885, GS-0938, and GS-5816.

Title/ Trial Sponsor	Study Design	Comparators	Patient Population	Primary Outcomes	Estimated Completion Date
Simeprevir or SMV (TMC435)					
<p>An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegIFNα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegIFNα-2a and Ribavirin Therapy (ATTAIN)</p> <p>NCT01485991</p>	<p>RCT</p> <p>Double blind</p> <p>Placebo-controlled</p> <p>Non-inferiority</p> <p>N = 766</p>	<p>SMV 150 + PR</p> <p>TVR 750 mg every 8 hours + PR</p>	<ul style="list-style-type: none"> • Genotype (GT) 1 • Treatment-experienced 	<p>SVR12</p>	<p>March 2014</p>
<p>3-year Follow-up Study in Patients Previously Treated With a TMC435 for the Treatment of Hepatitis C Virus (HCV) Infection</p> <p>NCT01349465</p>	<p>Cohort</p> <p>N = 249</p>	<p>None</p>	<ul style="list-style-type: none"> • Treated with simeprevir in a phase 2 or phase 3 study 	<p>SVR at 3 years</p>	<p>February 2016</p>
<p>An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients (Phase 3)</p> <p>NCT01725529</p>	<p>RCT</p> <p>Double-blind</p> <p>Placebo (PBO) controlled</p> <p>N = 457</p>	<p>SMV 150 + PR</p> <p>SMV 100 + PR</p> <p>PBO + PR</p>	<ul style="list-style-type: none"> • GT 1 • Treatment-naïve 	<p>SVR12</p>	<p>October 2014</p>
<p>A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study</p> <p>NCT01323244</p>	<p>Cohort</p> <p>Open-label</p> <p>N = 270</p>	<p>SMV 150 + PR</p>	<ul style="list-style-type: none"> • GT 1 • Did not achieve SVR in the placebo arm of prior trials of simeprevir 	<p>SVR12</p>	<p>January 2015</p>

Title/ Trial Sponsor	Study Design	Comparators	Patient Population	Primary Outcomes	Estimated Completion Date
<p>A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-naïve Patients</p> <p>COSMOS Cohorts 1 and 2</p> <p>NCT01466790</p>	<p>RCT</p> <p>Open-label</p> <p>N = 168</p>	<p>SMV + sofosbuvir (SOF) 12 Weeks</p> <p>SMV + SOF + R 12 Weeks</p> <p>SMV + SOF 24 Weeks</p> <p>SMV + SOF + R 24 Weeks</p>	<ul style="list-style-type: none"> • GT 1 • Naïve and Experienced • METAVIR F3 or F4 	<p>SVR12</p>	<p>January 2014</p>
<p>A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-naïve or Treatment-experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients (RESTORE)</p> <p>Phase 3</p> <p>NCT01567735</p>	<p>Cohort</p> <p>Open-label</p> <p>N = 107</p>	<p>SMV 150 + PR</p>	<ul style="list-style-type: none"> • GT 4 • Naïve and Experienced 	<p>SVR12</p>	<p>March 2014</p>
<p>A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus (HIV)-Type 1</p> <p>NCT01479868</p>	<p>Cohort</p> <p>Open-label</p> <p>N = 109</p>	<p>SMV 150 + PR</p>	<ul style="list-style-type: none"> • GT 1 • HIV-1 infection 	<p>SVR24</p>	<p>August 2013</p>
<p>A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection</p> <p>NCT01846832</p>	<p>Cohort</p> <p>Open label</p> <p>N = 225</p>	<p>SMV 150 + PR</p>	<ul style="list-style-type: none"> • GT 1 or 4 • Naïve • METAVIR F0-F2 	<p>SVR12</p>	<p>October 2014</p>

Title/ Trial Sponsor	Study Design	Comparators	Patient Population	Primary Outcomes	Estimated Completion Date
Sofosbuvir (GS-7977, PSI-7977)					
Sofosbuvir + R for 16 or 24 Weeks and Sofosbuvir + PR for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection NCT01962441	RCT Open label N= 600	SOF 400 + R 16 Weeks SOF 400 + R 24 Weeks SOF 400 + PR 12 Weeks	<ul style="list-style-type: none"> • GT 2 with cirrhosis or GT 3 • Naïve or experienced 	SVR12	December 2014
Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 (STEADFAST) NCT01994486	Cohort Open label N = 20	SOF + TVR 12 Weeks	<ul style="list-style-type: none"> • GT 1 • Naïve 	SVR12	July 2014
Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-naïve Adults With Genotype 1 and 3 Chronic HCV Infection. NCT01896193	RCT Open label N= 120	SOF 400 + R 16 Weeks SOF 400 + R 24 Weeks	<ul style="list-style-type: none"> • GT 1 or 3 • Naïve 	SVR12	April 2014
Sofosbuvir Plus Ribavirin in Subjects With HCV Infection and Renal Insufficiency NCT01958281	Non-randomized Open label N = 40	SOF 200 + R 200 24 Weeks SOF 400 + R 200 24 Weeks	<ul style="list-style-type: none"> • GT 1 or 3 • Naïve • Renal insufficiency 	SVR12	July 2016
A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Treatment-naïve and Treatment-experienced Japanese Subjects With Chronic Genotype 2 HCV Infection NCT01910636	Cohort Open label N = 134	SOF 400 + R 12 Weeks	<ul style="list-style-type: none"> • GT 2 • Naïve or experienced 	SVR12	April 2014

Title/ Trial Sponsor	Study Design	Comparators	Patient Population	Primary Outcomes	Estimated Completion Date
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Subjects With Chronic HCV Infection NCT02021643	RCT Open label N=450	SOF 400 + R 12 Weeks SOF 400 + R 16 Weeks SOF 400 + R 24 Weeks	<ul style="list-style-type: none"> • Naïve with GT 1, 2, 3, or 6 • Experienced with GT 2 	SVR12	May 2015
Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon-in Aggressive Post-transplant Hepatitis C NCT01779518	Cohort Open label N = not provided	SOF 400 + R or PR 24 Weeks	<ul style="list-style-type: none"> • Post-liver transplant • Aggressive HCV infection 	-	-
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects NCT01667731	Cohort Open label N = 230	SOF 400 + R 12-24 Weeks	<ul style="list-style-type: none"> • GT 1, 2, or 3 • HIV-1 infection 	SVR12	November 2013
Sofosbuvir (GS-7977) in Combination With P and Ribavirin for 12 Weeks in Treatment-experienced Subjects With Chronic HCV Infection Genotype 2 or 3 NCT01808248	Cohort Open label N = 47	SOF 400 + PR 12 Weeks	<ul style="list-style-type: none"> • GT 2 or 3 • Experienced 	SVR12	September 2013
An Open-Label Study to Explore the Clinical Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant NCT01559844	Cohort Open label N= 50	SOF 400 + R	<ul style="list-style-type: none"> • HCV Infection • HCC awaiting liver transplant 	Post-transplant virologic response	September 2013

Title/ Trial Sponsor	Study Design	Comparators	Patient Population	Primary Outcomes	Estimated Completion Date
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects NCT01783678	Non-randomized Open label N = 270	SOF 400 + R 12 Weeks SOF 400 + R 24 Weeks	<ul style="list-style-type: none"> • GT 1, 2, 3, or 4 • HIV-1 infection • Naïve or experienced 	SVR12	April 2014
Open-Label Study of Sofosbuvir + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies NCT01625338	Non-randomized Open label N = 600	SOF 400 + R 12 Weeks SOF 400 + R 24 Weeks SOF 400 + PR 12 Weeks	<ul style="list-style-type: none"> • Enrolled in prior sponsored studies of sofosbuvir 	SVR12	July 2014
GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation NCT01687257	RCT Open label N = 50	SOF 400 + R 48 Weeks Observe x 24 Weeks then SOF 400 + R 48 Weeks	<ul style="list-style-type: none"> • HCV infection, any genotype • Cirrhosis with Child-Pugh score < 10 • Esophageal or gastric varices 	SVR12	August 2014
Safety of Efficacy of GS-7977 and Ribavirin in Subjects With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant NCT01687270	Non-randomized Open label N = 40	SOF 400 + R 24 Weeks	<ul style="list-style-type: none"> • HCV infection, any genotype • Liver transplant 0.5 to 12 years prior to treatment 	SVR12	January 2014


6. Evidence Review (Methods & Results)

The goal of this technology assessment is to evaluate the comparative effectiveness and value of the new DAAs simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection. There were no randomized or other studies that directly compared therapies based on simeprevir to those based on sofosbuvir or to the two first generation protease inhibitors boceprevir and telaprevir. We therefore performed a network meta-analysis to provide indirect evidence about the relative efficacy of the drug combinations available using currently FDA approved therapies.

The Medline database, Embase, Cochrane clinical trials database, Cochrane reviews database, the Database of Abstracts of Reviews of Effects (DARE), the Web of Science, and BIOSIS previews were searched using the key words “simeprevir” OR “sofosbuvir.” The search was performed for the period from 1945 through January 8, 2014. Full details of the search are in the Appendix. The bibliographies of systematic reviews and key articles were manually searched for additional references. The abstracts of citations were reviewed for relevance and all potentially relevant articles were reviewed in full. Because of the paucity of published data, we included meeting abstracts, FDA documents, and press releases as sources of information. There were peer-reviewed publications for 11 of the 26 studies identified. We included all studies of simeprevir or sofosbuvir for genotypes 1, 2, or 3 that reported SVR12 or SVR24 as an outcome in at least one study arm. For the results of a study to be included in the network meta-analysis, at least one study group must have received a treatment regimen with dosing similar to the final FDA indications. For example, we did not include data from the Japanese studies of simeprevir that used 100 mg rather than 150 mg daily in our analysis, although we have included the studies in our tables. We did not treat the data from study abstracts or FDA documents differently from that abstracted from published studies. If both were available, we preferentially used data from the published study. The major phase 3 trials of telaprevir and boceprevir were included for the network meta-analysis.⁵¹⁻⁵⁸

The search identified 327 potentially relevant studies (see Figure 1 on the next page). After elimination of duplicate and non-relevant references, the search identified 21 publications and abstracts describing clinical trials of simeprevir^{37,59-68} or sofosbuvir.^{62,69-79} The primary reasons for study exclusion were (a) early dose finding studies, (b) lack of SVR or other clinical outcomes, or (c) reviews and commentaries.

Figure 1. Selection of Studies for Inclusion in Review.



The four most important outcomes in chronic HCV infection are the development of decompensated liver cirrhosis, hepatocellular carcinoma, liver transplantation, or death from liver-related causes. Because HCV has such a long natural history (20-40 years before the development of cirrhosis), large randomized trials with long follow-up are needed to demonstrate improvement in these outcomes. None of the studies identified in the search evaluated these four outcomes. For new drug evaluation, the primary outcome has been the sustained absence of HCV viral RNA for at least 24 weeks after the end of therapy (SVR24). The FDA has accepted recent studies with a primary outcome of SVR 12 weeks after the end of therapy, and SVR12 was the primary outcome for all of the phase 3 studies of simeprevir and sofosbuvir.

The vast majority of patients with SVR at 24 weeks (SVR24) remain HCV free during long-term follow-up. In several studies with five or more years of follow-up, 91% to 100% of patients remained virus free.⁸⁰⁻⁸³ Additionally, patients with SVR24 have marked improvements or normalization of their ALT as well as improvements in liver histology.⁸⁰⁻⁸⁵ More importantly, SVR24 has been associated with improvements in quality of life and a reduction in fatigue within months of treatment.^{86,87} Recent studies have demonstrated that SVR24 is associated with decreases in decompensated liver disease, hepatocellular carcinoma, liver transplant, and all-cause mortality.^{80,88-92} For example, in the HALT-C trial, the investigators prospectively followed 549 patients with advanced fibrosis who received treatment with PR (140 patients with SVR; 309 patients with non-response to therapy) for a median of approximately 7 years.⁸⁹ The primary outcomes were death, liver transplant, death from liver-related causes, and decompensated liver failure. There was more than an 80% reduction in all clinically important outcomes including death or liver transplantation (HR=0.17, 95% CI: 0.06–0.46), decompensated liver disease or death from liver-related causes (HR=0.15, 95% CI: 0.06–0.38), and incident HCC (HR=0.19, 95% CI: 0.04–0.80).

In a much larger observational study of VA patients using data from their electronic medical record, the benefits of achieving SVR were somewhat lower. Over six years of follow-up, there was a 27% reduction in liver-related complications (HR 0.73, 95% CI 0.66 to 0.82) and a 45% reduction in all-cause mortality (HR 0.55, 95% CI 0.47 to 0.64). The VA study compared patients with an undetectable viral load at one point in time following therapy to those with no documentation of an undetectable viral load.⁹² Confounding by indication (sicker patients may be more likely to receive treatment) in the VA study may explain some of the difference between it and studies like HALT-C, which compared responders to non-responders in a population of treated patients.

All of the studies linking SVR to clinical outcomes are observational and thus may be subject to residual confounding. In addition, it is important to note that among patients with SVR, those with cirrhosis prior to treatment were still at risk for HCC during follow-up.^{80,81,83,88,89,93} Thus achieving an SVR24 will not prevent the complications of chronic HCV infection for all patients.

6.1 Overview of the Key Studies of Simeprevir and Sofosbuvir

There are data available from 11 trials of simeprevir (see Table 3 on next page). There are two published phase 2 trials (PILLAR, ASPIRE), three unpublished phase 3 trials (QUEST-1, QUEST-2, PROMISE), one published Japanese trial (DRAGON), and four additional unpublished Japanese trials (CONCERTO 1-4). There are also data presented at conferences on a trial combining simeprevir with sofosbuvir (COSMOS). All 11 trials enrolled only patients with genotype 1 HCV infections who were eligible to receive interferon. Six of the trials enrolled treatment-naïve patients and five enrolled treatment-experienced patients. For completeness, an ongoing trial in HIV co-infected patients is

also listed in the table. None of the trials (except the ongoing trial in HIV co-infected patients) compared simeprevir plus PR to either boceprevir or telaprevir plus PR.

Table 3. Overview of the Clinical Trials of Simeprevir (aka TMC435).

Study	Publication	Treatment	Control	Genotypes	Treatment	IFN Eligible	Prevalence of Cirrhosis (%)
<i>Phase 2</i>							
PILLAR	Fried 2013	SMV + PR	PR	1	Naïve	Yes	0
ASPIRE	Zeuzem 2014	SMV + PR	PR	1	Experienced	Yes	18
<i>Phase 3</i>							
QUEST 1		SMV + PR	PR	1	Naïve	Yes	12
QUEST 2		SMV + PR	PR	1	Naïve	Yes	9
PROMISE		SMV + PR	PR	1	Experienced	Yes	15
<i>Japan</i>							
CONCERTO-1		SMV + PR	PR	1	Naïve	Yes	
CONCERTO-2		SMV + PR		1	Experienced	Yes	
CONCERTO-3		SMV + PR		1	Experienced	Yes	
CONCERTO-4		SMV + PR		1	Naïve/Exp	Yes	
DRAGON	Hayashi 2013	SMV + PR	PR	1	Naïve	Yes	0
<i>Other</i>							
COSMOS	Cohort 1	SOF + SMV ± R	None	1	Experienced	Yes	0
<i>HIV co-infected</i>							
C212		SMV + PR	None	1	Naïve/Exp	Yes	12

The clinical trial data for sofosbuvir are more complex (see Table 4 on the next page). There are data available from 12 trials of sofosbuvir plus one ongoing trial in HIV co-infected patients and one trial in patients awaiting transplant for HCC. There are three published phase 2 trials (PROTON, ELECTRON, ATOMIC), two unpublished phase two trials (P7977-0221, QUANTUM), four published phase 3 trials (FISSION, POSITRON, FUSION, NEUTRINO), one unpublished phase 3 trial (VALENCE), and one published NIH trial (SPARE). The same trial that combines simeprevir with sofosbuvir (COSMOS) is also included in the table. The trials of sofosbuvir enrolled a mix of patients with genotypes 1 through 6 and a mix of treatment-naïve and experienced patients, although they primarily focused on genotypes 2 and 3. One study focused on patients with genotypes 2 and 3 who were unwilling or unable to take interferon or were intolerant of interferon (POSITRON). Three of the 12 trials were randomized trials with PR control groups (P7977-0221, PROTON, FISSION), and one randomized trial had a placebo only control group (POSITRON). The remaining eight trials had no control group. None of the trials compared sofosbuvir to PR plus either boceprevir or telaprevir.

Table 4. Overview of the Clinical Trials of Sofosbuvir (GS-7977).

Study	Publication	Treatment	Control	Genotypes	Treatment	IFN Eligible	Prevalence of Cirrhosis (%)
<i>Phase 2</i>							
P7977-O221	-	SOF + PR	PR	1	Naïve	Yes	0
PROTON	Lawitz 2013b	SOF + PR	PR	1, 2, 3	Naïve	Yes	0
ELECTRON	Gane 2013	SOF + PR	None	1, 2, 3	Naïve/Exp	Yes	0
ATOMIC	Kowdley 2013	SOF + PR	None	1, 4, 5, 6	Naïve	Yes	0
QUANTUM	-	SOF + R	None	1, 2, 3, 4, 5, 6	Naïve	Yes	6
<i>Phase 3</i>							
FISSION	Lawitz 2013a	SOF + R	PR	2, 3	Naïve	Yes	20
POSITRON	Jacobson 2013	SOF + R	Placebo	2, 3	Naïve/Exp	Intolerant, unwilling, or ineligible	16
FUSION	Jacobson 2013	SOF + R	None	2, 3	Experienced	Yes	34
NEUTRINO	Lawitz 2013a	SOF + PR	None	1, 4, 5, 6	Naïve	Yes	17
VALENCE		SOF + R	None	2, 3	Naïve/Exp	Yes	
<i>Other</i>							
SPARE	Osinusi 2013	SOF + R	None	1	Naïve	Yes	23
COSMOS		SOF + SMV ± R	None	1	Experienced	Yes	
<i>HIV co-infected</i>							
PHOTON-1		SOF + R	None	1, 2, 3	Naïve GT 1 Exp GT 2/3	Not specified	Up to 20
<i>Pre-transplant</i>							
P7977-2025		SOF + R	None	Any	Naïve/Exp	Yes	100% HCC

Several key differences between the studies of simeprevir and sofosbuvir emerge when looking at Tables 3 and 4. First, simeprevir has only been studied in patients infected with genotype 1, while sofosbuvir has been studied across all genotypes. Second, all three of the phase 3 studies of simeprevir were randomized trials with PR as the control. Only one of the phase 3 trials of

sofosbuvir was a randomized trial with PR as a control (FISSION), and one trial had a placebo control (POSITRON). The phase 3 randomized, placebo controlled trials for sofosbuvir were all in patients infected with HCV genotypes 2 or 3. Third, seven of the sofosbuvir trials are interferon-free. The only interferon-free regimen that includes simeprevir is a regimen in which simeprevir is combined with sofosbuvir (COSMOS). Finally, none of the trials in patients with HCV genotype 1 were randomized trials comparing a new regimen to the previous standard of care for the treatment of genotype 1: boceprevir or telaprevir plus PR.

6.2 SVR Outcomes of Treatment of HCV Genotype 1 in Treatment-naïve Patients

Table 5 on the following page summarizes the results of the major studies of the two new DAAs in treatment-naïve patients with genotype 1. All of the studies excluded patients with HIV, hepatitis B, decompensated cirrhosis, or other significant illnesses. The treatment dosing regimens that match the FDA indication are highlighted and in bold. The primary outcome for most studies was SVR12, but some of the early studies were designed to look at SVR24 and some studies report both. No studies report long-term outcomes.

Interferon-eligible Patients

The PILLAR study was a randomized, double-blind, placebo controlled dose finding study comparing four different dosing regimens for simeprevir to standard PR therapy. The primary outcome was SVR24, which ranged from 75% to 86% compared to 65% for PR. The SVR12 results were slightly higher. The DRAGON study performed in Japan used a similar design with slightly lower doses of simeprevir and found similar results.

The two phase 3 trials, QUEST-1 and QUEST-2, randomized almost 400 patients 2:1 to 12 weeks of simeprevir 150 mg daily plus PR or to a placebo plus PR. The studies had almost identical results: the SVR12 was 80% for simeprevir plus PR versus 50% for PR alone. Subgroup analyses that pooled the results for these two studies showed expected differences by risk factors for poor response to PR. In the IL28B CC genotype subgroup, the SVR12 was 95% for simeprevir plus PR and 80% for PR alone; in the less favorable IL28B TT genotype, the SVR12 was 61% for simeprevir plus PR and 21% for PR alone. The findings were similar in subgroups defined by the METAVIR fibrosis score and by genotype 1a and 1b: outcomes were worse across all poor prognosis subgroups, but the SVR12 of simeprevir plus PR was significantly greater than that of PR alone.

Table 5. HCV Genotype 1 Treatment-naïve Patients.

Study	Treatment Arm	N	SVR12	SVR24
<i>IFN-eligible</i>				
PILLAR	SMV 75 12 Weeks + PR	78	83%	82%
	SMV 75 24 Weeks + PR	75	76%	75%
	SMV 150 12 Weeks + PR	77	80%	80%
	SMV 150 24 Weeks + PR	79	86%	86%
	PBO + PR	77	66%	65%
QUEST 1	SMV 150 12 Weeks + PR	264	80%	
	PBO + PR	130	50%	
QUEST 2	SMV 150 12 Weeks + PR	257	81%	
	PBO + PR	134	50%	
DRAGON	SMV 50 12 Weeks + PR	27	78%	
	SMV 50 24 Weeks + PR	13	77%	
	SMV 100 12 Weeks + PR	26	77%	
	SMV 100 24 Weeks + PR	13	92%	
	PR	13	46%	
CONCERTO-1	SMV 100 12 Weeks + PR	123	89%	
	PBO + PR	60	62%	
CONCERTO-4	SMV 100 12 Weeks + PR	24	92%	
P7977-0221	SOF 100 4 Weeks + PR	16		56%
	SOF 200 4 Weeks + PR	18		83%
	SOF 400 4 Weeks + PR	15		80%
	PBO + PR	14		21%
PROTON	SOF 200 12 Weeks + PR	48	90%	85%
	SOF 400 12 Weeks + PR	47	91%	89%
	PBO + PR	26	58%	58%
ELECTRON	SOF 400 + R 12 Weeks	25	84%	84%
ATOMIC	SOF 400 12 Weeks + PR	52	90%	89%
	SOF 400 24 Weeks + PR	109	93%	89%
	SOF 400 36 Weeks + PR	155	91%	87%
QUANTUM	SOF 400 + R 12 Weeks	19	53%	
	SOF 400 + R 24 Weeks	19	47%	
NEUTRINO	SOF 400 12 Weeks + PR	292	89%	
SPARE	SOF 400 12W + Wt R	10	90%	
	SOF 400 12W + Wt R	25	68%	
	SOF 400 12W + low R	25	48%	
<i>IFN-ineligible</i>				
- No studies				

Note: The treatment dosing regimens that match the FDA indication are highlighted and in bold.


The one exception was for patients with the Q80K polymorphism. The prevalence of the Q80K polymorphism was 16%, and it occurred almost exclusively in HCV genotype 1a. Among the 128 patients with the Q80K polymorphism, the SVR12 was only 58% for simeprevir and 52% for PR (difference NS). However, among the 648 patients without the Q80K polymorphism, the SVR12 was 85% for simeprevir and 49% for PR (difference NS). Most coverage policies and guidelines recommend using simeprevir in patients without the Q80K polymorphism.

The studies of sofosbuvir in treatment-naïve patients infected with genotype 1 were primarily dose finding studies. The largest was the ATOMIC study, which compared 12, 24, and 36 weeks of sofosbuvir in conjunction with PR but had no control group without sofosbuvir. The SVR12 ranged from 90% to 93%. The NEUTRINO study was an open-label, single group study of sofosbuvir plus PR for 12 weeks that had the largest group of participants receiving the FDA indication dosing. The SVR12 in NEUTRINO was 89%. As with simeprevir, the SVR12 of sofosbuvir + PR varied by subgroups defined by known predictors of response to PR therapy. In the NEUTRINO study, the SVR12 for the IL28B CC genotype subgroup was 98% and in the less favorable non-CC genotype, the SVR12 was 87%. There was no control group for comparison. The SVR12 was 92% in patients with no cirrhosis and 80% in those with cirrhosis. Similarly, the SVR12 was 92% in patients with genotype 1a and 82% in those with genotype 1b.

Network Meta-Analysis Comparing Drug Regimens for Genotype 1 Treatment-naïve Patients

The lack of head-to-head trials makes it difficult to assess the relative efficacy of the different drug regimens for treatment-naïve patients infected with HCV genotype 1. Boceprevir + PR, telaprevir + PR, simeprevir + PR, and sofosbuvir + PR have all been compared to PR alone, but not to each other. Since the mix of patients with risk factors that influence response to therapy (IL28B genotype, fibrosis score, genotype 1a versus 1b, viral load, sex, race, age, etc.) vary from study to study, the SVR12 for any treatment group is not a fair assessment of the overall effectiveness of a treatment regimen. To assess the relative efficacy of the five treatment options, we performed a network meta-analysis, a form of indirect comparison that synthesizes direct and indirect evidence in a network of clinical trials that compare multiple interventions for the same indication.¹²⁵⁻¹²⁷ Network meta-analysis allows for indirect comparisons between therapies as long as they have the same type of control group (often placebo) in randomized trials. We used frequentist estimation procedures implemented in Stata version 13.1 (College Station, Texas) to perform the network meta-analysis; a random-effects approach was employed to account for inconsistency in SVR estimates across trials.^{125,128} The structure of our network meta-analysis is depicted graphically in Figure 2 on the following page.

Figure 2. Network Plot for Clinical Trials of Treatment-naïve Patients with HCV Genotype 1.



The size of each node represents the number of participants receiving that treatment. The thickness of the line connecting them represents the number of patients in the comparison.

For the studies of simeprevir, we excluded subjects with the Q80K polymorphism. Three of the four trials of sofosbuvir in treatment-naïve patients with genotype 1 infections did not have a PR control group. Because these three trials (ELECTRON, ATOMIC, NEUTRINO) represent 93% of the patients treated with sofosbuvir, we think it is important to include them in the network meta-analysis. For each of the three trials, we assumed that there was a control group with an equal number of participants as the sofosbuvir + PR treatment group and assumed that the SVR12 in the control group would be the same as that observed in the control group of the PROTON trial (57.7%). Under those assumptions, the results of the network meta-analysis are shown in Table 6 on the following page.

Table 6. Summary Estimates from the Network Meta-Analysis for SVR12 Among Treatment-naïve Patients Infected with HCV Genotype 1.

Treatment	SVR12	95% CI	P versus PR
PR	47%	41% to 52%	-
Boceprevir + PR	73%	68% to 77%	<0.001
Telaprevir + PR	74%	69% to 79%	<0.001
Simeprevir + PR*	84%	78% to 88%	<0.001
Sofosbuvir + PR	83%	79% to 87%	<0.001

*Excludes patients with the Q80K polymorphism

The summary estimates suggest that both the simeprevir and sofosbuvir regimens have similar SVR12 results and that both are superior to triple therapy using either boceprevir or telaprevir. Although the confidence intervals look similar, it is important to remember that the sofosbuvir + PR estimate is based on extrapolations from uncontrolled trials and should be considered to have greater uncertainty than the confidence interval suggests.

The summary estimates for simeprevir and sofosbuvir from the network meta-analysis are lower than those observed in the clinical trials. This is because the meta-analysis estimates are based on the relative improvement in SVR compared to the SVR for the PR control group. The summary SVR estimate from the meta-analyses for PR was 47%, which is similar to accepted estimates from the literature (40% to 50%).³⁹⁻⁴¹ However, the PR control groups in the trials of simeprevir and sofosbuvir had higher SVRs (50% to 65% for simeprevir and 57.7% for sofosbuvir). These differences in the SVR for the PR control groups likely reflect the underlying distribution of risk factors for response to therapy, with patients enrolling in the trials of simeprevir and sofosbuvir having a higher prevalence of favorable risk factors (or fewer unfavorable risk factors). For instance, the prevalence of cirrhosis was relatively low among patients in the trials of simeprevir and sofosbuvir (see Tables 3 and 4 above). The trials of the newer drugs may also have more patients with the favorable IL28B CC genotype and more patients with 1a rather than 1b genotype. One of the advantages of the network meta-analysis is that it partially accounts for the differences in the response rates for the control groups across all of the studies.

Interferon-ineligible Patients

There were no studies for interferon-ineligible patients in this population. However, the COSMOS trial evaluated four interferon-free regimens in treatment-experienced patients and had a high SVR12. Treatment-naïve patients usually have higher SVR12s than similar patients who are treatment-experienced, so it is likely that the combination of simeprevir plus sofosbuvir would result in an SVR12 > 90% in treatment-naïve, interferon-ineligible patients.

In addition, there were 19 treatment-naïve patients treated with the FDA-approved alternate regimen of sofosbuvir plus ribavirin for 24 weeks. The SVR12 in that patient subset was 47%.

In summary, for treatment-naïve patients infected with HCV genotype 1, simeprevir + PR and sofosbuvir + PR have greater SVR12 than both PR alone and either boceprevir or telaprevir + PR. Simeprevir plus PR in patients without the Q80K polymorphism and sofosbuvir plus PR appear to have similar response rates, but most of the data for sofosbuvir come from uncontrolled studies. We did not identify any studies with SVR12 data on treatment-naïve patients who are interferon-ineligible, but the COSMOS study results, while uncontrolled, suggest that the combination of simeprevir plus sofosbuvir is promising.

6.3 SVR Outcomes of Treatment of HCV Genotype 1 in Treatment-experienced Patients

Table 7 on the following page summarizes the results of the major studies of simeprevir and sofosbuvir in treatment-experienced patients with genotype 1. All of the studies excluded patients with HIV, hepatitis B, decompensated cirrhosis, or other significant illnesses. The treatment dosing regimens that match the FDA indication are highlighted and in bold. The primary outcome for most studies was SVR12, but some of the early studies were designed to look at SVR24, and some studies report both. No studies report long-term outcomes.

Interferon-eligible Patients

The ASPIRE study was a randomized, double-blind, placebo controlled dose finding study comparing six different dosing regimens for simeprevir + PR to standard PR therapy. The primary outcome was SVR24, which ranged from 61% to 80% compared to 23% for PR. The SVR24 for the FDA approved dosing for simeprevir + PR was 67%. As expected, the results in this study are somewhat lower than those observed in the similar PILLAR study, which was performed in a treatment-naïve population.

Table 7. Clinical Trial Results for HCV Genotype 1 Treatment-experienced Patients.

Study	Treatment Arm	N	SVR12	SVR24
<i>IFN-eligible</i>				
ASPIRE	SMV 100 12 Weeks + PR	66		70%
	SMV 100 24 Weeks + PR	65		66%
	SMV 100 48 Weeks + PR	66		61%
	SMV 150 12 Weeks + PR	66		67%
	SMV 150 24 Weeks + PR	68		72%
	SMV 150 48 Weeks + PR	65		80%
	PBO + PR	66		23%
PROMISE	SMV 150 12 Weeks + PR	260	79%	
	PBO + PR	133	37%	
CONCERTO-2	SMV 100 12 Weeks + PR	53	53%	
	SMV 100 24 Weeks + PR	53	36%	
CONCERTO-3	SMV 100 12 Weeks + PR	49	96%	
CONCERTO-4	SMV 100 12 Weeks + PR	55	71%	
ELECTRON	SOF 400 + R 12 Weeks	10	10%	10%
COSMOS	SOF + SMV 12 Weeks	14	93%	
	SOF + SMV + R 12 Weeks	27	96%	
	SOF + SMV 24 Weeks	15	93%	
	SOF + SMV + R 24 Weeks	24	79%	
<i>IFN-ineligible</i>				
- No studies				

The phase 3 trial, PROMISE, randomized 400 patients 2:1 to 12 weeks of simeprevir 150 mg daily plus PR or to a placebo plus PR. It is worth noting that the participants were all patients who had relapsed following prior treatment and not partial or null responders. This group tends to have a better response to retreatment than patients who never achieved complete viral suppression during prior therapy. In the PROMISE trial, the SVR12 was 79% for simeprevir + PR and was 37% for PR alone. Subgroup analyses in PROMISE showed expected differences by risk factors for poor response to PR. For example, in the less favorable genotype 1a subgroup, the SVR12 was 70% for simeprevir + PR and 28% for PR alone; in the genotype 1b subgroup, the SVR12 was 86% for simeprevir + PR and 43% for PR alone. Among the 341 patients without the Q80K polymorphism, the SVR12 was 83% for simeprevir + PR and 38% for PR alone.

There is only one small, uncontrolled study of sofosbuvir in treatment-experienced patients infected with HCV genotype 1: a single arm of the ELECTRON study with 10 participants. These 10 individuals were treated with 400 mg of sofosbuvir and ribavirin for 12 weeks: only one participant achieved a sustained virologic response (SVR12 = 10%). This was an interferon-free regimen that does not correspond to the FDA-approved dosing. Because there were essentially no data on sofosbuvir in treatment-experienced patients, the manufacturer's application to the FDA extrapolated from the outcomes of the treatment-naïve patients in the NEUTRINO study who had


poor prognostic factors. Based on prior FDA publications,⁹⁴⁻⁹⁶ the manufacturer argued, and the FDA accepted, that this would be a reasonable estimate for the SVR12 for treatment-experienced patients retreated with sofosbuvir + PR. The SVR12 for the 52 patients in NEUTRINO with “poor prognostic factors” was 71%.

Finally, there is one small study (COSMOS) that evaluated the combination of simeprevir and sofosbuvir with and without ribavirin for 12 or 24 weeks in 80 treatment-experienced genotype 1 patients with METAVIR F0 to F2 scores. There was no control arm for the study. Three of the four arms had remarkable 93% to 96% SVR12 outcomes. The fourth arm was the most intense (24 weeks of the combination plus ribavirin) but had the lowest SVR12 (79%). This appears to be due to participants lost to follow-up, although the data have only been presented in abstract form, so the details are not clear. Of note, there is a second part of the COSMOS trial in patients with METAVIR F3 or F4 fibrosis scores that has not yet announced its SVR12 results.

Network Meta-Analysis Comparing Drug Regimens for Genotype 1 Treatment-experienced Patients

The lack of head-to-head trials makes it difficult to assess the relative efficacy of the different treatments for treatment-experienced patients infected with HCV genotype 1. To estimate the relative efficacy of the five treatment options, we performed a network meta-analysis (see Figure 3 on the following page).

Figure 3. Network Plot for Clinical Trials of Treatment-experienced Patients with HCV Genotype 1.



The size of each node represents the number of participants receiving that treatment. The thickness of the line connecting them represents the number of patients in the comparison.

As in the prior network meta-analysis, we excluded patients with the Q80K polymorphism from the simeprevir results. We did not include sofosbuvir + PR regimens because of the lack of data. However, we did include data on sofosbuvir plus simeprevir from the COSMOS trial. We pooled the results from the four arms of this study because the results were similar, and we wanted to increase the power to evaluate the combination therapy (72/80 = 90% SVR12). We had to assume that there was a control group with an equal number of participants as the simeprevir + sofosbuvir treatment group and assumed that the SVR12 in the control group would be the same as the summary estimate for the control group of the other trials (22%). Under those assumptions, the results of the network meta-analysis are shown in Table 8 on the following page.

Table 8. Summary Estimates for the Network Meta-Analysis for SVR12 Among Treatment-experienced Patients Infected with HCV Genotype 1.

Treatment	SVR12	95% CI	P versus PR
PR	22%	15% to 29%	-
Boceprevir + PR	64%	49% to 76%	<0.001
Telaprevir + PR	70%	61% to 77%	<0.001
Simeprevir + PR*	70%	58% to 79%	<0.001
Sofosbuvir + PR	?	?	?
Simeprevir + sofosbuvir	90%	78% to 96%	<0.001

* Excludes patients with the Q80K polymorphism

The summary estimates for the treatment-experienced population suggest that the SVR12 for simeprevir-based therapy is about the same as that for triple therapy with boceprevir and telaprevir with broadly overlapping confidence intervals. The combination of simeprevir plus sofosbuvir has the highest estimated SVR12, although it is important to remember that this estimate is based on extrapolations from one uncontrolled trial and should be considered to have greater uncertainty than the confidence interval suggests. There are no data for sofosbuvir + PR, and the small subgroup of 10 patients in the ELECTRON trial treated with sofosbuvir plus R only had an SVR of 10%.

It is worth noting that the summary estimate for the combination of simeprevir plus sofosbuvir from the network meta-analysis is identical to the SVR12 derived from the COSMOS study. This is because there was only one study for that combination, and the estimate that we used for the PR control group was assumed to be identical to the summary estimate (22%) for the PR control group across all studies of treatment-experienced patients. If the true SVR12 for the 80 control patients enrolled in the COSMOS trial is higher than 22%, then our estimate for simeprevir plus sofosbuvir would be too high. Conversely, if the true SVR12 for the patients enrolled in the COSMOS trial is lower than 22%, then our estimate for simeprevir plus sofosbuvir would be too low.

Interferon-ineligible Patients

There were no studies for interferon-ineligible patients in this population. However, the COSMOS trial evaluated four interferon-free regimens in treatment-experienced patients and had a high SVR12, which suggests that it could be considered for use in this population.

In summary, for treatment-experienced patients infected with HCV genotype 1, simeprevir + PR has a greater SVR12 than PR alone and appears to have similar response rates to boceprevir or telaprevir. The combination of simeprevir plus sofosbuvir may have the greatest SVR12, but the data are sparse, and it is not clear whether ribavirin is needed, although it appears that 12 weeks of treatment is about equivalent to 24 weeks of treatment. Finally there are insufficient data to evaluate sofosbuvir plus ribavirin and no data on sofosbuvir plus PR.

6.4 SVR Outcomes of Treatment of HCV Genotype 2 in Treatment-naïve Patients

The assessment of SVR outcomes is more straightforward for genotypes 2 and 3 because simeprevir, telaprevir, and boceprevir have not been evaluated or approved for genotypes 2 and 3. However, since the SVR24 for PR alone is between 75% and 85% in this population, there is less room for improvement. Table 9 on the following page summarizes the results of the major studies of sofosbuvir in treatment-naïve patients with genotype 2. Again, all of the studies excluded patients with HIV, hepatitis B, or other significant illnesses. The treatment dosing regimens that match the FDA indication are highlighted and in bold. The primary outcome for most studies was SVR12, but some of the early studies were designed to look at SVR24, and some studies report both. No studies report long-term outcomes.

Interferon-eligible Patients

The ELECTRON study was a randomized, double-blind, dose finding study comparing six different dosing regimens for sofosbuvir. The study did not include a control arm with standard PR therapy. It also included a mix of both genotype 2 and 3 patients. Five of the six arms of the study had 100% SVR24, and two of them were interferon-free. The sofosbuvir-only arm had a lower 60% SVR24. Several other relatively small studies had similar findings.

Table 9. Clinical Trial Results for HCV Genotype 2 Treatment-naïve Patients.

Study	Treatment Arm	N	SVR12	SVR24
<i>IFN-eligible</i>				
ELECTRON	SOF 400 + R 12 Weeks + P 0 Weeks	10*	100%*	100%*
	SOF 400 + R 12 Weeks + P 4 Weeks	9*	100%*	100%*
	SOF 400 + R 12 Weeks + P 8 Weeks	10*	100%*	100%*
	SOF 400 + R 12 Weeks + P 12 Weeks	11*	100%*	100%*
	SOF 400 12 Weeks	10*	60%*	60%*
	SOF 400 + PR 8 Weeks	10*	100%*	100%*
PROTON	SOF 400 12 Weeks + PR	25*	92%*	92%*
QUANTUM	SOF 400 + R 12 Weeks	6*	67%*	
	SOF 400 + R 24 Weeks	6*	67%*	
FISSION	SOF 400 + R 12 Weeks	70	97%	
	PR 24 Weeks	67	78%	
VALENCE	SOF 400 + R 12 Weeks	32	97%	
<i>IFN-ineligible</i>				
POSITRON**	SOF 400 + R 12 Weeks	109**	93%**	
	PBO	34**	0%**	

*Mix of GT 2 and 3: the results were not presented separately

** Mix of treatment-naïve and experienced, but ~ 81% were treatment-naïve

Note: The treatment dosing regimens that match the FDA indication are highlighted and in bold.

The phase 3 trial, FISSION, was an open-label study that randomized 137 treatment-naïve genotype 2 patients to 12 weeks of sofosbuvir plus ribavirin or 24 weeks of PR. In the FISSION trial, the SVR12 was 97% for sofosbuvir plus ribavirin and was 37% for PR. Subgroup analyses in FISSION showed expected differences by risk factors for poor response to PR (see Table 10 on the following page).

Table 10. SVR12 for Key Subgroups of Patients with Genotype 2 in the FISSION Study.

Risk factor	Sofosbuvir + ribavirin	PR
Cirrhosis		
Yes	98%	81%
No	91%	62%
IL28B genotype		
CC	100%	82%
Non-CC	95%	72%
HCV RNA viral load		
< 6 log ₁₀ IU/ml	100%	74%
≥ 6 log ₁₀ IU/ml	96%	80%
Race		
Black	75%	50%
Non-black	98%	78%
Body mass index		
< 30 kg/m ²	100%	78%
≥ 30 kg/m ²	90%	77%

Interferon-ineligible Patients

The POSITRON trial was a double-blind, placebo-controlled trial that randomized interferon-unwilling (47%), interferon-ineligible (44%) and interferon-intolerant (9%) patients to 12 weeks of sofosbuvir plus ribavirin or 12 weeks of identical placebos. It is the only trial addressing this group of patients. Because the majority of these patients (91%) were treatment-naïve, the results primarily apply to treatment-naïve patients. As expected, the SVR12 was higher in the active treatment group (93% versus 0%) and similar to the SVR12 observed in the VALENCE and FUSION trials.

In summary, for treatment-naïve patients with genotype 2, sofosbuvir is a clear improvement over the previous standard of care. This is in fact the only treatment group for which there is randomized trial evidence documenting a clinically and statistically significant improvement of a sofosbuvir-based regimen compared to standard treatment. In addition, the treatment time is decreased from 24 to 12 weeks, and interferon is no longer needed, so the burden of injections and the side effects of interferon are avoided. All patients with genotype 2 can be treated with this regimen including those unwilling, unable, or intolerant of interferon.

6.5 SVR Outcomes of Treatment of HCV Genotype 2 in Treatment-experienced Patients

Interferon-eligible Patients

There are fewer data for treatment-experienced patients with genotype 2 (see Table 11 below), and neither of the trials had a control group without sofosbuvir. In the FUSION trial, 36 treatment-experienced patients were treated with 12 weeks of sofosbuvir plus ribavirin. The SVR12 was 86% (95% CI 71% to 95%). Similarly, in the VALENCE trial, the SVR12 was 90% (95% CI 77% to 97%). Because both studies were uncontrolled, it is unclear how much better these results are than those that would have been obtained with retreatment with PR. In one recent published study, retreatment treatment-experienced patients with genotypes 2 or 3 with PR led to SVRs ranging from 53% to 81%.⁹⁷ However, a treatment regimen of sofosbuvir plus ribavirin has the advantage of being both shorter and interferon-free.

Table 11. Clinical Trial Results for HCV Genotype 2 Treatment-experienced Patients.

Study	Treatment Arm	N	SVR12	SVR24
<i>IFN-eligible</i>				
FUSION	SOF 400 + R 12 Weeks	36	86%	
	SOF 400 + R 16 Weeks	32	94%	
VALENCE	SOF 400 + R 12 Weeks	41	90%	
<i>IFN-ineligible</i>				
POSITRON*	SOF 400 + R 12 Weeks	17*	76%*	
	PBO	8*	0%*	

*Mix of GT 2 and 3: the results were not presented separately

Note: The treatment dosing regimens that match the FDA indication are highlighted and in bold.

Interferon-ineligible Patients

The POSITRON trial was a double-blind, placebo-controlled trial that randomized 25 interferon-intolerant patients to 12 weeks of sofosbuvir plus ribavirin or 12 weeks of identical placebos. The interferon-intolerant by definition must be treatment-experienced. The investigators did not present the data in this subgroup separately for genotype 2 and genotype 3. In the combined group, the SVR12 in the sofosbuvir + R group was 76.5% (95% CI 50% to 93%). It is the only trial addressing this group of patients.

6.6 SVR Outcomes of Treatment of HCV Genotype 3 in Treatment-naïve Patients

In contrast to findings for patients with genotype 2 infection, the clinical trial results for genotype 3 are a bit more complex (see Table 12 below). It should be noted that there are no randomized trial data demonstrating the superiority of sofosbuvir + PR to PR in interferon-eligible patients. The results from the dose-finding ELECTRON study were encouraging as described above. However, in the genotype 3 subgroup of the randomized phase 3 FISSION trial, 12 weeks of sofosbuvir plus ribavirin had a lower SVR12 than 24 weeks of PR (56% versus 62%). The SVR12 of the same regimen in the genotype 3 subgroup of the POSITRON study was similarly low at 61%. The uncontrolled VALENCE trial tested a longer 24 week regimen of sofosbuvir and ribavirin. In this cohort of patients infected with HCV genotype 3, the SVR12 was 93% (95% CI 87% to 97%). These results should be confirmed in a second trial, but they formed the basis for the FDA recommended dose. Again, this treatment has the advantage of being interferon-free, but for genotype 3, it is not shorter than PR retreatment.

Table 12. Clinical Trial Results for HCV Genotype 3 Treatment-naïve Patients.

Study	Treatment Arm	N	SVR12	SVR24
<i>IFN-eligible</i>				
ELECTRON	SOF + R 12 Weeks + P 0 Weeks	10*	100%*	100%*
	SOF + R 12 Weeks + P 4 Weeks	9*	100%*	100%*
	SOF + R 12 Weeks + P 8 Weeks	10*	100%*	100%*
	SOF + R 12 Weeks + P 12 Weeks	11*	100%*	100%*
	SOF 12 Weeks	10*	60%*	60%*
	SOF + R 8 Weeks	10*	100%*	100%*
PROTON	SOF 400 12 Weeks + PR	25*	92%*	92%*
QUANTUM	SOF + R 12 Weeks	6*	67%*	
	SOF + R 24 Weeks	6*	67%*	
FISSION	SOF + R 12 Weeks	183	56%	
	PR 24 Weeks	176	62%	
VALENCE	SOF 400 + R 24 Weeks	105	93%	
<i>IFN-ineligible</i>				
POSITRON**	SOF + R 12 Weeks	98**	61%**	
	PBO	37**	0%**	

*Mix of GT 2 and 3: the results were not presented separately

** Mix of treatment-naïve and experienced, but ~ 81% were treatment-naïve

6.7 SVR Outcomes of Treatment of HCV Genotype 3 in Treatment-experienced Patients

The story is similar for treatment-experienced patients with genotype 3 (see Table 13 on the next page). In the uncontrolled FUSION and VALENCE trials, the SVR12 increased from 30% to 62% to

77% as the length of treatment increased from 12 weeks to 16 weeks to 24 weeks. Because neither of these studies randomized patients to a PR arm, it is unclear if this represents an improvement over results potentially achieved with retreatment. However, it is interferon-free.

Table 13. Clinical Trial Results for HCV Genotype 3 Treatment-experienced Patients.

Study	Treatment Arm	N	SVR12	SVR24
<i>IFN-eligible</i>				
FUSION	SOF 400 + R 12 Weeks	64	30%	
	SOF 400 + R 16 Weeks	63	62%	
VALENCE	SOF 400 + R 24 Weeks	145	77%	
<i>IFN-ineligible</i>				
POSITRON*	SOF 400 + R 12 Weeks	17*	76%*	
	PBO	8*	0%*	

*Mix of GT 2 and 3: the results were not presented separately

Interferon-ineligible Patients

As noted for genotype 2 treatment-experienced patients, the POSITRON trial randomized 25 interferon-intolerant patients to 12 weeks of sofosbuvir plus ribavirin or 12 weeks of identical placebos. In the combined group of genotype 2 and 3 treatment-experienced patients, the SVR12 in the sofosbuvir + R group was 76.5% (95% CI 50% to 93%). This is much higher than the SVR12 reported in the other trials of 12 weeks of sofosbuvir + R for genotype 3, which suggests that the majority of the interferon-intolerant patients in the POSITRON study were genotype 2. It would be difficult to recommend 12 weeks of therapy for interferon-ineligible patients with genotype 3 after concluding that 24 weeks of the same therapy is required for both treatment-naïve and treatment-experienced genotype 3 patients.

In summary, for genotype 3 treatment-naïve and experienced patients, 24 weeks of sofosbuvir + R appears to be superior to 12 or 16 weeks of the same therapy. In the one trial comparing 12 weeks of sofosbuvir + R to 24 weeks of PR, the PR group had a nominally higher SVR12. The lack of control groups in the other trials makes it difficult to conclude that the SVR12 with 24 weeks of sofosbuvir + R is greater than that of 24 weeks of PR. The POSITRON data suggest that sofosbuvir + R is effective for interferon-ineligible patients with genotype 3, although the VALENCE trial suggests that 24 weeks of therapy would be more effective than 12 weeks.

6.8 Harms of Treatment

Harms of Treatment with Simeprevir

HCV genotype 1

It is reasonably straightforward to compare the harms of treatment with simeprevir in patients infected with HCV genotype 1 to the harms of treatment with PR because the three phase 3 trials (QUEST-1, QUEST-2, PROMISE) were all randomized comparisons with PR in patients with HCV genotype 1. In order to fairly assess the independent effect of simeprevir, just the first 12 weeks of therapy were compared. The adverse events (AEs) are summarized in Table 14 below.

Table 14. Summary of Adverse Events in the Randomized Trials of Simeprevir.

Adverse Event	Simeprevir + PR (12 weeks) N = 781	Placebo + PR (12 weeks) N = 397
Any Adverse Event	95%	95%
Significant Adverse Events	2.0%	2.5%
Grade 3 or 4 AE	23%	25%
Therapy stopped due to AE	2.6%	4.5%
<i>Common AEs</i>		
Fatigue	36%	40%
Headache	33%	36%
Flu-like illness	26%	21%
Insomnia	17%	17%
Anemia (hemoglobin < 10 g/dL)	12%	10%
<i>Likely associated with SMV</i>		
Pruritus	21%	14%
Nausea	22%	18%
Rash	14%	11%
Photosensitivity	3.3%	0.5%
Elevated bilirubin	2.0%	0.5%

Adverse events, significant adverse events, grade 3 or 4 AEs, and adverse events leading to treatment discontinuation were not more common with simeprevir. There was clearly more pruritis, photosensitivity-induced rashes, and hyperbilirubinemia due to simeprevir, but these were generally not severe and were easily managed. They did not result in the discontinuation of therapy. Importantly, there was no significant increase in anemia with the addition of simeprevir. As described in the background section above, the earlier protease inhibitors boceprevir and telaprevir nearly doubled the incidence of significant anemia.⁴² Overall, the addition of simeprevir to PR did not markedly increase the risk for adverse events.

Harms of Treatment with Sofosbuvir

HCV genotype 1

It is more difficult to carefully assess the relative impact of sofosbuvir on adverse events because few of the trials randomized patients to a regimen based on sofosbuvir versus a regimen without sofosbuvir. For patients infected with genotype 1, the relevant comparison is between patients on sofosbuvir plus PR and PR alone (see Table 15 below). Sofosbuvir plus PR was used in the NEUTRINO study and PR in the FISSION study. Since these are different studies and non-randomized comparisons, the comparisons may be between patients sampled from different populations.

Table 15. Summary of Adverse Events for Sofosbuvir + PR and PR Alone.

Adverse Event	Sofosbuvir + PR (12 weeks) N = 327	PR (24 weeks) N = 243
Any Adverse Event	95%	96%
Significant Adverse Events	1%	1%
Grade 3 or 4 AE	15%	19%
Therapy stopped due to AE	2%	11%
<i>Common AEs</i>		
Fatigue	59%	55%
Headache	36%	44%
Flu-like illness	16%	18%
Insomnia	25%	29%
Anemia (hemoglobin < 10 g/dL)	23%	14%
Pruritus	17%	17%
Nausea	34%	29%
Rash	18%	18%

HCV genotypes 2 and 3

For patients with genotype 2 and 3 infections, the relevant comparison is between patients on sofosbuvir plus R and PR alone. Sofosbuvir plus R was used in the FISSION, FUSION, and POSITRON studies and PR in the FISSION study. These adverse events are summarized in Table 16 on the next page. Since these are different studies and non-randomized comparisons, the comparisons may be between patients sampled from different populations.

Table 16. Summary of Adverse Events for Sofosbuvir + R and PR Alone.

Adverse Event	Sofosbuvir + R (12 weeks) N = 566	PR (24 weeks) N = 243
Any Adverse Event	88%	96%
Significant Adverse Events	4.0%	1%
Grade 3 or 4 AE	7.2%	19%
Therapy stopped due to AE	1.4%	11%
<i>Common AEs</i>		
Fatigue	40%	55%
Headache	23%	44%
Flu-like illness	2.8%	18%
Insomnia	16%	29%
Anemia (hemoglobin < 10 g/dL)	9%	14%
Pruritus	9%	17%
Nausea	20%	29%
Rash	8%	18%

It is evident here that the elimination of interferon from the treatment regimen markedly decreases the risk for most adverse events including fatigue, headache, flu-like illness, anemia, pruritus, nausea, and rashes. There were also significantly fewer grade 3 or 4 adverse events. This translates into a marked eight-fold reduction in discontinuation of therapy due to adverse events (from 11% with PR to 1.4% with sofosbuvir + R).

Harms of Treatment with the Combination of Simeprevir and Sofosbuvir with or without Ribavirin for 12 or 24 Weeks in Genotype 1 (COSMOS trial)

The harms of treatment are incompletely reported in the COSMOS trial. In Cohort 1, 100% of patients completed the 12 week regimen and 87% completed the 24 week regimen (three stopped, one due to an adverse event). No serious AEs were observed for either Cohort 1 or Cohort 2 during the 12 week regimens, but four patients treated for 24 weeks discontinued because of AEs. The most common AEs were fatigue, headache, nausea, and insomnia with more anemia and elevations in bilirubin observed in the treatment arms that included ribavirin.

6.9 Summary

Genotype 1

Table 17 on the next page summarizes the key benefits and harms for the treatment options for genotype 1. Among treatment-naïve patients, the first generation protease inhibitors increased the SVR12 from the 40% range with PR to the 70% range. The improved SVR was somewhat offset by an

increase in the complexity of the drug therapy. A large number of pills had to be taken about every 8 hours. In addition, there were burdensome new side effects added to the flu-like symptoms of interferon and the anemia and teratogenicity of ribavirin. These included a marked increase in anemia and nausea for both drugs, 20% more patients experiencing taste disturbance for boceprevir, and 20% more patients experiencing generalized pruritus with telaprevir. The drugs also have a large number of important drug interactions. Despite these problems, triple therapy with one of the two first generation protease inhibitors and PR was the previous standard of care for treatment of genotype 1.

Table 17. Summary of Benefits and Harms for Genotype 1 by Prior Treatment Status and Interferon Eligibility.

Treatment Approach (weeks)	SVR12 (Percent)	Treatment Burden	Adverse effects	Interferon-ineligible
Genotype 1				
<i>Treatment-naïve</i>				
PR (48)	47	48 weeks with weekly injections	Fatigue (50-60%), fever (40-45%), anemia ($\leq 30\%$)	No
BOC(24) + PR(48)	73	Add Q8 pills	Anemia ($\leq 50\%$), more nausea and dysgeusia, drug interactions	No
TVR(12) + PR(48)	74	Add Q8 pills	Anemia ($\leq 50\%$), more nausea and pruritus, drug interactions	No
SMV(12) + PR(24-48)*	84	Add 1 pill to PR	No increase in anemia	No
SOF(12) + PR(12)	83	Add 1 pill to PR Fewer weeks	No increase in anemia	No
SMV(12) + SOF(12)	No data (Likely >90)	No P, maybe no R	Not reported yet	Maybe
<i>Treatment-experienced</i>				
PR (48)	22	48 weeks with weekly injections	Fatigue (50-60%), fever (40-45%), anemia (up to 30%)	No
BOC(24) + PR(48)	64	Add Q8 pills	Anemia ($\leq 50\%$), more nausea and dysgeusia, drug interactions	No
TVR(12) + PR(48)	70	Add Q8 pills	Anemia ($\leq 50\%$), more nausea and pruritus, drug interactions	No
SMV(12) + PR(24-48)	67	Add 1 pill to PR	No increase in anemia	No
SOF(12) + PR(12)	No data (FDA estimate 71)	Add 1 pill to PR Fewer weeks	No increase in anemia	Maybe
SMV(12) + SOF(12)	90	No P, maybe no R	Not reported yet	Yes

Abbreviations: Q8 = taken every 8 hours; P = pegylated interferon; R = ribavirin

* Excluding patients with the Q80K mutation (approximately 10-15% of genotype 1 patients)

Simeprevir improves the SVR12 compared with triple therapy when used in patients without the Q80K polymorphism. The primary benefits of simeprevir are the reduced incidence of anemia and

the reduced pill burden: it only requires taking one pill a day. Adverse events specifically associated with simeprevir include pruritus, photosensitivity-induced rashes, and hyperbilirubinemia, but these were uncommon, generally not severe, and easily managed. The increase in pruritus compared to PR was less than that seen with telaprevir. One important finding specific to simeprevir is that its effectiveness is markedly diminished in patients with the Q80K genetic polymorphism in HCV genotype 1. If the Q80K polymorphism is present, simeprevir should not be used. Simeprevir requires PR and cannot be used to treat interferon-ineligible patients. The primary weakness in the data is the lack of head-to-head trials comparing simeprevir and one of the first generation protease inhibitors. As noted in section 5 above, there is a large (n=766) randomized trial comparing simeprevir to telaprevir that was expected to complete data collection for its primary outcome in March 2014. In addition, there are no data on the impact of treatment on long term outcomes such as the incidence of cirrhosis, liver decompensation, HCC, transplant, or death.

Sofosbuvir plus PR also appears to have less anemia and certainly has a lower pill burden than standard triple therapy. It also requires only 12 weeks of PR rather than the 24 to 48 weeks with the protease inhibitors. There are less robust comparative data on sofosbuvir + PR compared to PR alone than for simeprevir, and there are no data comparing it to PR plus simeprevir, boceprevir, or telaprevir. Because of the shorter course of PR, sofosbuvir + PR has fewer severe/life-threatening (grade 3 and 4) AEs and fewer patients discontinuing treatment due to AEs, with no consistent pattern of an increase in AEs other than anemia (23% versus 14% for PR). As with simeprevir, this combination cannot be used in patients who are interferon-ineligible, and there are no long-term outcome data.

The preliminary data on the combination of simeprevir plus sofosbuvir (an off-label use not indicated by the FDA) with or without ribavirin are encouraging. The available SVR12 data from treatment-experienced patients averaged 90%; the SVR12 of treatment-naïve patients should be even better. It is interferon-free, so can be used in interferon-ineligible patients. Since it is interferon-free (and perhaps ribavirin-free), it should have markedly lower adverse event rates than PR based treatment. The data come from four different regimens in one small study, none of which are FDA approved, and there are no detailed published results, so the findings should be considered preliminary at this point.

Genotype 2

The story is more straightforward for genotype 2 (see Table 18 on the next page). There is adequate evidence that the combination of sofosbuvir plus ribavirin improves SVR12 and is less burdensome compared to PR therapy. Among treatment-naïve patients, there was a large increase in SVR12 seen in the randomized FISSION trial and supported by the VALENCE trial, although that was not randomized. The SVR12 for treatment-experienced patients was 86% and 90% in the two

uncontrolled studies, but this was high enough to assume at least non-inferiority to PR therapy. The sofosbuvir-based regimen is interferon-free, which decreases grade 3 and 4 AEs, markedly decreases patients discontinuing therapy because of AEs, and reduces interferon-associated AEs such as fatigue, fever, myalgias, and headaches. Sofosbuvir therapy does not come with an increase in the anemia seen with the first generation protease inhibitors – in fact, the incidence of anemia was lower in the sofosbuvir arms of the trials. The treatment course is also half as long (12 versus 24 weeks). Since the sofosbuvir-based regimen is interferon-free, the benefits should be even greater in those genotype 2 patients who are treatment-naïve but ineligible for interferon because of psychiatric or other co-morbidities. In the POSITRON trial, the SVR12 was 93% compared to 0% for treatment-naïve patients, and 76% versus 0% for treatment-experienced patients.

Table 18. Summary of Benefits and Harms for Genotype 2 by Prior Treatment Status and Interferon Eligibility.

Treatment Approach (weeks)	SVR12 (Percent)	Treatment Burden	Adverse effects	Interferon-ineligible
Genotype 2				
<i>Treatment-naïve</i>				
PR (24)	78	24 weeks with weekly injections	Fatigue (50-60%), fever (40-45%), anemia (up to 30%)	No
SOF(12) + R(12)	97	Shorter, no P	Less fatigue, less anemia	Yes
<i>Treatment-experienced</i>				
PR (24)	No data	24 weeks with weekly injections	Fatigue (50-60%), fever (40-45%), anemia (up to 30%)	No
SOF(12) + R(12)	88	Shorter, no P	Less fatigue, less anemia	Yes

Abbreviations: P = pegylated interferon; R = ribavirin

Genotype 3

The story is more complex for genotype 3 (see Table 19 on the next page). The combination of sofosbuvir plus ribavirin for 12 weeks did not increase SVR12 compared to PR among treatment-naïve patients in the FISSION trial. However, the SVR12 consistently increased with increasing lengths of therapy to 16 and 24 weeks (56% to 93% in the uncontrolled VALENCE trial). The SVR12 for treatment-experienced patients increased from 30% (12 weeks) to 62% (16 weeks) to 77% (24 weeks). The sofosbuvir-based regimen is interferon-free, which as noted above, decreases grade 3 and 4 AEs, markedly decreases patients discontinuing therapy because of AEs, and reduces interferon-associated AEs such as fatigue, fever, myalgias, and headaches. Sofosbuvir therapy has a lower incidence of anemia than PR in the phase 3 trials. The treatment course is the same as PR, but without the injections and side effects of interferon. Since the sofosbuvir-based regimen is

interferon-free, the benefits should be even greater in those genotype 3 patients who are treatment-naïve but ineligible for interferon because of psychiatric or other co-morbidities. In the POSITRON trial, the SVR12 was 61% compared to 0% for treatment-naïve patients, and 76% versus 0% for treatment-experienced patients.

The quality of the evidence is much weaker for sofosbuvir in genotype 3 than in genotype 2. The randomized phase 3 trial (FISSION) reported a modestly lower SVR12 for sofosbuvir + R compared to PR. There is only one arm of an uncontrolled study (VALENCE) that reports SVR12 data on the FDA approved 24 week regimen of sofosbuvir + R. While the VALENCE study results are promising, they may overestimate the effectiveness of sofosbuvir + R for patients infected with genotype 3. Careful attention should be paid to the results of additional studies of this regimen for genotype 3.

Table 19. Summary of Benefits and Harms for Genotype 3 by Prior Treatment Status and Interferon Eligibility.

Treatment Approach (weeks)	SVR12 (Percent)	Treatment Burden	Adverse effects	Interferon-ineligible
Genotype 3				
<i>Treatment-naïve</i>				
PR (24)	62	24 weeks with weekly injections	Fatigue (50-60%), fever (40-45%), anemia (up to 30%)	No
SOF(24) + R(24)	93	Shorter, no P	Less fatigue, less anemia	Yes
<i>Treatment-experienced</i>				
PR (24)	No data	24 weeks with weekly injections	Fatigue (50-60%), fever (40-45%), anemia (up to 30%)	No
SOF(24) + R(24)	77	Shorter, no P	Less fatigue, less anemia	Yes

Abbreviations: P = pegylated interferon; R = ribavirin

7. Model of Clinical and Economic Outcomes of Treatment Strategies for Hepatitis C

As noted in this review, new medications for hepatitis C have the potential to change clinical expectations for achieving sustained virologic response in many more patients than previously thought possible. However, these medications also have the potential to substantially increase health system costs. We developed a cohort model to compare the possible clinical and economic outcomes from the use of sofosbuvir and simeprevir in multiple patient populations.

For comparison purposes, we also identified published studies of the cost-effectiveness of both existing and proposed treatment options for hepatitis C treatment, which are summarized in the section immediately following. We limited our summary to those studies published from 2011 onwards as representative of current costs of hepatitis C management. However, we also report on any available studies that used a “cost per treatment success” measure of cost-effectiveness, as that was a central output of our model (see Summary, Section 7.4).

7.1 Prior Published Evidence on Costs and Cost-effectiveness

We identified a number of studies published in the era of direct-acting antiviral agents (i.e., from 2011 to the present) that evaluated the economic impact of hepatitis C therapy, including an in-press publication examining the cost-effectiveness of sofosbuvir.⁹⁸ The methods and results of these studies are summarized below by therapeutic approach. As can be seen in these summaries, most model results were highly sensitive to the estimated cost of treatment, and all focused exclusively on improvements in overall or quality-adjusted life expectancy (i.e., impacts on intermediate outcomes such as disease progression and liver transplantation were not described).

Cost-Effectiveness of Sofosbuvir

As noted above, we identified a single study assessing the economic impact of sofosbuvir.⁹⁸ This was an industry-funded, lifetime simulation model conducted from the perspective of the Italian National Health Service, and it involved separate comparisons of triple therapy with sofosbuvir versus boceprevir and telaprevir in genotype 1 patients who were naïve to treatment and age 50 years. Strategies with an incremental cost per life-year gained less than €25,000 (~\$35,000) were considered to be cost-effective. Costs included those of therapy, management of side effects, and disease-related complications.

On an overall basis, sofosbuvir triple therapy (sofosbuvir + PR) was estimated to increase life expectancy by approximately eight months relative to boceprevir and three months versus telaprevir. Discounted lifetime costs in the sofosbuvir strategy (~\$63,000) were 35-40% higher than those in the boceprevir and telaprevir strategies, even after accounting for improved survival with sofosbuvir. Sofosbuvir was considered to be cost-effective in comparison to either of the competing strategies, but not universally so across all subgroups. For example, sofosbuvir was considered to be cost-effective among cirrhotic patients and those with the IL28b CC allele, but not in patients with lower levels of fibrosis or in patients with the genotype 1b subtype. Of interest for this analysis, model findings were most sensitive to changes in the price of sofosbuvir, which was assumed to be \$4,800 per week in the base case; the current price in the U.S. is \$7,000 weekly.

Cost-Effectiveness of All-Oral Hepatitis C Regimens

While all-oral treatment regimens for hepatitis C are not yet available, two simulation models have assessed the potential cost-effectiveness of hypothetical combinations of oral drugs.^{4,99} Hagan and colleagues assessed cost-effectiveness of a hypothetical 2-drug regimen over a lifetime versus standard care (i.e., triple therapy or PR) across all genotypes in a 50 year-old treatment-naïve cohort using a societal perspective in an NIH-funded analysis.⁴ All-oral therapy resulted in an overall gain of five months of quality-adjusted life expectancy while generating approximately \$20,000 more in costs. The resulting cost-effectiveness ratio was \$45,000 per quality-adjusted life year (QALY) gained. The base case cost estimate for a course of all-oral therapy was estimated to be \$70,000, and such therapy was no longer considered cost-effective in this model (at a \$50,000 per QALY threshold) at prices exceeding \$75,000. Given that the average wholesale prices for courses of sofosbuvir and simeprevir are already at least \$84,000 and \$66,000 respectively, the true cost of combination all-oral therapy will likely be much higher. A second, industry-funded analysis produced a lower cost-effectiveness ratio (\$15,709 per QALY gained), which appears to be closely tied to the assumption that all-oral drug costs would be equivalent to those of existing triple therapy with telaprevir.⁹⁹


Cost-Effectiveness of Telaprevir and/or Boceprevir

We also identified six recent studies evaluating the cost-effectiveness of telaprevir and boceprevir, all of which used simulation techniques to evaluate outcomes and costs on a lifetime basis.¹⁰⁰⁻¹⁰⁵ Cost-effectiveness ranged widely in these studies, from \$11,000-\$70,000 per QALY gained. Results were sensitive to whether patients had mild or advanced fibrosis, response to prior PR therapy, and of course, the assumed costs of therapy itself, as many of these studies assumed costs for telaprevir and boceprevir that are markedly less than current average wholesale prices for these agents.

7.2 Model Overview

To examine the potential clinical and economic impact of the introduction of sofosbuvir and simeprevir in California, we developed a cohort model that assessed these effects over time horizons of one year, five years, and 20 years. Our model examined outcomes in different hypothetical cohorts of chronic hepatitis C patients organized by genotype, prior treatment status (i.e., treatment-naïve versus treatment-experienced), and eligibility for interferon therapy. Within each of these strata, outcomes and costs were assessed for a cohort of 1,000 hypothetical patients, age 60 years. We focused on genotypes 1, 2, and 3, as these represent over 97% of the hepatitis C population in the US. Strata were designed to purposely align with those used in the recently published AASLD/IDSA/IAS treatment guidelines.¹⁰⁶ We adopted the perspective of a third-party payer for these analyses. Figure 4 below depicts the model schematic for 1,000 patients receiving telaprevir + PR.

Figure 4. Example of Model Schematic for 1,000 Patients Receiving Telaprevir + PR.



NOTE: "\$" indicates model elements with calculated cost

TEL: Telaprevir; PR: Pegylated interferon + ribavirin; SVR: Sustained virologic response

Patient Outcomes

We employed a variety of patient outcome measures for this analysis. The rates of SVR for each treatment strategy were drawn from the network meta-analysis or individual studies as previously described. Because the effectiveness of retreatment with newer regimens is not yet known, estimates of SVR (presented on a per 1,000 basis) were based on the *initial treatment course only*.

Pooled estimates of the percentage of patients discontinuing therapy due to an adverse event were obtained from all available trial reports for each treatment strategy (see Tables 14-16 on pages 47-49), and were also presented on a per 1,000 basis. Note that these estimates are presented for information only and did not affect other model parameters. For example, estimates of SVR already account for early drug discontinuation, as any patient not completing the full regimen due to an adverse event would already be recorded as not achieving SVR.

All patients were assumed to be at risk of downstream liver-related complications (e.g., cirrhosis, liver cancer, transplantation). Relatively little is known about the detailed natural history of hepatitis C infection. However, a systematic review of 57 epidemiologic studies estimated the rate of advanced liver disease/cirrhosis at 20 years to be 24%, and suggested that the rate of progression was reasonably linear.²³ We used this as our estimate of liver-related complications at 20 years across all patients, and derived a 5-year estimate of 6% based on the linear assumption. For patients with advanced liver fibrosis (i.e., METAVIR scores of F3 or F4), we assumed that the rate of progression would be double that of the overall cohort (i.e., 48% and 12% at 20 and five years respectively) based on a comparison of findings in patients with advanced fibrosis versus all patients in a second systematic review of observational studies of hepatitis C complications.¹⁰⁷ These rates were applied to patients who would not achieve SVR with initial therapy. Among patients achieving SVR, rates of liver-related complications were assumed to be reduced by 80% (i.e., rate ratio of 0.2), as multiple observational studies have shown risk reductions of this level or better for a variety of liver-related complications.^{90,107,108} Rates of liver-related complications averted were presented per 1,000 patients treated.

The 20-year time horizon employed in this model suggests that many patients followed for such a time period would be at competing risks of morbidity and mortality. We did not estimate these competing risks in the model, as our focus was on outcomes expected to be directly influenced by choice of treatment strategy. For example, inclusion of estimates of mortality would have resulted in patient attrition over 20 years of follow-up, which would have served to lower estimates of liver-related complications experienced and cost offsets. However, the *relative* rates of events and estimates of cost offset between treatment regimens would not have been materially affected, as there are no data directly linking any one treatment regimen to reductions in mortality relative to others.

Treatment Strategies

Treatment strategies varied by cohort and included a “previous standard” regimen prior to the availability of simeprevir and sofosbuvir. Additional treatment strategies were based on those recommended in the 2014 AASLD/IDSA/IAS guidelines. Strategies of interest, along with estimated SVR rates, are presented in Table 20 on the following page. SVR rates were obtained from the network meta-analysis or individual studies as appropriate (see Section 6). The guidelines do not make distinctions regarding interferon eligibility in some cases. We therefore assumed that pooled SVR rates within subpopulations of genotype/prior treatment status were equivalent for those eligible and not eligible for interferon (unless study/meta-analysis data were available within interferon eligibility strata). Also of note, we used triple therapy with first generation protease inhibitors as a “referent” strategy for genotype 1. However, because boceprevir and telaprevir involve markedly different dosing and duration, we opted to focus on triple therapy with telaprevir as the previous standard for our model given that it held a 70% share of the triple therapy market prior to the introduction of the newer DAAs.¹⁰⁹ Impact was assessed during the year of treatment initiation as well as five and 20 years after treatment.

We also assessed the impact of use of newer drug regimens by applying the measures above to the entire California chronic hepatitis C population based on expected numbers of patients within each genotype who would present for treatment; scenarios were employed alternatively for all patients as well as those with advanced liver fibrosis (i.e., fibrosis score of F3 or F4) only (see page 78 for a summary of methods and results of these analyses).

Table 20. Treatment Strategies of Interest, by HCV Genotype, Prior Treatment Status, and Interferon Eligibility.

Prior Treatment Status, IFN eligibility	Genotype 1	SVR (%)	Genotype 2	SVR (%)	Genotype 3	SVR (%)
Treatment-naïve						
IFN-eligible	TEL + PR (12/24)	74	PR (24)	78	PR (24)	62
	<i>SMV + PR (12/24)</i>	84	<i>SOF + R (12)</i>	97	<i>SOF + R (24)</i>	93
	<i>SOF + PR (12)</i>	83				
IFN-ineligible	No Rx	0*	No Rx	0*	No Rx	0*
	<i>SOF + R (24)</i>	72	<i>SOF + R (12)</i>	93	<i>SOF + R (24)</i>	63
	<i>SOF + SMV + R (12)</i>	90				
Treatment-experienced						
IFN-eligible	TEL + PR (12/24)	70	PR (24)	71	PR (24)	51
	<i>SMV + PR (12/24)</i>	70	<i>SOF + R (12)</i>	88	<i>SOF + R (24)</i>	77
	<i>SOF + PR (12)</i>	71				
	<i>SOF + SMV + R (12)</i>	90				
IFN-ineligible	No Rx	0*	No Rx	0*	No Rx	0*
	<i>SOF + R (24)</i>	61	<i>SOF + R (12)</i>	88	<i>SOF + R (24)</i>	63
	<i>SOF + SMV + R (12)</i>	90				

NOTES: Duration of therapy in parentheses; “/” indicates situations in which different components have different durations.

SVR rates obtained from ICER network meta-analysis or individual studies as necessary

“Previous standard of care” italicized and highlighted in yellow

TEL: Telaprevir; R: ribavirin; PR: pegylated interferon/ribavirin; SMV: simeprevir; SOF: sofosbuvir; No Rx: no standard treatment available

*Assumed rate of 0 for No Rx category (no assumed spontaneous SVR)

Costs

The model first presents the estimated cost per patient for the initial course of therapy. Based on this cost and the estimated SVR rate, the cost per additional SVR is calculated (also on a per patient basis). We also calculated expected *total* drug costs in the first year, based on an assumption that those not achieving SVR initially would be retreated with the most effective regimen available within each genotype, prior treatment status, and interferon eligibility combination (see Table 20 above for most effective regimens). It is important to note that this was done only to provide an accurate picture of likely drug costs over one year for the cohort, *not* to assess the potential impact of SVR from sequential treatment. Total one-year drug costs are presented for the entire 1,000

patient cohort in order to compare these costs to any cost offsets from prevention of liver-related complications and greater achievement of SVR (see below).

Annual costs of liver-related complications (\$25,728) were calculated based on an analysis of median costs among patients with and without advanced liver disease in Florida Medicaid claims.¹¹⁰ Of note, we did not attempt to model the time course of these events, but rather assigned the full 5- and 20-year costs to any patient experiencing a liver-related complication during these time periods. Annual costs of maintenance care for patients achieving and not achieving SVR were derived from a study comparing post-treatment costs by SVR status among patients treated in the Kaiser health system.¹¹¹ In this study, the annual costs of care following hepatitis C treatment were estimated for patients achieving and not achieving SVR, including outpatient care, inpatient care, laboratory, and pharmacy. Costs were approximately \$3,800 higher for patients without SVR versus those with successful treatment.

We estimated the costs of medication using published wholesale acquisition costs or average wholesale prices.¹¹² Of note, however, telaprevir costs have increased substantially over the past 1.5 years, even as its use has declined to near zero.⁹⁷ We chose to model telaprevir costs using estimates from the time period in which it was considered the previous standard of care for triple therapy (\$4,920 per week) rather than using a more current (and likely artificially-inflated) price.

All costs were expressed in 2013 dollars. Costs incurred in future years were discounted by 3% in accordance with generally-accepted practice for economic evaluations.¹¹³ We did not consider short-term costs of adverse-event management or monitoring during treatment (consistent with the Manos study that focused on costs after treatment was completed). We also based our estimates of treatment success on data from the initial course of treatment only. The cost offsets associated with prevention of liver-related complications and greater achievement of SVR at five and 20 years after treatment are presented on a per 1,000 basis to facilitate comparisons to one-year drug costs (see above). To further illustrate the effects of these cost offsets in patients of differing severity of liver disease, we conducted alternative analyses for genotype 1 in which model outputs were generated assuming all patients alternatively had no-to-mild liver disease or advanced liver disease respectively (see page 65).

All derived costs (such as cost per additional SVR and cost offsets at 5 and 20 years) were rounded to the nearest \$1,000 to reflect the uncertainty in these estimates from reliance on published prices and literature-based cost estimates rather than primary data.

Key model estimates are presented in Table 22 on page 62. Key model assumptions, many of which are described above, are also summarized in Table 21 on the following page.

Table 21. Key Assumptions Used in Model Development.

Key Assumption	Rationale
Cost per SVR and downstream cost offsets based on effectiveness of initial course of therapy only	No available data on effectiveness of retreatment with newer regimens
Patients would complete and be fully compliant with therapy	Compliance data not available for all regimens and populations of interest
Clinical benefits limited to SVR and its effects on downstream liver-related complications	Intent was to develop policy-based model rather than to document natural history
Costs limited to drug therapy and downstream management of liver disease and other medical care	Intent was to develop policy-based model rather than to create full accounting of costs
No differential costs assumed for identification and management of side effects and other drug-related harms	Inclusion of such measures would dilute the model focus on differential SVR rates and their impact on downstream events and costs
Costs were measured for assumed retreatment regimens, but effectiveness was not	Focus of model was on clinical impact of initial course of therapy
No inclusion of estimates of competing morbidity and mortality risks	Focus of model was on differential effects between treatment regimens (i.e., SVR status and its sequelae)

Table 22. Estimates for Cohort Model of Hepatitis C Treatment.

Measure	Estimate	Sources
Discontinuation due to adverse events, %		CTAF Evidence Review
PR	8.4	
Telaprevir (+PR)	14.0	
Simeprevir (+PR)	6.4	
Sofosbuvir (+PR)	5.5	
Sofosbuvir (+R)	1.3	
Sofosbuvir + simeprevir (\pm R)	5.0	
Risk of liver-related complications, %		Freeman, 2001; Singal, 2010
At 5-years		
All patients	6.0	
Advanced fibrosis only	12.0	
At 20-years		
All patients	24.0	
Advanced fibrosis only	48.0	
Hazard ratio for composite liver complications with SVR	0.20	Van der Meer, 2012; Singal, 2010; Pearlman, 2011
Annual costs of care, \$		
Patients with liver complications	25,728	Menzin, 2012
Patients without SVR	10,149	Manos, 2013
Patients with SVR	6,301	Manos, 2013
Weekly drug costs, \$		Red Book® Online, 2012 & 2014
Ribavirin	348	
Pegylated interferon	691	
Telaprevir	4,920*	
Simeprevir	5,530	
Sofosbuvir	7,000	

PR: Pegylated interferon plus ribavirin

*Price deemed to be representative of period in which telaprevir was the standard of care

7.3 Model Results

Genotype 1, Treatment-naïve, Interferon-eligible

Table 23 on the following page presents model results for all patients with genotype 1 who are treatment-naïve. Among a population of 1,000 interferon-eligible patients, we estimate that SVR will be achieved for 830 treated with sofosbuvir + PR; for 840 treated with simeprevir + PR; and for 740 patients treated with telaprevir + PR. Ten patients would require treatment with simeprevir + PR to obtain one additional SVR when compared with the SVR rates of telaprevir + PR; the corresponding figure is 11 patients per additional SVR for sofosbuvir + PR. The number of patients discontinuing therapy due to adverse events is 2-3 times greater for telaprevir + PR versus the newer regimens.

Drug costs for the initial treatment course are 9% and 15% greater for the newer regimens (\$91,296 and \$96,468 for simeprevir and sofosbuvir, respectively) than for the first generation DAA triple therapy (\$83,976). The cost per additional SVR when looking just at the initial treatment course was estimated to be \$73,000 for simeprevir + PR and \$139,000 for sofosbuvir + PR. A cost per additional SVR could not be calculated for sofosbuvir + PR versus simeprevir + PR, as the latter was found to be comparable in effectiveness to sofosbuvir + PR and slightly less costly.

Total drug costs over one year were tabulated for an entire 1,000-person cohort under the assumption that all patients who do not achieve SVR with initial therapy are then prescribed simeprevir + PR. These costs were estimated to total \$108 million for telaprevir, \$106 million for simeprevir, and \$112 million for sofosbuvir. The incremental one-year drug costs for the entire 1,000 patient cohort over the costs for telaprevir + PR would be \$4.3 million for sofosbuvir + PR. A cohort initially treated with simeprevir + PR would realize a savings of \$1.8 million versus telaprevir + PR, as these two agents are closer in price and fewer simeprevir + PR patients would require retreatment.

Over five years, the simeprevir and sofosbuvir regimens would reduce the number of liver-related complications per 1,000 when compared with telaprevir + PR by five and four patients, respectively. The cost offset over five years per 1,000 patients that is created by savings from fewer liver complications and greater number of patients achieving SVR is estimated to be approximately \$2.4 million for simeprevir + PR and \$2.1 million for sofosbuvir + PR. Over a 20-year time horizon, simeprevir and sofosbuvir regimens would result in 19 and 17 fewer liver-related complications per 1,000, respectively. At 20 years, the cost offset for simeprevir + PR would be approximately \$7.7 million (or a total of \$9.5 million including savings in one-year drug costs), while the offset for sofosbuvir + PR would be approximately \$7 million, which would completely offset the initial incremental drug cost and result in net savings.

Table 23. Clinical and Economic Impact of Treatment Options Among 1,000 60 year-old Patients with Hepatitis C Genotype 1 Who Are New to Treatment (Treatment-naïve).

Population/regimen	Evidence Review Data					Modeled 1-Year Drug Costs		Modeled Long-Term Effects of Achieving SVR			
	SVR per 1000	NNT for 1 add'l SVR	Discontinued due to AE (per 1000)	Cost for initial Rx (per patient)	Cost per add'l SVR	Total Drug Costs (per 1000)	Incremental (vs. pre-DAA)	Liver Events Averted 5 years (per 1000)	Liver Events Averted 20 years (per 1000)	Total Estimated Cost Offset 5 years (per 1000, vs. pre-DAA)	Total Estimated Cost Offset 20 years (per 1000, vs. pre-DAA)
<i>IFN-eligible</i>											
TEL + PR (12/24) (pre-DAA)*	740	---	140	\$83,976	---	\$107,712,960	---	---	---	---	---
SMV + PR (12/24)*	840	10	64	\$91,296	\$73,000	\$105,903,360	(\$1,810,000)	(5)	(19)	(\$2,393,000)	(\$7,730,000)
SOF + PR (12)*	830	11	55	\$96,468	\$139,000	\$111,988,320	\$4,275,000	(4)	(17)	(\$2,154,000)	(\$6,957,000)
<i>IFN-ineligible</i>											
No Rx (pre-DAA)	0	---	0	\$0	---	\$0	---	---	---	---	---
SOF + R (24)†	720	1	13	\$176,352	\$245,000	\$219,622,080	\$219,622,000	(35)	(138)	(\$17,233,000)	(\$55,653,000)
SOF + SMV + R (12)‡	900	1	0	\$154,536	\$172,000	\$169,989,600	\$169,990,000	(43)	(173)	(\$21,541,000)	(\$69,566,000)

*ICER network meta-analysis

†Pooled data from PHOTON-1 and QUANTUM

‡Pooled data from COSMOS treatment arms

Total drug costs Include initial therapy and retreatment with most effective regimen available for those not achieving SVR initially

Total estimated cost offset includes cost savings from liver events averted and reduced annual costs from greater numbers of patients achieving SVR

SVR: sustained virologic response; NNT: number needed to treat; DAA: direct-acting antivirals

Genotype 1, Treatment-naïve, Interferon-ineligible

Among interferon-ineligible patients, comparisons were made between sofosbuvir + R (24 weeks), sofosbuvir + simeprevir + R (12 weeks), and no drug therapy (as these patients previously had no treatment options). The combination of sofosbuvir + simeprevir + R was most effective (900 achieving SVR per 1,000 versus 710 for sofosbuvir + R) and resulted in little to no discontinuation due to adverse events. Both regimens are very expensive: ~\$176,000 for 24 weeks of sofosbuvir + R and ~\$155,000 for 12 weeks of sofosbuvir + simeprevir + R. Assuming retreatment of patients failing to achieve SVR with sofosbuvir + simeprevir + R, one-year drug costs for 1,000 patients treated with sofosbuvir + R for 24 weeks would total \$220 million, while sofosbuvir + simeprevir + R for 12 weeks would generate \$170 million in drug costs per 1,000 patients.

At five years, cost offsets per 1,000 patients due to averted liver complications and greater achievement of SVR would total approximately \$17 million for sofosbuvir + R and \$22 million for sofosbuvir + simeprevir + R, or about 10% of incremental drug costs for these regimens; even at 20 years, cost offsets relative to no drug treatment would represent 40% of these totals at most (for sofosbuvir + simeprevir + R).

Alternative Analysis Based on Severity of Liver Disease

Primary analyses focused on the effects of preventing liver-related complications among patients at all stages of liver disease. For the genotype 1, treatment-naïve population, we also explored the number of liver-related complications averted if all 1,000 patients alternatively had no-to-mild liver disease (i.e., METAVIR F0-F2) and if all patients had advanced liver disease (METAVIR F3-F4). The full set of findings is presented in Tables A1 and A2 in the Appendix. A summary of the key clinical findings at 20 years is presented in Table 24 on the following page.

Table 24. Effects of Treatment on Liver-related Complications at 20 Years, Among 1,000 Genotype 1 Treatment-naïve Patients at Varying Levels of Liver Disease.

Regimen	All Patients		METAVIR F0-F2 Only		METAVIR F3-F4 Only	
	Events Averted (per 1,000)	NNT	Events Averted (per 1,000)	NNT	Events Averted (per 1,000)	NNT
<i>IFN-eligible (vs. TEL + PR)</i>						
SMV + PR	19	52	10	103	38	26
SOF + PR	17	58	9	115	35	29
<i>IFN-ineligible (vs. No Rx)</i>						
SOF + R	138	7	70	14	276	4
SOF + SMV + R	173	6	87	11	346	3

NNT: Number needed to treat

Among interferon-eligible patients, simeprevir + PR and sofosbuvir + PR would avoid 19 and 17 liver-related complications per 1,000 over 20 years when compared to telaprevir + PR when all stages of liver disease are considered; corresponding numbers needed to treat to avoid one liver-related complication were 52 and 58 respectively. If all 1,000 patients had no-to-mild liver disease only, the number of events averted would be approximately 50% of the estimates for patients at all stages of liver disease, and the number needed to treat would approximately double. In the scenario assuming that all patients had advanced liver disease, simeprevir + PR and sofosbuvir + PR would avoid 38 and 35 liver-related complications per 1,000 over 20 years respectively, with corresponding NNT figures of 26 and 29 to avoid one liver-related complication.

Absolute differences between regimens were greater among interferon-ineligible patients, given the lack of a prior standard of care. Sofosbuvir + R and sofosbuvir + simeprevir + R would avoid 138 and 173 liver-related complications per 1,000 over 20 years respectively when all stages of liver disease are considered, resulting in relatively low NNT figures (7 and 6, respectively). These figures are again halved when only patients with no-to-mild liver disease are considered but still result in relatively low numbers needed to treat (14 and 11, respectively). When all 1,000 patients are assumed to have advanced liver disease, approximately 28% and 35% of patients treated with sofosbuvir + R and sofosbuvir + simeprevir + R respectively would avoid liver-related complications, with corresponding NNT figures of 4 and 3 to avoid one liver-related complication.

Data on cost offsets are also presented in the Appendix. In comparison to primary analyses involving patients at all stages of liver disease, cost offsets would decline by approximately 25% if all 1,000 patients had no-to-mild liver disease and would increase by roughly the same percentage if all patients had advanced liver disease.

Genotype 1, Treatment-experienced, Interferon-eligible

Findings for genotype 1 patients who have been treated previously can be found in Table 25 on the following page. Among patients eligible for interferon therapy, comparisons were made for simeprevir + PR, sofosbuvir + PR, and sofosbuvir + simeprevir + R versus a previous standard of telaprevir + PR. Based on the network meta-analysis findings as well as data derived from an FDA algorithm for sofosbuvir, both simeprevir + PR and sofosbuvir + PR were as effective but more expensive than the first generation DAA triple therapy. Based on data from the COSMOS trial, sofosbuvir + simeprevir + R was the most effective therapy (900 SVR per 1,000 patients versus 710 and 700 for sofosbuvir + PR and telaprevir + PR, respectively). Five patients would need to be treated with sofosbuvir + simeprevir + R to achieve one additional SVR over the other available regimens.

Table 25. Clinical and Economic Impact of Treatment Options Among 1,000 60 year-old Patients with Hepatitis C Genotype 1 Who Have Been Treated Previously (Treatment-experienced).

Population/regimen	Evidence Review Data					Modeled 1-Year Drug Costs		Modeled Long-Term Effects of Achieving SVR			
	SVR per 1000	NNT for 1 add'l SVR	Discontinued due to AE (per 1000)	Cost for initial Rx (per patient)	Cost per add'l SVR	Total Drug Costs (per 1000)	Incremental (vs. pre-DAA)	Liver Events Averted 5 years (per 1000)	Liver Events Averted 20 years (per 1000)	Total Estimated Cost Offset 5 years (per 1000, vs. pre-DAA)	Total Estimated Cost Offset 20 years (per 1000, vs. pre-DAA)
<i>IFN-eligible</i>											
TEL + PR (12/24) (pre-DAA)*	700	---	140	\$83,976	---	\$130,336,800	---	---	---	---	---
SMV + PR (12/24)*	700	N/C	64	\$91,296	N/C	\$137,656,800	\$7,320,000	0	0	\$0	\$0
SOF + PR (12)†	710	100	55	\$96,468	\$1,249,000	\$141,283,440	\$10,947,000	(0)	(2)	(\$239,000)	(\$773,000)
SOF + SMV + R (12)‡	900	5	0	\$154,536	\$353,000	\$169,989,600	\$39,653,000	(10)	(38)	(\$4,787,000)	(\$15,459,000)
<i>IFN-ineligible</i>											
No Rx (pre-DAA)	0	---	0	\$0	---	\$0	---	---	---	---	---
SOF + R (24)Ω	610	2	13	\$176,352	\$289,000	\$236,621,040	\$236,621,000	(29)	(117)	(\$14,600,000)	(\$47,150,000)
SOF + SMV + R (12)‡	900	1	0	\$154,536	\$172,000	\$169,989,600	\$169,990,000	(43)	(173)	(\$21,541,000)	(\$69,566,000)

*ICER network meta-analysis

†FDA estimate based on data from NEUTRINO among patients with "poor prognostic factors"

‡Pooled data from COSMOS treatment arms

ΩNo available data. Data pooled from PHOTON-1 and QUANTUM and adjusted downward based on decrement from Rx-naïve to Rx-experienced with SOF+PR (83% vs. 71%)

Total drug costs Include initial therapy and retreatment with most effective regimen available for those not achieving SVR initially

Total estimated cost offset includes cost savings from liver events averted and reduced annual costs from greater numbers of patients achieving SVR

N/C: Not calculable

SVR: sustained virologic response; NNT: number needed to treat; DAA: direct-acting antivirals

The cost per additional SVR could not be calculated for simeprevir + PR because it was equally effective in comparison to telaprevir + PR. The cost per additional SVR for sofosbuvir + PR was very high (\$1.2 million) given the small difference in effectiveness (SVR achieved in 710 per 1,000 versus 700 for telaprevir + PR). The cost per additional SVR for sofosbuvir + simeprevir + R was \$353,000, as the treatment cost is nearly twice that of telaprevir + PR (~\$155,000 versus ~\$84,000). When the sofosbuvir regimens were compared to each other, the cost per SVR of sofosbuvir + simeprevir + R was estimated to be \$306,000 (data not shown).

Over one year, the use of simeprevir + PR and sofosbuvir + PR is projected to increase overall drug costs per 1,000 patients by approximately \$7.3 and \$11 million respectively relative to telaprevir + PR, but almost none of these costs would be offset due to the similarity in effectiveness between regimens. The sofosbuvir + simeprevir + R treatment regimen would increase drug spending by approximately \$40 million per every 1,000 treated patients relative to first generation DAA triple therapy. While liver-related complications would be substantially reduced at both five and 20 years (by 10 and 38 patients per 1,000 respectively), cost offsets would total at most 39% of drug costs.

Genotype 1, Treatment-experienced, Interferon-ineligible

Among treatment-experienced patients with genotype 1 not eligible for interferon, no active treatment was previously available for these patients. Newer regimens examined included sofosbuvir + simeprevir + R for 12 weeks as described above as well as a 24-week regimen of sofosbuvir + R, the identical regimens assessed for treatment-naïve patients. No data on SVR were available for sofosbuvir + R in this population; we therefore derived an estimate based on the difference in effectiveness for sofosbuvir regimens between treatment-naïve and treatment-experienced interferon-eligible patients (i.e., 83% versus 71%). Based on this assumption, the incremental drug costs at one year for 1,000 patients receiving this regimen would be \$237 million. The effectiveness of sofosbuvir + simeprevir + R was assumed to be identical to that among treatment-naïve patients, resulting in an incremental cost of \$170 million. Even at 20 years, cost offsets relative to no drug treatment would represent at most 40% of these totals.

Genotype 1: Considerations of Duration of PR Therapy

Because telaprevir therapy is response-guided, some patients will require 48 weeks of PR therapy rather than the 24 weeks assumed for these analyses. Similarly, simeprevir requires 48 weeks of PR for the proportion of treatment-experienced patients who are null or partial responders. For telaprevir, assumption of PR therapy duration consistent with the Phase III clinical trials (~60% for 24 weeks, ~40% for 48 weeks) yields a blended cost estimate of \$93,950 (versus \$83,976 in the base case). Among treatment-naïve patients, this does not materially affect the direction of model results, as simeprevir + PR would continue to produce cost savings at 1 year, and sofosbuvir + PR remains more expensive than telaprevir + PR. While the proportion of prior partial or null

responders to telaprevir + PR who would be candidates for simeprevir + PR is unknown, it is likely that extending the duration of PR therapy for some proportion of treatment-experienced simeprevir + PR patients would make this regimen more expensive than all other regimens except for sofosbuvir + simeprevir + R.

Genotype 2, Treatment-naïve, Interferon-eligible

Table 26 on the following page presents results for patients with genotype 2 who are new to hepatitis C treatment. Among interferon-eligible patients, a regimen of 12 weeks of sofosbuvir + R was compared to the previous standard of 24 weeks of PR alone. Based on pooled data from the VALENCE and FISSION trials, sofosbuvir + R was highly effective in this population (970 per 1,000 achieving SVR initially), but PR is also relatively effective in genotype 2 patients (780 per 1,000). The number needed to treat to achieve an additional SVR for sofosbuvir + R was 5. Rates of discontinuation due to adverse events was very low in the sofosbuvir + R group (13 versus 84 per 1,000 for PR). The costs of sofosbuvir + R are nearly four times that of PR (~\$88,000 versus ~\$25,000), resulting in a cost per additional SVR of \$333,000.

Over one year, sofosbuvir + R would be expected to generate an additional \$46 million in drug costs per 1,000 patients treated. The newer regimen would prevent nine and 36 liver-related complications per 1,000 over five and 20 years respectively, and it would generate cost offsets of approximately \$4.5 and \$15 million during these periods. These offsets represent 10% of the incremental drug costs for sofosbuvir at five years and 32% of drug costs at 20 years.

Genotype 2, Treatment-naïve, Interferon-ineligible

Among patients with genotype 2 not eligible for interferon, 12 weeks of sofosbuvir + R is estimated to be slightly less effective than in interferon-eligible patients, resulting in achievement of SVR by 930 patients per 1,000 treated (based on data from the POSITRON trial). Use of this regimen would generate approximately \$94 million in drug costs per 1,000 patients treated over one year in a population without any historical treatment options. Sofosbuvir + R would prevent 45 and 179 liver-related complications per 1,000 over five and 20 years, respectively; because of the relatively low cost of sofosbuvir + R (~\$88,000) versus other sofosbuvir-based regimens, cost offsets at these time points (\$22 million and \$72 million, respectively) represented a higher percentage of drug expenditures (24% and 76%).

Table 26. Clinical and Economic Impact of Treatment Options Among 1,000 60 year-old Patients with Hepatitis C Genotype 2 Who Are New to Treatment (Treatment-naïve).

Population/regimen	Evidence Review Data					Modeled 1-Year Drug Costs		Modeled Long-Term Effects of Achieving SVR			
	SVR per 1000	NNT for 1 add'l SVR	Discontinued due to AE (per 1000)	Cost for initial Rx (per patient)	Cost per add'l SVR	Total Drug Costs (per 1000)	Incremental (vs. pre-DAA)	Liver Events Averted 5 years (per 1000)	Liver Events Averted 20 years (per 1000)	Total Estimated Cost Offset 5 years (per 1000, vs. pre-DAA)	Total Estimated Cost Offset 20 years (per 1000, vs. pre-DAA)
<i>IFN-eligible</i>											
PR (24) (pre-DAA)*	780	---	84	\$24,936	---	\$44,334,720	---	---	---	---	---
SOF + R (12)*	970	5	13	\$88,176	\$333,000	\$90,821,280	\$46,487,000	(9)	(36)	(\$4,547,000)	(\$14,686,000)
<i>IFN-ineligible</i>											
No Rx (pre-DAA)	0	---	---	\$0	---	\$0	---	---	---	---	---
SOF + R (12)†	930	1	13	\$88,176	\$95,000	\$94,348,320	\$94,348,000	(45)	(179)	(\$22,259,000)	(\$71,885,000)

*Pooled data from VALENCE and FISSION

†Based on data from POSITRON

Total drug costs Include initial therapy and retreatment with most effective regimen available for those not achieving SVR initially

Total estimated cost offset includes cost savings from liver events averted and reduced annual costs from greater numbers of patients achieving SVR

SVR: sustained virologic response; NNT: number needed to treat; DAA: direct-acting antivirals

Genotype 2, Treatment-experienced, Interferon-eligible

Table 27 on the following page presents model findings for 1,000 genotype 2 patients previously treated for hepatitis C. For interferon-eligible patients, the previous standard is 24 weeks of PR, and newer options include 12 weeks of sofosbuvir + R (note: sofosbuvir + PR is also recommended in treatment guidelines, but we assumed that such therapy would be unlikely in a group of patients that may have already failed prior PR therapy). Sofosbuvir + R resulted in SVR in 880 of 1,000 patients (based on pooled data from VALENCE and FUSION), versus 710 for PR therapy [no available data; based on an estimate of 78% for treatment-naïve patients adjusted downward based on the difference in effectiveness between treatment-naïve and treatment-experienced patients for sofosbuvir + R (97% versus 88%)]. The resulting number needed to treat for sofosbuvir + R to achieve one additional SVR over PR was 13. The number of patients discontinuing therapy due to adverse events was six times greater for PR (84 versus 13 for sofosbuvir + R). The cost per additional SVR was approximately \$372,000 for sofosbuvir + R, owing to a therapy cost over three times higher for sofosbuvir + R relative to the previous standard.

Over one year, sofosbuvir + R would be expected to add nearly \$50 million in drug costs for a 1,000-patient cohort, and would prevent liver-related complications in eight and 33 patients per 1,000 at five and 20 years, respectively. Cost offsets at five years were modest (\$4.1 million, or 8% of incremental drug costs), as the incremental reductions in liver complications compared to treatment with PR were smaller in this population. At 20 years, cost offsets were estimated to be \$13.1 (27% of incremental drug costs).

Genotype 2, Treatment-experienced, Interferon-ineligible

Among genotype 2 patients previously-treated for hepatitis C who are not eligible for interferon, there has been no standard effective treatment. Sofosbuvir + R for 12 weeks is now recommended by the 2014 AASLD/IDSA/IAS guidelines and would be expected to achieve SVR in 880 patients per 1,000 treated (note: data were only available from a small arm of the POSITRON study [n=17]; we therefore assumed the same SVR rate as observed for interferon-eligible patients receiving this treatment). Over one year, use of this regimen would generate approximately \$99 million in drug costs for the 1,000-patient cohort. Because a large number of liver-related complications would be averted relative to no treatment (42 and 169 per 1,000 at five and 20 years), potential cost offsets are relatively high. At five years, cost offsets would total \$21 million (20% of drug costs). At 20 years, these offsets would total approximately \$68 million (70% of drug costs).

Table 27. Clinical and Economic Impact of Treatment Options Among 1,000 60 year-old Patients with Hepatitis C Genotype 2 Who Have Been Treated Previously (Treatment-experienced).

Population/regimen	Evidence Review Data					Modeled 1-Year Drug Costs		Modeled Long-Term Effects of Achieving SVR			
	SVR per 1000	NNT for 1 add'l SVR	Discontinued due to AE (per 1000)	Cost for initial Rx (per patient)	Cost per add'l SVR	Total Drug Costs (per 1000)	Incremental (vs. pre-DAA)	Liver Events Averted 5 years (per 1000)	Liver Events Averted 20 years (per 1000)	Total Estimated Cost Offset 5 years (per 1000, vs. pre-DAA)	Total Estimated Cost Offset 20 years (per 1000, vs. pre-DAA)
<i>IFN-eligible</i>											
PR (24) (pre-DAA)*	710	---	84	\$24,936	---	\$50,507,040	---	---	---	---	---
SOF + R (12)†	880	6	13	\$88,176	\$372,000	\$98,757,120	\$48,250,000	(8)	(33)	(\$4,069,000)	(\$13,140,000)
<i>IFN-ineligible</i>											
No Rx (pre-DAA)	0	---	0	\$0	---	\$0	---	---	---	---	---
SOF + R (12)‡	880	1	13	\$88,176	\$100,000	\$98,757,120	\$98,757,000	(42)	(169)	(\$21,062,000)	(\$68,020,000)

*No available data. Data pooled from VALENCE and FISSION and adjusted downward based on decrement from Rx-naïve to Rx-experienced with SOF+R (97% vs. 88%)

†Pooled data from VALENCE and FUSION

‡Data only available from small arm of POSITRON study (n=17). Rate assumed to be equivalent to that among IFN-eligible patients

Total drug costs Include initial therapy and retreatment with most effective regimen available for those not achieving SVR initially

Total estimated cost offset includes cost savings from liver events averted and reduced annual costs from greater numbers of patients achieving SVR

SVR: sustained virologic response; NNT: number needed to treat; DAA: direct-acting antivirals

Genotype 3, Treatment-naïve, Interferon-eligible

For the genotype 3 population, the previous standard of care was PR therapy for 24 weeks. Newer regimens available for comparison included sofosbuvir + R for 24 weeks (note: sofosbuvir + PR is also recommended in treatment guidelines, but as with genotype 2, we assumed that patients would opt for an interferon-free regimen if available). The numbers of patients per 1,000 achieving SVR were estimated to be 620 for PR therapy (based on data from FISSION) and 930 for sofosbuvir + R (based on data from VALENCE), resulting in a number needed to treat of 3 to obtain an additional SVR (see Table 28 on the following page). As with prior comparisons, PR therapy would result in a greater rate of discontinuation due to adverse events per 1,000 (84) compared with sofosbuvir + R (13). However, the estimated cost of the 24-week sofosbuvir + R regimen (\$176,352) is over seven times the cost of PR alone, resulting in a high cost per additional SVR (\$488,000) for sofosbuvir + R.

Under the assumption that all patients failing to achieve SVR would receive the sofosbuvir + R regimen, the 24-week sofosbuvir + R regimen would increase drug costs by approximately \$97 million in this 1,000-person cohort. The numbers of patients avoiding liver-related complications at five and 20 years with sofosbuvir + R were 15 and 60 per 1,000 respectively. Cost offsets are estimated to total approximately \$7 million and \$24 million at five and 20 years respectively, which represent 8% and 25% of incremental drug costs for sofosbuvir + R.

Genotype 3, Treatment-naïve, Interferon-ineligible

Among patients with genotype 3 not eligible for interferon therapy, there has been no standard effective treatment. The 24-week sofosbuvir + R regimen has now been recommended in the 2014 AASLD/IDSA/IAS treatment guidelines. The effectiveness of this regimen is lower among patients not eligible for interferon, however, with SVR achieved in only 630 per 1,000 (based on pooled data from the treatment-naïve and treatment-experienced arms of the POSITRON study) versus 930 per 1,000 among interferon-eligible patients. As a result, the use of this regimen, including retreatment for those not achieving SVR initially, would add \$242 million in drug costs per 1,000 patients treated. While use of sofosbuvir + R would reduce liver-related complications per 1,000 by 30 at five years and 121 at 20 years, cost offsets at these time points would be \$15 million and \$49 million, respectively, or just 6% and 20% of one-year incremental drug costs.

Table 28. Clinical and Economic Impact of Treatment Options Among 1,000 60 year-old Patients with Hepatitis C Genotype 3 Who Are New to Treatment (Treatment-naïve).

Population/regimen	Evidence Review Data					Modeled 1-Year Drug Costs		Modeled Long-Term Effects of Achieving SVR			
	SVR per 1000	NNT for 1 add'l SVR	Discontinued due to AE (per 1000)	Cost for initial Rx (per patient)	Cost per add'l SVR	Total Drug Costs (per 1000)	Incremental (vs. pre-DAA)	Liver Events Averted 5 years (per 1000)	20 years (per 1000)	Total Estimated Cost Offset 5 years (per 1000, vs. pre-DAA)	20 years (per 1000, vs. pre-DAA)
<i>IFN-eligible</i>											
PR (24) (pre-DAA)*	620	---	84	\$24,936	---	\$91,949,760	---	---	---	---	---
SOF + R (24)†	930	3	13	\$176,352	\$488,000	\$188,696,640	\$96,747,000	(15)	(60)	(\$7,420,000)	(\$23,962,000)
<i>IFN-ineligible</i>											
No Rx (pre-DAA)	0	---	---	\$0	---	\$0	---	---	---	---	---
SOF + R (24)‡	630	2	13	\$176,352	\$280,000	\$241,602,240	\$241,602,000	(30)	(121)	(\$15,079,000)	(\$48,696,000)

*Based on data from FISSION

†Based on data from VALENCE

‡Based on overall data from POSITRON (Rx-naïve and Rx-experienced)

Total drug costs Include initial therapy and retreatment with most effective regimen available for those not achieving SVR initially

Total estimated cost offset includes cost savings from liver events averted and reduced annual costs from greater numbers of patients achieving SVR

SVR: sustained virologic response; NNT: number needed to treat; DAA: direct-acting antivirals

Genotype 3, Treatment-experienced, Interferon-eligible

Outcomes and costs for patients with genotype 3 who have received prior hepatitis C therapy are presented in Table 29 on the following page. The previous standard of care has been PR for 24 weeks. As with treatment-naïve genotype 3 patients, sofosbuvir + R for 24 weeks is recommended, but the incremental effectiveness is less than that seen among treatment-naïve patients. Among treatment-experienced patients eligible for interferon, PR for 24 weeks is still estimated to produce SVR in 510 patients per 1,000 treated (no available data; estimated based on data from FISSION downgraded to reflect the difference in effectiveness for sofosbuvir + R for treatment-naïve versus treatment-experienced patients). The 24-week sofosbuvir + R regimen would achieve SVR in 770 patients per 1,000 (based on data from VALENCE). The number needed to treat to obtain an additional SVR was four for sofosbuvir + R. Because cost differences were the same as for treatment-naïve patients but incremental effectiveness was lower, the cost per additional SVR for sofosbuvir + R is higher in this population (\$582,000 versus \$488,000 for treatment-naïve patients).

Over one year, sofosbuvir + R would be expected to add \$106 million in drug costs per 1,000 treated. The numbers of liver-related complications averted would total 12 and 50 per 1,000 at five and 20 years respectively, which would translate into cost offsets of \$6 million and \$20 million at these time points (representing 6% and 19% of drug costs).

Genotype 3, Treatment-experienced, Interferon-ineligible

Because there were no studies evaluating the effectiveness of sofosbuvir + R in genotype 3 who had received prior hepatitis C therapy and were ineligible for interferon, we assumed the same effectiveness for this regimen as among patients who were treatment-naïve (630 achieving SVR per 1,000 treated). Use of this regimen would increase drug costs by \$242 million per 1,000 treated, would prevent 30 and 121 liver-related complications per 1,000 at five and 20 years respectively, and would result in offsets to this cost of approximately \$15 million (6%) and \$49 million (20%) at five and 20 years.

Table 29. Clinical and Economic Impact of Treatment Options Among 1,000 60 year-old Patients with Hepatitis C Genotype 3 Who Have Been Treated Previously (Treatment-experienced).

Population/regimen	Evidence Review Data					Modeled 1-Year Drug Costs		Modeled Long-Term Effects of Achieving SVR			
	SVR per 1000	NNT for 1 add'l SVR	Discontinued due to AE (per 1000)	Cost for initial Rx (per patient)	Cost per add'l SVR	Total Drug Costs (per 1000)	Incremental (vs. pre-DAA)	Liver Events Averted 5 years (per 1000)	Liver Events Averted 20 years (per 1000)	Total Estimated Cost Offset 5 years (per 1000, vs. pre-DAA)	Total Estimated Cost Offset 20 years (per 1000, vs. pre-DAA)
<i>IFN-eligible</i>											
PR (24) (pre-DAA)*	510	---	84	\$24,936	---	\$111,348,480	---	---	---	---	---
SOF + R (24)†	770	4	13	\$176,352	\$582,000	\$216,912,960	\$105,564,000	(12)	(50)	(\$6,223,000)	(\$20,097,000)
<i>IFN-ineligible</i>											
No Rx (pre-DAA)	0	---	---	\$0	---	\$0	---	---	---	---	---
SOF + R (24)‡	630	2	13	\$176,352	\$280,000	\$241,602,240	\$241,602,000	(30)	(121)	(\$15,079,000)	(\$48,696,000)

*No available data. Based on data from FISSION and adjusted downward based on decrement from Rx-naïve to Rx-experienced with SOF+R (93% vs. 77%)

†Based on data from VALENCE

‡Based on overall data from POSITRON (Rx-naïve and Rx-experienced)

Total drug costs Include initial therapy and retreatment with most effective regimen available for those not achieving SVR initially

Total estimated cost offset includes cost savings from liver events averted and reduced annual costs from greater numbers of patients achieving SVR

SVR: sustained virologic response; NNT: number needed to treat; DAA: direct-acting antivirals

Estimates of Budget Impact in California for Different Treatment Scenarios

As mentioned above, we also applied estimates of the budgetary impact as well as 5- and 20-year clinical benefits and cost offsets to the California hepatitis C population. In this case, the budgetary impact over one year was compared for the previous standard of care and the most effective regimen in each genotype/prior treatment status/interferon eligibility stratum based on the estimated drug costs for *initial therapy* with these regimens—we did not assume any retreatment for population-based analyses. We estimated liver complication rates and related costs as well as annual costs for patients achieving and not achieving SVR for each patient subgroup of interest. We also discounted future costs in this analysis.


We estimated the size of the chronic hepatitis C population in California to be approximately 560,000 based on information from the 1999-2002 screening round of the National Health and Nutrition Examination Survey (NHANES)⁷ as well as estimates of the numbers of incarcerated and homeless individuals living with the disease.^{114,115} Of these patients, approximately 540,000 (97%) would be infected with genotypes 1, 2, or 3.¹⁷

It is commonly recognized, however, that a substantial percentage of patients do not know they are infected. This proportion has been historically reported to be approximately 50% of infected patients,²⁹ but in recent years more patients may have become aware of their status due to efforts to increase awareness of the disease and expand screening efforts. We therefore alternatively evaluated budgetary impact based on assumptions that either 50% (~270,000) or 75% (~405,000) of infected individuals would know they were infected and would be considered for treatment.

Figure 5 on the following page shows the estimated distribution of the California hepatitis C population by genotype using the assumption that 50% of infected individuals know they are infected. The distribution of patients by genotype was obtained from an analysis of 275 NHANES participants with laboratory-confirmed hepatitis C.¹⁷

As described previously in this report, genotype 1 is dominant, representing over 80% of the 270,000 Californians who have chronic hepatitis C and are aware of the infection, followed by genotypes 2 (13%) and 3 (6%) respectively.

Figure 5. Estimated Numbers of Californians with Chronic Hepatitis C, by Genotype (Based on Assumption of Awareness of Infection by 50% of Infected Individuals).




Within each genotype, we also estimated the number of patients who would be treatment-naïve versus previously treated, as well as the number who would be expected to be eligible for interferon therapy versus not. We estimated that 75% of patients would be naïve to treatment based on the proportion of previously-treated patients in a large VA patient registry.⁹² Estimates of ineligibility for interferon therapy vary greatly and have been reported to be as high as 60% at the VA.¹¹⁶ We used a more conservative estimate of 40% based on expert opinion regarding the proportion of patients in broader insured populations who know they are infected and have contraindications to interferon therapy such as significant psychiatric disorders, autoimmune disease, and severe cardiovascular or pulmonary disease (personal communication, Lisa M. Nyberg, MD).

For the California population of hepatitis C patients, we evaluated two different treatment scenarios. In Scenario 1, all patients with known hepatitis C infection are treated. In Scenario 2, only those patients with advanced liver fibrosis (METAVIR scores of F3 or F4) receive treatment. The proportion of infected patients with F3 or F4 scores was estimated to be 33.1% based on a multicenter study of the natural history of fibrosis progression.¹¹⁷ Within each genotype, analyses of clinical and economic outcomes were based on a change from the previous standard of care to the most effective therapeutic regimen within each of the strata defined by prior treatment status and interferon eligibility.

Results of California-based Analyses

Figure 6 below depicts the budgetary impact and potential cost offsets if 50% of the estimated total California chronic hepatitis C population were to be treated (n=217,839). Drug costs to treat all these patients with the previous standard of care are estimated to total approximately \$12 billion across all genotypes. Were these patients all treated instead with the most effective new regimen, treatment costs would grow by \$22 billion to a total of \$34 billion. Over five years, our model estimates that only approximately 15% of the \$22 billion in additional costs would be offset by reductions in the cost of treating liver-related complications and other medical care for patients not achieving SVR. By 20 years, however, cost offsets would grow to \$16 billion, or nearly three-quarters of the additional drug expenditures incurred initially.


Figure 6. Total Budgetary Impact and Potential Cost Offsets from Use of Newer Drug Regimens in the Chronic Hepatitis C Population in California: 50% of Infected Patients Are Treated (n=270,525).



In our second scenario, we measured the impact of a switch to the most effective new treatment regimens only for patients with evidence of advanced liver fibrosis (i.e., METAVIR scores F3 or F4). As shown in Figure 7 on the following page, treating this smaller group resulted in an increase in drug expenditures of approximately \$7 billion in the first year, only one-third of the extra amount needed to treat all infected patients. Costs saved by reducing liver-related complications in this

subgroup would total approximately \$1.2 billion (17% of added drug costs) at five years. But at 20 years, estimated cost offsets of \$8 billion would exceed the initial incremental drug expenditures of \$7 billion, producing a net savings of approximately \$1 billion.

Figure 7. Total Budgetary Impact and Potential Cost Offsets from Use of Newer Drug Regimens in the Chronic Hepatitis C Population with Advanced Fibrosis in California: 50% of Infected Patients Are Treated (n=89,544).



We repeated all these different treatment scenarios under the alternative assumption that 75% of the chronic hepatitis C population in California would be aware of their infection and present for treatment. Figures 8 and 9 on the following page depict the increases in drug expenditures and potential cost offsets at five and 20 years if all patients were treated and if only those with advanced fibrosis were treated. The budget impact of initial treatment is obviously higher with more patients treated, but the relation of potential downstream cost offsets remains the same, with relatively little cost offset over the initial five years and an estimated net savings after 20 years if only those patients with advanced liver fibrosis are treated.

Figure 8. Total Budgetary Impact and Potential Cost Offsets from Use of Newer Drug Regimens in the Chronic Hepatitis C Population in California: 75% of infected Patients Are Treated (n=405,788).





Figure 9. Total Budgetary Impact and Potential Cost Offsets from Use of Newer Drug Regimens in the Chronic Hepatitis C Population with Advanced Fibrosis in California: 75% of Infected Patients Are Treated (n=134,316).



The proportion of hepatitis C patients who are aware of their infection and are actually treated has historically been much lower than these estimates. Rates as low as 7-11% of those estimated to have chronic hepatitis C have been reported,⁹ which may be due in part to a prior lack of palatable treatment options as well as system challenges in referring appropriate candidates for therapy. With the advent of interferon-free regimens and efforts to increase hepatitis C screening, treatment rates are likely to increase, however. To explore these possible countervailing effects, we conducted a third scenario (presented in Figures A1 and A2 in the Appendix) in which an assumed 25% of the chronic hepatitis C population in California received treatment. Under this scenario, drug costs would increase by approximately \$11 billion. After inclusion of 20-year cost offsets, the increase in drug costs would be reduced by approximately 75%, to \$3 billion. If only patients with advanced liver disease are treated, drug costs would increase by approximately \$3.5 billion, a difference that would be completely eliminated with inclusion of 20-year cost offsets.

7.4 Summary

Consistent with the findings of the systematic review, our model demonstrates that therapeutic regimens containing sofosbuvir or simeprevir have the potential to substantially increase the number of patients achieving SVR relative to previous therapeutic options; for sofosbuvir, there is the added potential to provide the first effective interferon-free option to patients ineligible or intolerant to interferon. These advantages are considerable.

For many patient subpopulations, however, the benefits of sofosbuvir and simeprevir come at a substantially increased cost. The costs for initial treatment regimens including sofosbuvir or simeprevir are expected to range from a low of approximately \$88,000 to a high exceeding \$175,000 per patient, depending on the drugs selected and the duration of initial treatment. Many patients who are treated with an initial course and who fail to achieve a prolonged SVR would be expected to be retreated, adding further to the estimated treatment costs over a one-year time frame.

Among treatment-naïve patients with genotype 1 who are eligible for interferon and are candidates for newer regimens (i.e., without Q80k polymorphism for simeprevir), the findings of our model suggest that the increased costs of simeprevir and sofosbuvir are offset by downstream savings from reductions in liver-related complications and greater numbers of patients achieving SVR. However, for many other comparisons with the previous standard of care, the incremental cost required to achieve one additional SVR with newer treatment regimens is greater than \$300,000. While the “cost per additional SVR” is not a common measure of cost-effectiveness in the literature, the costs per SVR generated in this analysis are generally higher than those previously published for telaprevir versus PR (\$189,000),¹¹⁸ alternative regimens of PR versus standard PR therapy (\$17,000-\$24,000),¹¹⁹ and even highly active antiretroviral therapy in HIV patients (\$1,000-\$79,000).¹²⁰

The clinical advantages of newer treatment regimens would come with a substantial potential impact on health care budgets should a large number of patients be treated. As estimated by our model, we anticipate the average increase in treatment costs to be approximately \$70,000 per patient for the newer agents. For example, in an employer-sponsored group health plan with 1 million enrollees, with an assumed underlying infection rate of 1.7%, there would be approximately 17,000 patients in this population infected with hepatitis C. If even 50% of this population comes forward for treatment, the immediate one-year budget impact for the plan would be estimated to be nearly \$600 million, or approximately \$50 on a per member, per month basis. It would be impossible for this magnitude of immediate increased spending to be accommodated within the budgets established by current health care premium structures, provider risk-sharing contracts, and patient co-payments.

Using an estimate of the number of infected individuals in California who know of their infection and would be considered for treatment, we estimate that replacing current care with simeprevir- and sofosbuvir-based regimens would raise drug expenditures by \$22-33 billion in a single year, assuming 50-75% of infected individuals were aware of their infection and presented for treatment. We looked for potential cost offsets to drug treatment resulting from downstream reductions in liver-related complications that would be expected with successful treatment of hepatitis C infection. At a 5-year time horizon, however, cost offsets would be estimated to represent less than 10-20% of upfront treatment costs. Even at a 20-year horizon, if all patients infected with hepatitis C are treated with new regimens, the cost offset will only cover approximately three-quarters of initial drug costs.

The budget impact and cost offset figures change substantially under our second treatment scenario in which only patients with advanced liver fibrosis are started on the new treatment regimens, with other patients treated with existing pre-DAA regimens. Treating this smaller group of patients is estimated to result in an increase in initial drug expenditures of “only” \$7 billion for the population of California, one-third of the extra amount needed to treat all infected patients. Costs saved by reducing liver-related complications in this subgroup would total only 17% of added drug costs at five years, but at 20 years, estimated cost offsets would produce a net savings to the statewide health care system of approximately \$1 billion.

Some of the public comments received suggested that our estimate of the costs of liver-related complications was overly conservative, and that cost offsets would be more fully realized if other data had been used. In fact, one might consider our approach to be less than conservative, as we applied the annual cost of liver-related complications to each year of the 5- or 20-year time horizon; in many cases, these events will occur toward the end of the timeframe, and increased costs will only be realized for a portion of that time.

We nevertheless explored the effects of using one of the suggested estimates, a comparison of costs among patients with hepatitis C in the Henry Ford Health System.¹²⁹ The comparison of mean monthly costs among those with end-stage liver disease (\$4,931) versus those with non-cirrhotic liver disease (\$1,420) yields a net cost of \$3,511, or \$42,132 on an annual basis. This estimate is 64% higher than our base case estimate of \$25,728. However, when applied to the genotype 1 analysis, total cost offsets at five and 20 years rise by only 15%. For example, the cost offset at 20 years for SOF + SMV + R versus no therapy among interferon-ineligible patients is \$69.6 million using the base case liver complication cost and rises to \$80.3 million using the Gordon et al (2012) estimate. This is because liver-related events only occurred for a proportion of the treated cohort, and because this increase does not affect the other source of cost offset—the reduction in annual maintenance care costs from greater achievement of SVR. In any event, the results do not change the overall picture of the model—the incremental cost of newer regimens is completely offset at 20 years versus the previous standard of care among interferon-eligible patients, but only a portion of these costs are offset for the interferon-ineligible subgroup.

We must emphasize several limitations of our analysis. First, while there were sufficient data to perform a network meta-analysis for patients with genotype 1 infection, estimates could not be generated for all stratifications of interest for the model, and we could not even attempt quantitative synthesis for patients with genotypes 2 or 3. We therefore often had to resort to basing the input to the model on point estimates from individual studies, which in some cases involved small numbers of patients. Our results are therefore quite sensitive to the estimates of drug effectiveness and should therefore be viewed with caution.

In addition, as described previously, we modeled only the immediate clinical effects of treatment as well as the potential downstream benefits of preventing liver-related complications and having greater numbers of patients achieve SVR. While we presented pooled rates of discontinuation due to adverse events from available clinical trial data, we assumed equally across all drug regimens that all patients completed their course of therapy and were fully compliant while doing so, and we did not assume additional costs from management of specific side effects such as anemia (which may be more pronounced with some regimens than with others). These assumptions may not adequately reflect the drawbacks associated with the previous standard of care or the potential benefits of newer regimens, particularly those free of interferon. However, as noted previously, use of SVR as our primary measure of effectiveness already takes therapy compliance into account, as any patient not completing a full course of therapy is recorded as not having achieved SVR.

Finally, our analysis did not consider other possible benefits to patients from greater treatment success, such as improved quality of life and reduced absenteeism from work or school. Regarding the former, however, analyses of quality-of-life data from the sofosbuvir trials suggest that any differential effects between regimens are temporary, as quality of life reverts to baseline levels once treatment is complete for all regimens.¹³⁰ In any event, full analysis of all potential outcomes

and costs of these new treatment options will only be possible through additional data collection and/or the development of simulation models that approximate the natural history of hepatitis C and its treatment.

This is the first review of this technology by the California Technology Assessment Forum.

8. Questions and Discussion

During CTAF public meetings, the CTAF Panel deliberates and votes on key questions related to the systematic review of the clinical evidence, a cost analysis of the applications of the medical technologies or treatments under examination, and the supplementary information presented. At the March 10, 2014 meeting, the CTAF Panel discussed issues regarding the application of the available evidence to help patients, providers, and payers address the important questions related to new treatments for hepatitis C. The key questions are developed by the research team for each assessment, with input from the CTAF Advisory Board to ensure that the questions are framed to address the issues that are most important in applying the evidence to support clinical practice and medical policy decisions.

Following the evidence presentation and public comments, the CTAF Panel voted on questions concerning the comparative clinical effectiveness and comparative value of new treatments for hepatitis C. The voting results are presented below, along with comments reflecting considerations mentioned by CTAF Panel members during the voting process.

When voting on comparative value, the CTAF Panel was asked to assume the perspective of Medi-Cal (the state Medicaid program) or a public payer that must make resource decisions within a relatively fixed budget for care. The CTAF Panel is not given prescribed boundaries or thresholds for budget impact or incremental cost-effectiveness ratios to guide its judgment of low, reasonable/comparable, or high value. However, the CTAF Panel did make use of a value framework designed for the CTAF process with different categories of evidence on effectiveness and cost to assist the CTAF Panel in assigning an overall value rating of low, reasonable/comparable, or high value (see Figure 10 on the following page).

Figure 10. Evidence Categories for Ratings of Low, Reasonable/Comparable, and High Value.

Low Value	Reasonable/ Comparable Value*	High Value
1. Worse outcomes; Higher or equivalent cost	5. Worse outcomes; Lower cost	9. Comparable outcomes; Lower cost
2. Comparable outcomes; Higher cost	6. Comparable outcomes; Comparable cost	10. Promising but inconclusive evidence of better outcomes; Lower cost
3. Promising but inconclusive evidence of better outcomes; Higher cost	7. Promising but inconclusive evidence of better outcomes; Comparable cost	11. Better outcomes; Lower or comparable cost
4. Better outcomes; Too high a cost	8. Better outcomes; Reasonable higher cost	12. Better outcomes; Slightly higher cost

* For comparisons of one drug or a set of drugs to another drug or set of drugs, the term “comparable” is used in the value assessment; for comparisons of one drug or a set of drugs to no treatment, the term “reasonable” is used in the value assessment.

8.1 Summary of the Votes and Considerations for Policy

I. Genotype 1: treatment-naïve, interferon eligible

- Do you agree that SMV + PR and SOF + PR are superior to TEL + PR because of adequate evidence of equal to better SVR and fewer side effects?

CTAF Panel Vote: **14 yes** 1 no

Comment: The CTAF Panel member who voted no stated that there were too many uncertainties remaining about the comparative effectiveness of these drug regimens because the evidence base is composed largely of uncontrolled studies using surrogate endpoints.

- If yes, what is the comparative value of SMV + PR vs. TEL + PR?

CTAF Panel Vote: **8 low** 3 comparable 3 high

Comment: One of the CTAF Panel members who voted high value said that the model results indicating that simeprevir would cost less than telaprevir at one year were persuasive, and that there were even more savings when a longer time frame was considered. One of the CTAF Panel members who voted low value stated that interferon was still a required part of treatment for simeprevir, and as a result, a number of patients would not complete treatment, thereby diminishing its comparative value.

b. *If yes, what is the comparative value of SOF + PR vs. TEL + PR?*

CTAF Panel Vote: 11 low 1 comparable 2 high

Comment: The same value considerations came into play for the voting on sofosbuvir, emphasizing its high upfront costs.

2. Do you agree that the evidence is inadequate to distinguish between the clinical effectiveness of SOF + PR and SMV + PR?

CTAF Panel Vote: 15 yes

II. Genotype 1: treatment-naïve, interferon ineligible

3. Do you agree that SOF + R is superior to no treatment?

CTAF Panel Vote: 12 yes 3 no

Comment: It was noted prior to the vote that patients who are interferon ineligible currently have no other FDA-approved options. One of the CTAF Panel members who voted no justified the vote by noting that there were only two small studies and no controlled trials in this population.

a. *If yes, what is the comparative value of SOF + R vs. no treatment?*

CTAF Panel Vote: 10 low 2 reasonable

4. Is the evidence adequate to demonstrate that SOF + SMV + R is superior to no treatment?

CTAF Panel Vote: 8 yes 7 no

Comment: One CTAF Panel member justified voting yes by highlighting the excellent outcomes in the COSMOS trial among “treatment-experienced” patients. If these data are extrapolated to treatment-naïve patients, results should be even better. One of the CTAF Panel members who voted no expressed concerns about the very small sample size of the COSMOS trial and the lack of long-term outcomes, leaving this Panel member hesitant to give full credence to a limited evidence base given the large size of the patient population that could be treated with this regimen.

a. *If yes, what is the comparative value of SOF + SMV + R vs. no treatment?*

CTAF Panel Vote: 6 low 2 reasonable

5. Is the evidence adequate to demonstrate that SOF + SMV + R is equivalent or superior to SOF + R?

CTAF Panel Vote: 6 yes 9 no

III. Genotype 1: treatment-experienced, interferon eligible

6. Do you agree that SMV + PR is superior to TEL + PR because of adequate evidence of equivalent SVR and fewer side effects?

CTAF Panel Vote: **13 yes** 2 no

- a. *If yes, what is the comparative value of SMV + PR vs. TEL + PR?*

CTAF Panel Vote: **6 low** 5 comparable 2 high

Comment: One of the CTAF Panel members who voted high value noted the reduced side effects with simeprevir.

7. Is the evidence adequate to demonstrate that SOF + PR is superior to TEL + PR?

CTAF Panel Vote: **11 yes** 4 no

- a. *If yes, what is the comparative value of SOF + PR vs. TEL + PR?*

CTAF Panel Vote: **7 low** 2 comparable 2 high

8. Is the evidence adequate to demonstrate that SOF + SMV + R is superior to TEL + PR?

CTAF Panel Vote: **10 yes** 5 no

- a. *If yes, what is the comparative value of SOF + SMV + R vs. TEL + PR?*

CTAF Panel Vote: **6 low** 4 comparable

9. Is the evidence adequate to demonstrate that SOF + SMV + R is superior to SMV + PR?

CTAF Panel Vote: **8 yes** 7 no

- a. *If yes, what is the comparative value of SOF + SMV + R vs. SMV + PR?*

CTAF Panel Vote: **5 low** 3 comparable

IV. Genotype 1: treatment-experienced, interferon ineligible

10. Is the evidence adequate to demonstrate that SOF + R is superior to no treatment?

CTAF Panel Vote: **10 yes** 5 no

- a. *If yes, what is the comparative value of SOF + R vs. no treatment?*

CTAF Panel Vote: **7 low** 3 reasonable

11. Is the evidence adequate to demonstrate that SOF + SMV + R is superior to no treatment?

CTAF Panel Vote: **11 yes** 4 no

- a. *If yes, what is the comparative value of SOF + SMV + R vs. no treatment?*

CTAF Panel Vote: **6 low** 3 reasonable 2 high

12. Is the evidence adequate to demonstrate that SOF + SMV + R is superior to SOF + R?

CTAF Panel Vote: 7 yes 8 no

V. Genotype 2, treatment-naïve or treatment-experienced

13. Do you agree that SOF + R is superior to PR for interferon eligible patients and that SOF + R is superior to no treatment for interferon ineligible patients?

CTAF Panel Vote: 14 yes 1 no

a. *If yes, what is the comparative value of SOF + R vs. PR for interferon eligible patients?*

CTAF Panel Vote: 6 low 8 comparable

b. *If yes, what is the comparative value of SOF + R vs. no treatment for interferon ineligible patients?*

CTAF Panel Vote: 3 low 11 reasonable

Comment: The shift in value votes toward more “reasonable” votes for sofosbuvir treatment of patients with genotype 2 infections was accompanied by comments noting that the evidence base for this genotype included more patients and the only controlled trial for sofosbuvir. This added strength of evidence on clinical effectiveness, paired with the lack of first-generation anti-viral options, was described as influential in Panel votes.

VI. Genotype 3, treatment-naïve or treatment-experienced

14. Do you agree that SOF + R is superior to PR for interferon eligible patients and that SOF + R is superior to no treatment for interferon ineligible patients?

CTAF Panel Vote: 15 yes

a. *If yes, what is the comparative value of SOF + R vs. PR for interferon eligible patients?*

CTAF Panel Vote: 7 low 8 comparable

b. *If yes, what is the comparative value of SOF + R vs. no treatment for interferon ineligible patients?*

CTAF Panel Vote: 7 low 8 reasonable

CTAF Panel members who voted that the evidence was inadequate to demonstrate comparative clinical effectiveness were asked to abstain from voting on the comparative value questions. Some CTAF Panel members mentioned that this resulted in more positive assessments of value than if these panelists had also been asked to vote, since their votes would have likely been for “low” value on the basis of inadequate evidence of comparative clinical effectiveness.

8.2 Roundtable Discussion and Key Policy Implications

Following its deliberation on the evidence and subsequent voting, the CTAF Panel engaged in a moderated discussion with a Policy Roundtable composed of clinical experts, a patient advocate, payer representatives, and a representative from a manufacturer of one of the new agents. The names of the participants on the Policy Roundtable are shown below.

- Sylvia Carlisle, MD, MBA, Managing Medical Director, Anthem Blue Cross
- Ryan Clary, Executive Director, National Viral Hepatitis Roundtable
- Rena K. Fox, MD, Professor of Clinical Medicine, Division of General Internal Medicine, UCSF
- R. Todd Frederick, MD, Transplant Hepatologist and Fellowship Director of Transplant Hepatology, Department of Transplantation, Division of Hepatology, California Pacific Medical Center
- Amandeep Sahota, MD, MS, Transplant Hepatologist and Southern California Permanente Medical Group Regional Hepatitis C Champion, Kaiser Permanente
- Robert Snediker, Principal Liaison, HECOR, Janssen Pharmaceuticals, Inc.
- John Yao, MD, MBA, MPH, Senior Medical Director, Blue Shield of California

The roundtable discussion explored the implications of CTAF Panel votes for clinical practice and medical policy, considered real life issues critical for developing best practice recommendations in this area, and identified potential avenues for applying the evidence to improve patient care within a value context. The main themes and recommendations from the discussion are summarized below.

- 1) *Despite having voted that the evidence is adequate to demonstrate the superior clinical effectiveness of the new drugs in most patient subpopulations, the CTAF Panel emphasized in discussion that serious limitations in the evidence base remain.*

During the voting process and the ensuing roundtable discussion, the CTAF Panel noted that their judgments of clinical superiority were influenced strongly by the lower side effect profile of the new drugs, especially when regimens do not include interferon, and upon the relatively consistent large magnitude of difference in SVR between the new drugs and prior treatment options. Several CTAF Panel members expressed strong opinions, however, that small, uncontrolled trials should not be the standard to which new treatments in this clinical area should be held going forward. The evidence was noted as being particularly limited for genotype 1, treatment-experienced patients, and for all genotype 3 patients. The CTAF Panel found the indirect comparisons made through the network meta-analysis quite helpful, but they said that direct head-to-head trials or analyses of observational real-world data should be performed to buttress our understanding of the comparative clinical effectiveness of these drug regimens, particularly since new drug combination options are likely to be introduced over the next 1-2 years. Further research to evaluate the

relationship of short-term SVR outcomes to longer-term patient-centered outcomes of liver-related complications, mortality, and quality of life is also needed.

- 2) *For most patient subpopulations, the CTAF Panel found the new drug treatments for hepatitis C to represent a “low value” due to the magnitude of the potential impact on health care budgets of treating large numbers of patients with these high-priced drug regimens.*

A consistent consensus was expressed by CTAF Panel members that the new drug treatments for hepatitis C represented a low value from the perspective of a state Medicaid program. A majority continued to judge these drugs as low value across multiple patient subpopulations, even those for which the evidence was deemed adequate to demonstrate clinical superiority to previous options. Only for the smaller populations of patients infected with genotypes 2 and 3 were the votes more split between “low” and “reasonable/comparable” value. For none of the patient subpopulations did a majority of the CTAF Panel vote that the new drug regimens were a “high value.”

Among those CTAF Panel members voting for “low value”, there was a mix of those who: a) indicated that they judged the evidence on comparative clinical effectiveness to be promising but inconclusive, while costs were higher, and b) those who voted for low value because they felt the evidence demonstrated superior outcomes but at too high a cost. Discussion of the information provided in the report on costs suggested that the CTAF Panel did not consider the additional cost per SVR, a measure of cost-effectiveness, to be as influential in their thinking as was the information on the potential budget impact of new drug regimens. The substantial budget impact figures raised concerns among the Panel about the opportunity cost of the new drugs in the current health care system, as well as concerns about the potential impact on overall health care insurance premiums across the entire insured population.

- 3) *Because the financial impact of using these new drugs to treat all eligible patients with hepatitis C is untenable, policy makers should seek avenues to achieve reductions in the effective price of these medications.*

Very large numbers of patients could potentially benefit from receiving the new drugs for hepatitis C. However, the prices of the new drugs, highlighted by sofosbuvir’s price of \$1,000/pill and \$84,000 per 12 weeks of treatment, when multiplied by the number of eligible patients, create a financial burden that was considered by the CTAF Panel and several of the Policy Roundtable participants to be untenable. Although mechanisms to lower prices were not a specific focus of the conversation, several of the Policy Roundtable participants expressed that without reductions in price, the only options for the health care system involved prioritizing (i.e., limiting the number of) patients considered for treatment. There was some discussion of the possibility that additional treatment options expected to be available within the next 1-2 years might create market

competition that would lower the price of the current set of new drugs or equally effective options, but some skepticism was also voiced that competition would achieve this goal. Alternative policy mechanisms that have been used in other drug classes include payer contracts that vary the price by subpopulation (i.e., higher prices to treat some patient subpopulations and lower prices for others); risk-sharing contracts in which manufacturers rebate the price paid for patients who do not achieve the desired clinical outcome; reference pricing that involves setting the price for a new treatment at the lowest "reference" price paid for any existing treatment with equivalent effectiveness (note, for example, that the CTAF Panel voted that the evidence cannot distinguish between the effectiveness of simeprevir and sofosbuvir for treatment-experienced patients with genotype 1); and price setting to some external standard, such as the cost per quality-adjusted life year gained. Although these mechanisms were not discussed during the CTAF meeting, the price of the new drug regimens was frequently mentioned as the primary policy issue driving the concerns around their coverage by insurers and their use by clinicians.

- 4) *In recognition of limitations of the clinical infrastructure for initiating treatment among a very large patient population, patients, physicians, and payers should work together to encourage informed, shared decision-making about whether patients need to initiate treatment immediately or whether they are well enough to postpone treatment.*

During the discussion, several members of the CTAF Panel referenced the information presented earlier in the meeting showing that most patients with chronic hepatitis C infection do not progress to severe liver dysfunction over the course of their lifetimes. While noting that overt symptoms of liver dysfunction are not an appropriate way to monitor for the onset of liver damage, the clinical experts on the Policy Roundtable commented that many patients with hepatitis C, especially those diagnosed through broad screening efforts, will not need immediate treatment, although they should be evaluated thoroughly and monitored closely to assess for worsening liver function. It was acknowledged that the idea of postponing treatment would not come naturally to many patients, but that it was not unreasonable given the current limited number of clinicians with significant experience caring for patients undergoing treatment for hepatitis C, the promise of additional options for interferon-free regimens in the near future, and the uncertain balance of risks and benefits of immediate treatment for patients who show no current signs of liver dysfunction. All Policy Roundtable participants stressed the importance of shared decision-making between an informed patient and clinician as the appropriate goal for considerations of whether to initiate or postpone treatment. Educational resources for patients (and clinicians) are needed that can support a full dialogue based on an objective view of the evidence and full appreciation for the individual patient values surrounding the potential risks and benefits of the various treatment options.

- 5) *Given the limited number of experienced treating clinicians, the balance of risks and benefits for immediate treatment of patients without significant liver damage, and the financial impact of current high prices, it is reasonable to consider prioritization of treatment by level of liver fibrosis.*

The clinical experts on the Policy Roundtable suggested, and the CTAF Panel agreed, that treating all eligible patients with the new drug regimens is not clinically required nor is it feasible given constraints on clinical infrastructure and financial resources. Under these circumstances, it is reasonable for payers and provider groups to consider prioritizing treatment with the new drugs for patients who have some evidence of liver fibrosis but do not have advanced liver disease (decompensation). The clinical experts on the Policy Roundtable indicated that patients with advanced fibrosis and cirrhosis (METAVIR scores of F3-F4), those who have liver cancer and are awaiting transplant, and those who are post-liver transplant have the greatest chance of benefiting from immediate treatment. It was also noted that the analyses developed for the CTAF report suggested that immediate treatment of only these patient subpopulations would moderate the short-term financial impact on the health care system while offering greater likelihood of long-term clinical benefits and cost-offsets from reduced cases of liver failure.

- 6) *Additional policy measures to increase the likelihood of clinical benefit from treatment while reducing the financial impact should be considered. Payers seeking to achieve these goals should consider developing prior authorization criteria that a) require patient commitment to and compliance with the treatment regimen, b) utilize “futility rules” that define when a lack of early response should lead to discontinuation of treatment, and c) require that prescriptions of simeprevir and sofosbuvir be written by specialist physicians with experience treating patients with hepatitis C.*

In a discussion about prior authorization criteria, it was noted that the new drugs have fewer side effects and that greater patient compliance is expected. However, given the high cost of initial treatment, the risk that poor adherence would lead to the development of resistant viral strains, and the additional cost if a patient stops treatment and then starts again with a new treatment course, it was suggested that coverage be contingent upon a documented patient commitment to the planned course of treatment, including anticipated blood tests and office visits during and after treatment.

Given that good adherence to the new drugs is extremely likely to result in dramatic reductions in viral load within the first four weeks of treatment if the treatment is going to work at all, another prior authorization option would be to develop “futility rules” that require a check on viral load at 4 weeks and that would lead to cessation of coverage for further pills should the results show inadequate response.

Also discussed during the roundtable was the idea that, at least in the short term, it may make clinical and financial sense to limit prescribing of the new drugs to experienced hepatitis C experts. These clinicians have the knowledge to engage in shared decision-making over initiating treatment; they know well the side effects and adherence issues that are critical components of successful treatment; and they know how to monitor and care for patients who are on regimens combined with interferon and ribavirin. Over time, and with the introduction of more all-oral drug regimens, the care of patients with hepatitis C may be shared on a growing basis with primary care clinicians, but for the short-term it seems wise to consider limiting prescription of the newest drugs to specialists. Provider groups should start working now, however, on mechanisms to coordinate the care between primary care and specialty care, including guidelines for primary care clinicians on the tests that should be ordered at the time a patient is first diagnosed with hepatitis C infection.

Among the approaches that payers may take as part of prior authorization, the Policy Roundtable participants did not support “fail-first” policies that would require patients to try and fail to achieve SVR with one of the first generation anti-viral treatments or interferon and ribavirin alone before receiving coverage for sofosbuvir or simeprevir. Comments made regarding fail-first approaches suggested that the side effect profiles and relative effectiveness of previous treatment options were viewed as so inferior to the newer drugs that a fail-first approach would itself fail to find support within the clinical community.

7) *Although there is very little evidence regarding the off-label use of simeprevir and sofosbuvir in combination to treat interferon-ineligible genotype 1 patients, payers may wish to consider covering these drugs on a limited basis for certain patients needing immediate treatment.*

The CTAF Panel’s votes on the comparative clinical effectiveness of the off-label use of 12 weeks of simeprevir and sofosbuvir were divided. A slight majority of the CTAF Panel (8 members) voted that the evidence was adequate to demonstrate that this combination was more effective than no treatment at all for genotype 1 patients who were ineligible for interferon and therefore left with no treatment option before the advent of the new drugs, but only six members of the CTAF Panel voted that the evidence was adequate to show that the off-label combination was better than 24 weeks of sofosbuvir plus ribavirin. Even when compared with no treatment, however, the CTAF Panel rated sofosbuvir plus simeprevir as “low value” on the basis of its potential budget impact. During the discussion, the clinical experts on the Policy Roundtable indicated that for certain select patients who are truly ineligible for interferon and who are also felt to require immediate treatment, it may make sense to consider using sofosbuvir plus simeprevir since it can be used for only 12 weeks instead of 24 for sofosbuvir alone, and is thus likely to be more effective and less expensive.

- 8) *Specialty society clinical guidelines should be developed using best practices, including ratings of strength of evidence, transparency regarding the role of various organizations involved in guideline development, and full transparency regarding potential conflicts of interest of individual guideline committee members, with limits on the proportion of committee members who receive direct or indirect financial support from manufacturers.*

The Policy Roundtable noted the important role in informing patients and clinicians served by the clinical guidelines for the treatment of hepatitis C developed by the American Association for the Study of Liver Diseases (AASLD), the Infectious Disease Society of America (IDSA), and the International Anti-Viral Society-USA. This coordinated effort has produced online guidelines that recommend use of the new drugs either alone or in combination as the first choice for all subtypes of hepatitis C. It was noted that these guidelines do not attempt to address which patients should (or should not) be treated; nor do the guidelines include consideration of the costs of different treatment options. A concern was raised regarding the difficulty in ascertaining the degree of drug industry support for the organizations involved in guideline development, and concern was also expressed that well over half of individual guideline committee members, including the committee chairmen, had either direct (e.g., consulting) and/or indirect support (for research) from the manufacturers of the new hepatitis C drugs. The CTAF Panel agreed that the process for creating clinical guidelines should be as transparent and conflict-free as possible, especially given how consequential the specialty society guidelines are likely to be. This will allow patients, providers, and other stakeholders to fully trust in the objectiveness and trustworthiness of key clinical guidelines.

- 9) *Further evidence should be generated to evaluate more fully the comparative clinical effectiveness and value of these new treatment regimens for patients with hepatitis C.*

As noted above, the CTAF Panel discussed the limited evidence available (single arm, open-label, non-randomized studies with small numbers of patients) to assess the comparative clinical effectiveness of the new treatments for hepatitis C. The CTAF Panel stated that more robust studies are needed moving forward, both for the current FDA-approved drugs and for subsequent additions to the range of therapeutic options. During the discussion it was suggested that manufacturers consider engaging with payers and independent review organizations to discuss evidence standards at the same time they are generating evidence for review by the FDA. It was also recommended that payers implement policies to support evidence generation – e.g., provide coverage only if patients are enrolled in a practical clinical trial or an observational registry. The relative paucity of evidence for genotype 1, treatment-experienced patients and for genotype 3 patients in particular were noted as the most significant needs for further evidence at this time.

References

1. Kim WR. The burden of hepatitis C in the United States. *Hepatology*. Nov 2002;36(5 Suppl 1):S30-34.
2. United States Department of Veterans Affairs. National Hepatitis C Program Office. Interferon and Ribavirin Treatment Side Effects. <http://www.hepatitis.va.gov/provider/reviews/treatment-side-effects.asp>. Accessed January 8, 2014.
3. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. *Clin Infect Dis*. Jan 1 2012;54(1):96-104.
4. Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. *Journal of Viral Hepatitis*. Dec 2013;20(12):847-857.
5. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: Is it worth it? *Hepatology*. Feb 3 2014.
6. Hepatitis C--global prevalence (update). *Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations*. Dec 10 1999;74(49):425-427.
7. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. *Annals of Internal Medicine*. May 16 2006;144(10):705-714.
8. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. *Liver International: Official Journal of the International Association for the Study of the Liver*. Sep 2011;31(8):1090-1101.
9. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. *The New England Journal of Medicine*. May 16 2013;368(20):1859-1861.
10. Kershenobich D, Razavi HA, Cooper CL, et al. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. *Liver International: Official Journal of the International Association for the Study of the Liver*. Jul 2011;31 Suppl 2:4-17.
11. Chinnadurai R, Velazquez V, Grakoui A. Hepatic transplant and HCV: a new playground for an old virus. *American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. Feb 2012;12(2):298-305.
12. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. *The Journal of General Virology*. Nov 1993;74 (Pt 11):2391-2399.

13. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. *Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association*. Jun 2011;9(6):509-516.e501.
14. Blatt LM, Mutchnick MG, Tong MJ, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. *Journal of Viral Hepatitis*. May 2000;7(3):196-202.
15. Germer JJ, Mandrekar JN, Bendel JL, Mitchell PS, Yao JD. Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States. *Journal of Clinical Microbiology*. Aug 2011;49(8):3040-3043.
16. Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. *Journal of Medical Virology*. Nov 2012;84(11):1744-1750.
17. Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. *Gastroenterology*. Aug 2006;131(2):478-484.
18. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. *Annals of Internal Medicine*. Oct 15 1996;125(8):634-639.
19. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. *The New England Journal of Medicine*. Jul 11 1991;325(2):98-104.
20. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. *The New England Journal of Medicine*. Dec 31 1992;327(27):1899-1905.
21. Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. *Hepatology*. Mar 1995;21(3):639-644.
22. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. *Hepatology*. Aug 2008;48(2):418-431.
23. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. *Hepatology*. Oct 2001;34(4 Pt 1):809-816.
24. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature*. Oct 8 2009;461(7265):798-801.

25. Grebely J, Petoumenos K, Hellard M, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. *Hepatology*. Oct 2010;52(4):1216-1224.
26. Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. *Gastroenterology*. Nov 2010;139(5):1586-1592, 1592.e1581.
27. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nature Genetics*. Oct 2009;41(10):1100-1104.
28. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. *Alimentary Pharmacology & Therapeutics*. Jul 2012;36(2):91-103.
29. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. *Hepatology*. Jun 2012;55(6):1652-1661.
30. Moorman AC, Gordon SC, Rupp LB, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. *Clin Infect Dis*. Jan 2013;56(1):40-50.
31. Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine*. Sep 3 2013;159(5):349-357.
32. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. *Annals of Internal Medicine*. Dec 4 2012;157(11):817-822.
33. Bonis PA, Tong MJ, Blatt LM, Conrad A, Griffith JL. A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. *The American Journal of Gastroenterology*. Jun 1999;94(6):1605-1612.
34. Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS. Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. *Hepatology*. Nov 2011;54(5):1527-1537.
35. Ghany MG, Lok AS, Everhart JE, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. *Gastroenterology*. Jan 2010;138(1):136-146.
36. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. *The New England Journal of Medicine*. Jun 1 1995;332(22):1463-1466.

37. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. *Hepatology*. Dec 2013;58(6):1918-1929.
38. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. *Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association*. Nov 2011;9(11):923-930.
39. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *The New England Journal of Medicine*. Sep 26 2002;347(13):975-982.
40. Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. *Journal of Hepatology*. Feb 2012;56(2):320-325.
41. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. *Journal of Hepatology*. Jun 2004;40(6):993-999.
42. Gaetano JN, Reau N. Hepatitis C: management of side effects in the era of direct-acting antivirals. *Current Gastroenterology Reports*. Jan 2013;15(1):305.
43. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. *Hepatology*. Oct 2011;54(4):1433-1444.
44. Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. *Canadian Journal of Gastroenterology = Journal Canadien de Gastroenterologie*. Jun 2012;26(6):359-375.
45. Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. *Alimentary Pharmacology & Therapeutics*. Mar 2012;35(6):647-662.
46. Hezode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. *Liver International: Official Journal of the International Association for the Study of the Liver*. Feb 2012;32 Suppl 1:32-38.
47. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. *Journal of Hepatology*. Sep 2013;59(3):434-441.
48. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. *Gastroenterology*. Oct 2006;131(4):997-1002.

49. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. *Hepatology*. Dec 2009;50(6):1709-1718.
50. Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing Hepatitis C Direct-acting Antivirals, for use in large-scale treatment access programs in developing countries. *Clin Infect Dis*. Jan 6 2014.
51. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. *The New England Journal of Medicine*. Mar 31 2011;364(13):1207-1217.
52. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *The New England Journal of Medicine*. Apr 30 2009;360(18):1839-1850.
53. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. *The New England Journal of Medicine*. Jun 23 2011;364(25):2405-2416.
54. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. *Lancet*. Aug 28 2010;376(9742):705-716.
55. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *The New England Journal of Medicine*. Apr 30 2009;360(18):1827-1838.
56. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. *The New England Journal of Medicine*. Apr 8 2010;362(14):1292-1303.
57. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. *The New England Journal of Medicine*. Mar 31 2011;364(13):1195-1206.
58. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. *The Lancet Infectious Diseases*. Jul 2013;13(7):597-605.
59. Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. *Journal of Gastroenterology*. Sep 5 2013.
60. Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (Tmc435) with Peginterferon/Ribavirin for Chronic Hcv Genotype-1 Infection in Treatment-naïve Patients: Results from Quest-1, a Phase Iii Trial. *Journal of Hepatology*. Apr 2013;58(Suppl. 1):S574-S574.

61. Jacobson IM, Dore GJ, Foster G, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic hcv genotype-1 infection in treatment-naïve patients: Results from quest-1, a phase III trial. *Gastroenterology*. 2013;144(5):S374.
62. Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. *Hepatology*. Dec 2013;58(6):1379A-1380A.
63. Lawitz E, Forns X, Zeuzem S, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic hcv genotype 1 infection in patients who relapsed after previous interferon-based therapy: Results from promise, a phase III trial. *Gastroenterology*. 2013;144(5):S151.
64. Manns M, Marcellin P, Poordad FPF, et al. Simeprevir (Tmc435) with Peginterferon/Ribavirin for Treatment of Chronic Hcv Genotype-1 Infection in Treatment-naïve Patients: Results from Quest-2, a Phase Iii Trial. *Journal of Hepatology*. Apr 2013;58(Suppl. 1):S568-S568.
65. Poordad F, Manns MP, Marcellin P, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic hcv genotype-1 infection in treatment-naïve patients: Results from quest-2, a phase III trial. *Gastroenterology*. 2013;144(5):S151.
66. Scott J, Gilles L, Fu M, et al. Patients with chronic hepatitis C virus treated with simeprevir added to peginterferon and ribavirin experienced less time with fatigue, depressive symptoms, and functional limitations: Results from patients in the quest-1, quest-2, and promise studies. *Value in Health*. 2013;16(7):A362.
67. Scott JA, Gilles L, Fu M, et al. Adding simeprevir to peginterferon/ribavirin for HCV shortens time with patient-reported symptoms and impairment in quality of life: Results from the simeprevir Phase III QUEST 1, QUEST 2 and PROMISE studies. *Hepatology*. 2013;58(4):753A.
68. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. *Gastroenterology*. Feb 2014;146(2):430-441 e436.
69. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. *The New England Journal of Medicine*. Jan 3 2013;368(1):34-44.
70. Gane EJ, Stedman CA, Hyland RH, et al. All-Oral Sofosbuvir-Based 12-Week Regimens for the Treatment of Chronic Hcv Infection: The Electron Study. *Journal of Hepatology*. Apr 2013;58:S6-S7.
71. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *The New England Journal of Medicine*. May 16 2013;368(20):1867-1877.

72. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. *Lancet*. Jun 15 2013;381(9883):2100-2107.
73. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. *The Lancet Infectious Diseases*. May 2013;13(5):401-408.
74. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. *The New England Journal of Medicine*. May 16 2013;368(20):1878-1887.
75. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. *JAMA*. Aug 28 2013;310(8):804-811.
76. Sulkowski M, Rodriguez-Torres M, Lalezari JP. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infections in patients co-infected with HIV (PHOTON-1). 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013, 2013; Washington, D.C.
77. Younossi Z, Stepanova M, Gerber L, et al. Successful treatment with sofosbuvir (SOF) regimen improves patient-reported outcomes (PROS) in patients with chronic Hepatitis C (CH-C). *American Journal of Gastroenterology*. 2013;108:S144.
78. Younossi ZM, Stepanova M, Lawitz E, et al. Successful treatment with sofosbuvir regimen improves fatigue scores in patients with chronic hepatitis C (CHC). *Hepatology*. 2013;58(4):1277A.
79. Zeuzem S, Dusheiko G, Salupere R. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or: the VALENCE trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013, 2013; Washington, D.C.
80. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. *Journal of Hepatology*. May 2010;52(5):652-657.
81. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. *Hepatology*. Mar 2009;49(3):729-738.
82. Giannini EG, Basso M, Savarino V, Picciotto A. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. *Alimentary Pharmacology & Therapeutics*. Feb 15 2010;31(4):502-508.

83. Trapero-Marugan M, Mendoza J, Chaparro M, et al. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. *World Journal of Gastroenterology : WJG*. Jan 28 2011;17(4):493-498.
84. Koh C, Heller T, Haynes-Williams V, et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. *Alimentary Pharmacology & Therapeutics*. May 2013;37(9):887-894.
85. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. *Annals of Internal Medicine*. Nov 15 1997;127(10):875-881.
86. Arora S, O'Brien C, Zeuzem S, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. *Journal of Gastroenterology and Hepatology*. Feb 2006;21(2):406-412.
87. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. *Hepatology*. Apr 2005;41(4):790-800.
88. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. *Annals of Internal Medicine*. Mar 5 2013;158(5 Pt 1):329-337.
89. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. *Hepatology*. Sep 2010;52(3):833-844.
90. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA*. Dec 26 2012;308(24):2584-2593.
91. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. *Annals of Internal Medicine*. Nov 20 2007;147(10):677-684.
92. McCombs J, Matsuda T, Tonnu-Mihara I, et al. The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C: Results From an Analysis of Data From a Department of Veterans Affairs Clinical Registry. *JAMA Internal Medicine*. Nov 5 2013.
93. Ferreira Sda C, Carneiro Mde V, Souza FF, et al. Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon. *The Brazilian Journal of Infectious Diseases : An Official Publication of the Brazilian Society of Infectious Diseases*. Jul-Aug 2010;14(4):330-334.

94. Florian J, Jadhav PR, Amur S, et al. Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects. *Hepatology*. Mar 2013;57(3):903-907.
95. Liu J, Florian J, Birnkrant D, Murray J, Jadhav PR. Interferon responsiveness does not change in treatment-experienced hepatitis C subjects: implications for drug development and clinical decisions. *Clin Infect Dis*. Sep 2012;55(5):639-644.
96. Liu J, Jadhav PR, Amur S, et al. Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects. *Hepatology*. Mar 2013;57(3):897-902.
97. National AIDS Treatment Advocacy Project. Website: http://www.natap.org/2012/HCV/102312_02.htm
98. Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of Sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. *Hepatology*. 2014:n/a-n/a.
99. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon-free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. *Journal of Hepatology*. Nov 19 2013.
100. Chan K, Lai MN, Groessl EJ, et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naïve patients with chronic HCV genotype 1 infection in the veterans health administration. *Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association*. Nov 2013;11(11):1503-1510.
101. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. *Annals of Internal Medicine*. Feb 21 2012;156(4):279-290.
102. Camma C, Petta S, Cabibbo G, et al. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. *Journal of Hepatology*. Oct 2013;59(4):658-666.
103. Camma C, Petta S, Enea M, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. *Hepatology*. Sep 2012;56(3):850-860.
104. Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. *Journal of Medical Economics*. Jan 2014;17(1):65-76.
105. Ferrante SA, Chhatwal J, Brass CA, et al. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. *BMC Infect Dis*. Apr 27 2013;13(1):190.

106. AASLD/IDSA/IAS. Recommendations for Testing, Managing, and Treating Hepatitis C. 2014; <http://www.hcvguidelines.org/full-report-view>. Accessed 2014, 2014.
107. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. *Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association*. Mar 2010;8(3):280-288, 288.e281.
108. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. *Clin Infect Dis*. Apr 1 2011;52(7):889-900.
109. Xu KY, Petti F. HCV Protease Sales/ Vertex ALS2200 Future. 2012; http://www.natap.org/2012/HCV/102312_02.htm. Accessed January, 2014.
110. Menzin J, White LA, Nichols C, Deniz B. The economic burden of advanced liver disease among patients with Hepatitis C Virus: a large state Medicaid perspective. *BMC Health Services Research*. 2012;12:459.
111. Manos MM, Darbinian J, Rubin J, et al. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. *J Manag Care Pharm*. 2013;19(6):438-447.
112. Red Book® Online. Thomson Reuters (Healthcare) Inc.; 2013.
113. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. *JAMA*. 1996;276(15):1253-1258.
114. Fox RK, Currie SL, Evans J, et al. Hepatitis C virus infection among prisoners in the California state correctional system. *Clin Infect Dis*. 2005;41(2):177-186.
115. Gelberg L, Robertson MJ, Arangua L, et al. Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in Los Angeles. *Public Health Reports*. Jul-Aug 2012;127(4):407-421.
116. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. *The American Journal of Gastroenterology*. Aug 2005;100(8):1772-1779.
117. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. *Lancet*. 1997;349(9055):825-832.
118. Bichoupan K, Martel-Laferrriere V, Sachs D, et al. Costs of Telaprevir-based Triple Therapy Including Adverse Event Management at the Mount Sinai Medical Center, NY: \$189,000 per SVR. Paper presented at: 64th Annual Meeting of the American Association for the Study of Liver Diseases; 2013/11/05, 2013; Washington, DC.

119. Buti M, Casado MA, Esteban R. Evaluating the cost of sustained virologic response in naïve chronic hepatitis C patients treated a la carte. *Alimentary Pharmacology & Therapeutics*. Sep 1 2007;26(5):705-716.
120. Hill AM, Clotet B, Johnson M, Stoll M, Bellos N, Smets E. Costs to Achieve Undetectable HIV RNA with Darunavir-Containing Highly Active Antiretroviral Therapy in Highly Pretreated Patients: the POWER Experience. *Pharmacoeconomics*. 2010;28 Suppl 1:69-81.
121. Centers for Disease Control and Prevention website:
<http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#>
122. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. *Ann Intern Med*. 2012 Feb 21;156(4):263-70.
123. Mahajan R, Xing J, Liu SJ, Ly KN, Moorman AC, Rupp L, Xu F, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Mortality Among Persons in Care With Hepatitis C Virus Infection: The Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. *Clin Infect Dis*. 2014 Apr;58(8):1055-61.
124. Pinchoff J, Drobnik A, Bornschlegel K, Braunstein S, Chan C, Varma JK, Fuld J. Deaths among people with hepatitis C in New York City, 2000-2011. *Clin Infect Dis*. 2014 Apr;58(8):1047-54.
125. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. *Annals of Internal Medicine*. Jul 16 2013;159(2):130-137.
126. Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. *Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research*. Jun 2011;14(4):429-437.
127. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. *Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research*. Jun 2011;14(4):417-428.]
128. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multi-variate meta-regression. *Res Syn Meth*. 2012;3:111-125.
129. Gordon, SC, Pockros, PJ, Terrault, NA, Hoop, RS, Buikema, A, Nerenz, D, and Hamzeh, FM. (2012). Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. *Hepatology*, 56: 1651–1660.

130. Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Nader F, Hunt S. Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). *J Hepatol*. 2014 Apr;60(4):741-7.

APPENDIX

Search Strategies

PubMed (NLM), run date 1/8/14

(sofosbuvir OR simeprevir) AND (randomized controlled trial[pt] OR randomized controlled trials[mh] OR controlled clinical trial[pt] OR controlled clinical trials as topic[mh] OR placebo[tiab] OR drug therapy[sh] OR random*[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT humans[mh]) NOT news[pt]

59 refs (trials)

(sofosbuvir OR simeprevir) AND (systematic[sb] OR meta-analysis[pt] OR systematic[tiab] OR meta-anal*[tiab] OR metaanal*[tiab] OR guideline*) NOT (animals[mh] NOT humans[mh]) NOT news[pt]

4 refs (systematic reviews/guidelines)

Embase (Elsevier), run date 1/8/14

139 (trials)

#2 sofosbuvir OR simeprevir AND ('controlled study'/de OR 'randomized controlled trial'/de OR 'randomized controlled trial (topic)'/de OR 'controlled clinical trial (topic)'/de OR 'controlled clinical trial'/de) OR ('hepatitis c' AND (sofosbuvir OR simeprevir) AND (placebo:ab,ti OR random*:ab,ti OR trial:ab,ti OR groups:ab,ti)) NOT ([animals]/lim NOT [humans]/lim)

23 (systematic reviews/guidelines)

#1 sofosbuvir OR simeprevir AND ([cochrane review]/lim OR [meta analysis]/lim OR [systematic review]/lim OR systematic:ab,ti OR 'meta-analysis' OR metaanaly* OR 'practice guideline') NOT ([animals]/lim NOT [humans]/lim)

The Cochrane Library (Wiley), run date 1/8/14

sofosbuvir or simeprevir (Word variations have been searched)

All Results (10): Cochrane Reviews (0) All Review Protocol Other Reviews
(0) **Trials (6)** Methods Studies (0) **Technology Assessments (4)** Economic
Evaluations (0) Cochrane Groups (0)

Cochrane Database of Systematic Reviews: Issue 1 of 12, January 2014

Cochrane Central Register of Controlled Trials (Central): Issue 12 of 12, Dec 2013

[Other Reviews \(DARE\)](#) Issue 4 of 4, Oct 2013

[Methods Studies](#) Issue 3 of 4, Jul 2012

[Technology Assessments](#) Issue 4 of 4 Oct 2013

[Economic Evaluations](#)

[Cochrane Groups](#) Issue 12 of 12, Dec 2013

BIOSIS Previews & Web of Science (Thomson Reuters), run date 1/8/14; search for meeting abstracts

Final count: 31 from WOS; 18 from BIOSIS = **49 meeting abstracts** (duplicates removed)

BIOSIS Previews

Set Results

- # 2 [41](#) Topic=(sofosbuvir OR simeprevir)
Refined by: Document Types=(MEETING)
Databases=BIOSIS Previews Timespan=All years
 - # 1 [67](#) Topic=(sofosbuvir OR simeprevir)
Databases=BIOSIS Previews Timespan=All years
-

WOS

Set Results

- # 2 [33](#) Topic=(sofosbuvir OR simeprevir)
Refined by: Document Types=(MEETING ABSTRACT)
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years
 - # 1 [76](#) Topic=(sofosbuvir OR simeprevir)
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years
-

Trip Database (<http://www.tripdatabase.com/>), run date 1/8/14

sofosbuvir OR simeprevir

43 refs

- 8 Evidence-based Synopses
- 4 Systematic Reviews
- 1 Guidelines
- 5 Key Primary Research
- 12 Controlled Trials
- 16 Extended Primary Research

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Table A1. Clinical and Economic Impact of Treatment Options Among 1,000 60 Year-old Patients with Hepatitis C Genotype 1 Who Are New to Treatment (Treatment-naïve) and Have No-To-Mild Liver Disease Only.

Population/regimen	<i>Evidence Review Data</i>					<i>Modeled 1-Year Drug Costs</i>		<i>Modeled Long-Term Effects of Achieving SVR</i>			
	SVR per 1000	NNT for 1 add'l SVR	Discontinued due to AE (per 1000)	Cost for initial Rx (per patient)	Cost per add'l SVR	Total Drug Costs (per 1000)	Incremental (vs. pre-DAA)	Liver Events Averted 5 years (per 1000)	Liver Events Averted 20 years (per 1000)	Total Estimated Cost Offset 5 years (per 1000, vs. pre-DAA)	Total Estimated Cost Offset 20 years (per 1000, vs. pre-DAA)
<i>IFN-eligible</i>											
TEL + PR (12/24) (pre-DAA)*	740	---	140	\$83,976	---	\$107,712,960	---	---	---	---	---
SMV + PR (12/24)*	840	10	64	\$91,296	\$73,000	\$105,903,360	(\$1,810,000)	(2)	(10)	(\$2,106,000)	(\$6,800,000)
SOF + PR (12)*	830	11	55	\$96,468	\$139,000	\$111,988,320	\$4,275,000	(2)	(9)	(\$1,895,000)	(\$6,120,000)
<i>IFN-ineligible</i>											
No Rx (pre-DAA)	0	---	0	\$0	---	\$0	---	---	---	---	---
SOF + R (24)†	720	1	13	\$176,352	\$245,000	\$219,622,080	\$219,622,000	(17)	(70)	(\$15,160,000)	(\$48,960,000)
SOF + SMV + R (12)‡	900	1	50	\$154,536	\$172,000	\$169,989,600	\$169,990,000	(22)	(87)	(\$18,950,000)	(\$61,200,000)

*ICER network meta-analysis

†Pooled data from PHOTON-1 and QUANTUM

‡Pooled data from COSMOS treatment arms

Total drug costs Include initial therapy and retreatment with most effective regimen available for those not achieving SVR initially

Total estimated cost offset includes cost savings from liver events averted and reduced annual costs from greater numbers of patients achieving SVR

SVR: sustained virologic response; NNT: number needed to treat; DAA: direct-acting antivirals

Table A2. Clinical and Economic Impact of Treatment Options Among 1,000 60 Year-old Patients with Hepatitis C Genotype 1 Who Are New to Treatment (Treatment-naïve) and Have Advanced Liver Disease Only.

Population/regimen	Evidence Review Data					Modeled 1-Year Drug Costs		Modeled Long-Term Effects of Achieving SVR			
	SVR per 1000	NNT for 1 add'l SVR	Discontinued due to AE (per 1000)	Cost for initial Rx (per patient)	Cost per add'l SVR	Total Drug Costs (per 1000)	Incremental (vs. pre-DAA)	Liver Events Averted 5 years (per 1000)	Liver Events Averted 20 years (per 1000)	Total Estimated Cost Offset 5 years (per 1000, vs. pre-DAA)	Total Estimated Cost Offset 20 years (per 1000, vs. pre-DAA)
<i>IFN-eligible</i>											
TEL + PR (12/24) (pre-DAA)*	740	---	140	\$83,976	---	\$107,712,960	---	---	---	---	---
SMV + PR (12/24)*	840	10	64	\$91,296	\$73,000	\$105,903,360	(\$1,810,000)	(10)	(38)	(\$2,975,000)	(\$9,608,000)
SOF + PR (12)*	830	11	55	\$96,468	\$139,000	\$111,988,320	\$4,275,000	(9)	(35)	(\$2,677,000)	(\$8,647,000)
<i>IFN-ineligible</i>											
No Rx (pre-DAA)	0	---	0	\$0	---	\$0	---	---	---	---	---
SOF + R (24)†	720	1	13	\$176,352	\$245,000	\$219,622,080	\$219,622,000	(69)	(276)	(\$21,420,000)	(\$69,174,000)
SOF + SMV + R (12)‡	900	1	50	\$154,536	\$172,000	\$169,989,600	\$169,990,000	(86)	(346)	(\$26,774,000)	(\$86,468,000)

*ICER network meta-analysis

†Pooled data from PHOTON-1 and QUANTUM

‡Pooled data from COSMOS treatment arms

Total drug costs Include initial therapy and retreatment with most effective regimen available for those not achieving SVR initially

Total estimated cost offset includes cost savings from liver events averted and reduced annual costs from greater numbers of patients achieving SVR

SVR: sustained virologic response; NNT: number needed to treat; DAA: direct-acting antivirals

Figure A1. Total Budgetary Impact and Potential Cost Offsets from Use of Newer Drug Regimens in the Chronic Hepatitis C Population in California: 25% of infected Patients Are Treated (n=135,263).




Figure A2. Total Budgetary Impact and Potential Cost Offsets from Use of Newer Drug Regimens in the Chronic Hepatitis C Population with Advanced Fibrosis in California: 25% of Infected Patients Are Treated (n=44,772).

